


Connecting The Vascular Community



Tuesday – Saturday, November 14-18, 2023



PROGRAM DUTLINE AT A GLANCE

TUFSDAY PROGRAMS

Program A (Sessions 1-8)

6:45 A.M. - 6:02 P.M.

Progress In The Treatment Of Diseases Of The Coronary Arteries, Heart Valves, And The Thoracic And Abdominal Aorta

Location: Grand Ballroom East, 3rd Floor

Program B (Sessions 9-16)

6:47 A.M. - 5:59 P.M.

Progress In Vascular Robotics, Guidance Systems, Laparoscopy, Simulation And COVID; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; New Technology Concepts And Artificial Intelligence (AI); Vascular Surgery Identity, Training, Manpower And Mentorship; Updates On Open And Hybrid Vascular Surgery And Treatment Of Aortic Coarctation Location: Grand Ballroom West, 3rd Floor

Program C-1 (Sessions 17-18)

7:00 A.M. - 12:00 P.M.

Management Of Pulmonary Embolism: The Ultimate Team Approach Location: Trianon Ballroom, 3rd Floor

Program C-2 (Sessions 19-22)

1:00 P.M. - 6:06 P.M.

Interesting Topics Related To Lower Extremity Occlusive Disease And Its Treatments Location: Trianon Ballroom, 3rd Floor

WEDNESDAY PROGRAMS

Program D (Sessions 23-30)

6:40 A.M. - 6:20 P.M.

Progress In Lower Extremity Occlusive Disease And Its Treatment

Location: Grand Ballroom East, 3rd Floor

Program E (Sessions 31-38)

6:40 A M - 6:30 PM

New Developments In Medical Treatments And New Drugs; Progress In Anti-Atherogenic And Anti-Hypertensive Treatments; Management Of Endoleaks; Recorded Live Cases From Leading Centers In The US And EU; Issues Of Interest; Outpatient And Office Based Vascular Treatment; Topics Related To Government, Reimbursement, SVS, VQI, FDA, Guidelines, Trials And Evidence Based Medicine

Location: Grand Ballroom West, 3rd Floor

Program F (Sessions 39-46)

6:50 A.M. - 6:30 P.M.

More New Developments In Thoracic Aortic Disease, TEVAR, Aortic Dissections, TAAAs, IUXTA- And Pararenal AAAs, Parallel Grafts, Fenestrated And Branched EVAR (F/B/ EVAR), Multilayer Bare Stents, Infrarenal AAAs And Standard EVAR, And Hot New Aortic And Carotid Topics Location: Trianon Ballroom, 3rd Floor

THURSDAY PROGRAMS

Program G (Sessions 47-54)

6:50 A.M. - 5:58 P.M.

Exciting New Or Rediscovered Techniques Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAAs; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety

Location: Grand Ballroom East, 3rd Floor

Program H (Sessions 55-63)

7:00 A.M. - 5:52 P.M.

New Or Improved Devices For: Standard EVAR, EVAS And More Complex AAAs; Repairs Of TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels

Location: Grand Ballroom West, 3rd Floor

Program I (Sessions 64-73)

7:00 A.M. - 6:40 P.M. Superficial Venous Disease

Location: Trianon Ballroom, 3rd Floor

Program J (Sessions 74-78)

8:00 A.M. -12:30 P.M.

Multidisciplinary Acute Stroke Management Location: Murray Hill Suites, 2nd Floor

FRIDAY PROGRAMS

Program K (Sessions 79-86)

6:40 A.M. - 5:56 P.M.

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACS), String Sign, Carotid Clot, Significance Of MRI Lesions, Carotid Controversies And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care Location: Grand Ballroom East, 3rd Floor

Program L (Sessions 87-94) 6:52 A.M. - 5:40 P.M.

New Developments In The Treatment Of Popliteal Disease: Aneurysms, Entrapment And Occlusive Lesions; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Augmented Reality And Artificial Intelligence; Recorded Live Complex Endovascular Cases From Münster, Germany; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular Trauma

Location: Grand Ballroom West, 3rd Floor

Program M (Sessions 95-104)

7:00 A.M. - 5:57 P.M. Deep Venous Disease

Location: Trianon Ballroom, 3rd Floor

SATURDAY PROGRAMS

Program N (Sessions 105-108)

7:00 A.M. - 12:40 P.M.

Topics Too Important To Miss In The Treatment Of Lower Extremity, Aortic Or Carotid Disease

Location: Grand Ballroom East, 3rd Floor

Program O (Sessions 109-113)

8:00 A M - 4:00 P M

Improving Outcomes In Hemodialysis Access Location: Grand Ballroom West, 3rd Floor

Program P (Sessions 114-123)

7:00 A.M. - 5:30 P.M.

Advances In Vascular Imaging And Diagnosis Location: Murray Hill Suites, 2nd Floor



CONTENTS

Program Outline At A GlanceInside	
Acknowledgments	4
Fellows Career Development Program	6-7
Special Non-CME & Other Industry Events	8-10
General Information	11-13
Accreditation	12
Faculty Disclosure	13
Hotel and Travel	13
Agenda	15-126
Faculty Listing	127-136
Registration	

ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational and in-kind grants* in support of this activity from:

Abbott Advanced Oxygen Therapy Inc. (AOTI) Artivion, Inc. Bentley InnoMed GmbH **Boston Scientific Corporation** Canon Medical Systems USA, Inc.* Cook Medical, LLC Cordis Corporation FujiFilm Sonosite* Gore & Associates Humacyte, Inc. Inari Medical **InspireMD** Janssen Scientific Affairs, LLC LimFlow, Inc. Medtronic Mindrav* Nano Endoluminal SA Parks Medical Electronics* Penumbra, Inc. **Philips** Shockwave Medical, Inc. Siemens Medical Solutions USA, Inc.

> Silk Road Medical Terumo Aortic



VASCULAR FELLOWS & RESIDENTS CAREER DEVELOPMENT PROGRAM

An Interactive Symposium for Vascular Surgery Fellows and Residents Preparing to Enter the Job Market!

Friday, November 18, 2023 • 8:00 A.M. - 5:00 P.M. • New York Hilton-Midtown, New York City Americas Hall 1, 3rd Floor | This is a Non-CME activity.

VEITHsymposium provides vascular surgeons and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.

We are pleased to offer the 8th VEITHsymposium Fellows & Residents Career Development Program this year. This Program is dedicated to bringing together the June 2024 graduating vascular trainee and their potential employers right at the time that the trainees are looking for their first post-training position. The Career Development Program will also provide an environment for career counseling and easy interaction between vascular trainees, senior vascular specialists, and potential employers.

WHO SHOULD ATTEND:

Graduating Fellows and Residents in Vascular Surgery Attending Vascular Specialists seeking new opportunity Potential Employers and Vascular Career Recruiters of Vascular Specialists

ACKNOWLEDGMENTS:

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational and in-kind grants* in support of this activity from:

Gore & Associates, Inari Medical, Medtronic, Shockwave Medical, and Terumo Aortic.

JOIN US IN NEW YORK CITY THIS NOVEMBER.
Register online for VEITH at: www.VEITHsymposium.org

PROGRAM DIRECTOR:James F. McKinsey, MD





VEITHSTREOSIUM Cleveland Clinic Vascular Fellows & Residents Career Development Curriculum

	James F. McKinsey, MD Venita Chandra, MD	11:32-11:40	Balancing Your Practice With Industry Relationships - From A Physician's Viewpoint
8:00 -8:05	Welcome James F. McKinsey, MD		Gustavo S. Oderich, MD
	Venita Chandra, MD	11:40-11:45	Discussion
SESSION 1 8:05 – 8:13	SELECTING YOUR FIRST JOB What Does A Vascular	11:45-11:53	What Industry Is Looking For In Collaboration With Vascular
0:03 - 0:13	Practice Look Like In The 21st		Interventionalists Mr. Samuel Arbefeuille
	Century; Academic, Hybrid Or Community Practice?	11:53-11:58	Discussion
0.40 0.40	James H. Black III, MD	11:58-12:10	Lunch Available
8:13 - 8:18 8:18 - 8:26	Discussion What To Prioritize In Your First	LUNCHEON	ADVANCEMENT IN THE
6.16 - 6.20	Practice Karan Garq, MD	PROGRAM:	TREATMENT OF VASCULAR DISEASE
8:26 - 8:31	Discussion	12:10 -12:25	Evolution Of DVT Treatment: Where We've Been & Where
8:31 – 8:39	Things I Wish I Had Known When I Was Selecting My First		We're Going
	Job	12:25-12:40	Steven D. Abramowitz, MD Advances In Patient Care Using
8:39 – 8:44	Nicole Ilanzo, MD Discussion		Endograft Branch Technology James F. McKinsey, MD
8:44 - 8:52	How To Evaluate A Group's	12:40-12:55	How Long-Term ENGAGE
	Commitment To Diversity, Equality And Inclusiveness Before Joining The Group Palma M. Shaw, MD, MBA		Study Outcomes Informs My Approach To Patient Management Frank R. Arko, MD
8:52 - 8:57	Discussion	12:55-1:09	Discussion
8:57 - 9:05	How Much Should I Get Paid? How Do I Know If I Am Getting	SESSION 4	LONG-TERM PRACTICE MANAGEMENT
	Paid Fairly? Sherene Shalhub, MD, MPH	1:10 - 1:18	Incorporating Social Media Into Your Vascular Practice
9:05 - 9:09	Panel Discussion With Q&A		Alan B. Lumsden, MD
SESSION 2	INTERVIEWING FOR YOUR FIRST	1:18 - 1:23	Discussion
0.00 0.17	JOB Interviewing 101, The Pight	1:23 – 1:31	Opportunities And Resources For Your Career – From The
9:09 – 9:17	Interviewing 101: The Right Questions To Ask When		Society For Vascular Surgery Joseph L. Mills, MD
	Interviewing Jeffrey J. Siracuse, MD	1:31 - 1:36	Discussion
9:17 - 9:22	Discussion	1:36 - 1:44	Opportunities And Resources For Your Career Available To You
9:22 - 9:32	How To Find Out What The		From Your Regional Vascular
	Practice Is Really Like And Understand The Options Within		Societies Kathleen J. Ozsvath, MD
	The Practice Ellen D. Dillavou, MD	1:44 - 1:49	Discussion
9:32 - 9:37	Discussion	1:49 – 1:57	Tips And Tricks To Managing Family, Wellness And Career
9:37 - 9:45	Do I Need To Hire A Lawyer		Development Vincent I. Rowe, MD
	To Review My Employment Contract?	1:57 - 2:02	Discussion
	Margaret Tracci, MD, JD	2:02 – 2:10	Medical Malpractice – How To
9:45 - 9:50 9:50 -10:00	Discussion How To Negotiate Your First		Avoid A Lawsuit O. William Brown, MD, JD
7.50 .0.00	Contract	2:10 - 2:15	Discussion
10.00 10.05	James F. McKinsey, MD	2:15 – 2:23	Incorporating Diversity, Inclusiveness And Equality Into
	Panel Discussion With Q&A Break - Visit Exhibits And		Your Practice
	Pavilions (2nd and 3rd	2:23 – 2:28	Dawn M. Coleman, MD
CECCION 2	Floors)	2:23 - 2:26	Discussion Tips/Tricks To Manage
SESSION 3	FIRST YEAR IN PRACTICE Keys To Building A Successful		Malignant Settings, Toxic
	Practice Venita Chandra, MD		Leadership, Difficult Partners And Turf Wars
10:33-10:38		2:36 - 2:41	Shang Loh, MD Discussion
	What Is The Value Of Dedicated	2:30 - 2:41	Financial Planning
	Vascular Programs Within A Vascular Practice; Aortic, PERT,		Consideration, Tips And Tricks
	Critical Limb Ischemia, Central		For The Young Surgeon Mr. Anthony R. Anzalone
	Line, Etc., And How Do I Set Them Up?	2:49 - 2:54	Discussion
	Anahita Dua, MD, MS, MBA	2:54 – 3:02	Long-Term Career Planning: What Are Your Long-Term
10:46-10:51 10:51-10:59	Discussion Building Your Practice:		Goals?
	Research Considerations	3:02 – 3:07	Timur P. Sarac, MD Discussion
10:59-11:04	Marc L. Schermerhorn, MD Discussion	3:07 - 3:15	Career Options Throughout
	Building Your Practice: Clinical		Your Career Peter Gloviczki, MD
	Considerations Keith D. Calligaro, MD	3:15 - 3:20	Discussion
11:12-11:17		3:20 - 3:25	Closing Remarks
11:17-11:27	Vascular Procedure Billing	3.25 _ 5.00	Frank J. Veith, MD Interactive Cocktail
	And Coding – What Do You Absolutely Need To Know Going Into Your First Job? Sean P. Roddy, MD	J:2J - 5:UU	Reception with Faculty, Fellows/Residents, Potential Employers and Industry
11:27-11:32	**		•

SPECIAL CME, NON-CME, AND OTHER INDUSTRY SPONSORED EVENTS

(PLEASE VISIT WWW.VEITHSYMPOSIUM.ORG FOR AN UPDATED LISTING OF THESE ACTIVITIES.)

MONDAY, NOVEMER 13, 2023

GORE & ASSOCIATES

Enabling solutions for complex disease: TIPS and AV access

Time: 12:00 P.M. - 1:00 P.M.

Location: Nassau Suite East and West, 2nd Floor

TUESDAY, NOVEMBER 14, 2023

GORE & ASSOCIATES

Lunch Symposium: Leading TEVAR innovation for over 25 years: Proven outcomes, new branched technology and trial insights

Time: 12:00 P.M. - 1:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

Evening Symposium: TEVAR Triumphant: Celebrating 25 years of

TEVAR innovation: The journey from inception to reality

Time: 6:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

PENUMBRA, INC.

Lunch Symposium: Thrombus Management with Computer Assisted Vacuum Thrombectomy (CAVT): Data & Case Based Discussion

Time: 12:00 P.M. - 1:00 P.M.

Location: Nassau Suites East & West, 2nd Floor

WEDNESDAY, NOVEMBER 15, 2023

BD

Lunch Symposium: Cross, Treat and Sustain - Solutions for Complex

PAD Lesions

Time: 12:35 P.M. - 1:35 P.M. **Location:** Gibson Suite, 2nd Floor

CONCEPT MEDICAL

Lunch Symposium: Sirolimus Coated Balloon for PAD

Time: 12:00 P.M. - 1:30 P.M.

Location: Nassau Suites East & West, 2nd Floor

GORE & ASSOCIATES

Lunch Symposium: Rethinking the role of covered stents for PAD:

Compelling long-term outcomes and new innovation

Time: 12:35 P.M. – 1:35 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

MEDTRONIC

Thanksgiving Lunch Buffet and Symposium:

Choosing the Optimal Treatment for PAD: How Recent Data on

Paclitaxel and Atherectomy Affect My Practice

Time: 12:35 P.M. – 1:35 P.M.

Location: Medtronic Pavilion, 3rd Floor

NECTERO MEDICAL

Afternoon Symposium & Cocktail Hour:

Nectero EAST® System: Innovative New Treatment for Small- to Mid-

Sized Abdominal Aortic Aneurysms (AAA)

Time: 5:15 P.M. - 7:30 P.M.

Location: Clinton Suite, 2nd Floor

SPECIAL CME, NON-CME, AND OTHER INDUSTRY SPONSORED EVENTS

VVV@Vs®

VENOUS VENOUS VENOUS® WORKSHOPS AT VEITHsymposium

Workshops will include Video Case Presentations, Lectures and Demonstration on vein management by experts, plus hands-on opportunities where participants can rotate through multiple training stations staffed by professionals to assist with your experience.

Time: 1:35 P.M. – 6:22 P.M.

Location: Americas Hall 2, 3rd Floor

THURSDAY, NOVEMBER 16, 2023

BD

Lunch Symposium: International Expert Panel: Latest Debates in

Venous Disease

Time: 12:00 P.M. - 1:00 P.M. Location: Gibson Suite, 2nd Floor

EnVVeno Medical Corporation (NVNO)

Lunch Symposium: Veno Valve for Deep Venous Reflux in Patients with

CVI

Time: 12:00 P.M. - 1:30 P.M. Location: Madison Suite, 2nd Floor

GORE & ASSOCIATES

Lunch Symposium: Together advancing complex EVAR

Time: 12:00 P.M. - 1:00 P.M.

Location: Mercury Rotunda & Ballroom, 3rd Floor

HUMACYTE

Dinner Symposium: Vascular Trauma Repair Clinical Study Results

with the Humacyte Human Acellular Vessel™

Time: 6:00 P.M.

Location: Clinton Suite, 2nd Floor

MEDTRONIC

Lunch Symposium: Medtronic: Optimizing Seal in Challenging TEVAR

Time: 12:00 P.M. - 1:00 P.M.

Location: Medtronic Pavilion, 3rd Floor

WORLD FEDERATION OF VASCULAR SURGERY at

VEITHsymposium



Moderators: Palma M. Shaw, MD, MBA, RVPI, Wei Zhou, MD and Enrico Ascher, MD

The World Federation of Vascular Societies (WFVS) exists to improve the quality of care of vascular patients worldwide, by providing a forum for the international exchange of scientific and educational knowledge related to the diagnosis, treatment and prevention of vascular diseases. The WFVS is composed of 8 member societies consisting of federated, national and affiliate vascular societies.

Time: 1:00 P.M. - 2:30 P.M.

Location: Murray Hill Suites, 2nd Floor

SPECIAL NON-CME AND OTHER INDUSTRY SPONSORED EVENTS

BEST-CLI- NEW DATA AND EVOLVING PERSPECTIVES



Moderators: Alik Farber, MD, MBA, Matthew T. Menard, MD and Kenneth Rosenfield, MD

The BEST-CLI trial will be the central focus for two hours on Thursday, November 16th from 3-5 P.M. at the VEITHsymposium in New York City. BEST-CLI Principal Investigators Drs. Alik Farber, Matthew Menard and Kenneth Rosenfield will moderate a deep and data-rich dive into recent work, future plans, comments from opinion leaders and a debate on the evolving interpretation of BEST-CLI.

The program will highlight recent analyses and forthcoming publications on Periprocedural Complications, Reinterventions, a number of novel but highly relevant Secondary Endpoints, a comprehensive BEST-CLI Investigator Survey and open and endo comparison of Infrapopliteal Interventions within the trial.

Time: 3:00 P.M. - 5:00 P.M.

Location: Murray Hill Suites, 2nd Floor

FRIDAY, NOVEMBER 17, 2023

BD

Lunch Symposium: More Options for Your Dialysis Access Treatment

Algorithm

Time: 12:00 P.M. - 1:00 P.M. Location: Gibson Suite, 2nd Floor

COOK MEDICAL

Latin American Luncheon at VEITHsymposium®:

Innovations in Vascular Disease Management: Clinical Cases and

Technical Strategies

Time: 12:00 P.M. - 1:00 P.M.

Location: Murray Hill Suites, 2nd Floor

FELLOWS & RESIDENTS CAREER DEVELOPMENT PROGRAM

Time: 8:00 A.M. - 5:00 P.M.

Location: Americas Hall 1, 3rd Floor

J. LEONEL VILLAVICENCIO LATIN-AMERICAN PROGRAM at VEITHsymposium



Course Leaders: Enrico Ascher, MD (USA), Jorge H. Ulloa, MD (COL), Rebeca Reachi, MD (MEX), Tulio P. Navarro, MD, PhD (BRA) and Frank J. Veith, MD (USA)

Five-minute presentations in English, Spanish, or Portuguese. Best

Presentation Award will be given. Time: 7:30 A.M. - 5:00 P.M.

Location: Murray Hill Suites, 2nd Floor

SATURDAY, NOVEMBER 18, 2023

GORE & ASSOCIATES

Lunch Symposium: Technical and clinical techniques for improving

patient outcomes – AV access revisions

Time: 12:00 P.M. – 1:00 PM

Location: Mercury Rotunda & Ballroom, 3rd Floor

GENERAL INFORMATION

NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered.

In addition, by having numerous short (5-6 minutes) talks followed by panel discussions and capturing the entire meeting on the web-based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Tuesday, the symposium offers over 1,300 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

OBIECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease
- Summarize the impact of data on therapeutic advances for stroke and carotid disease management
- Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease
- Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care
- Summarize recent data on treatment advances for venous disease and explain their clinical implications
- Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors
- Incorporate the Vascular Laboratory into the management of patients with vascular disease
- Identify and compare noninvasive tests that are available to aid in the diagnosis of vascular disease

GENERAL INFORMATION

TARGET AUDIENCE

Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists, Cardiac Surgeons, Vascular Technologists, Sonographers and all others interested in the management of vascular disease.

ASSOCIATE FACULTY GLOBAL PODIUM PRESENTATIONS

Wednesday – Friday, November 15-17, 2023 Location: Gramercy Suite East, 2nd Floor

In order to have more younger and less familiar vascular surgeons and vascular specialists play an active role as Associate Faculty at our meeting, we have initiated programs whereby they can present their scientific work at the podium. Vascular surgeons and vascular specialists participating in these programs will have submitted abstracts for a podium presentation, and these abstracts will be posted on our website. The best three abstracts will receive cash prizes of \$1,000 (1st place), \$500 (2nd place) and \$250 (3rd place). Please visit www.veithsymposium.org for additional information about the Associate Faculty Global Podium Presentations component of VEITHsymposium.

ONE-DAY COMPONENT SESSIONS WILL BE HELD AS FOLLOWS:

Multidisciplinary Acute Stroke Management

Thursday, November 16, 2023

Location: Murray Hill Suites, 2nd Floor

Hemodialysis Access

Saturday, November 18, 2023

Location: Grand Ballroom West, 3rd Floor

ACCREDITATION STATEMENT

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

American Medical Association (AMA)

Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 52 *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

American Nurses Credentialing Center (ANCC)

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 52 ANCC contact hours.

Certificate of Participation

A certificate of participation will be provided to other healthcare professionals for requesting credits in accordance with their professional boards and/or associations.

ABS CONTINUOUS CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of

GENERAL INFORMATION

the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to the ACCME for the purpose of granting ABS credit.

ETHICAL MEDTECH COMPLIANCE

VEITHsymposium is Compliant with the MedTech Europe Code of Ethical Business Practice.

CME CERTIFICATES AND COURSE EVALUATION FORMS

Your CME certificate will be available online within two weeks after the meeting. An e-mail with instructions on how to obtain the certificate and complete a brief course evaluation will be sent to all registered attendees. The e-mail will be sent to the e-mail address that was used to register the attendee. Please note that CME Certificates must be claimed by **February 29, 2024.**

FACULTY DISCLOSURE

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Integrity and Independence requiring mitigation of all faculty conflicts of interest. Faculty declaring a relevant financial relationship will be identified in the activity syllabus.

ADA STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request to VEITHsymposium by e-mail to admin@veithsymposium.org at least one month prior to the activity.

ONLINE ACCESS TO ABSTRACTS

Presentation slides will be used as abstracts and will be available on the program page of the VEITHsymposium website at www.veithsymposium.org after the meeting. Abstracts will be available on the website for one full year.

ONLINE CONFERENCE LIBRARY

The entire program with almost all the talks, slides, audio and videos fully synchronized - and the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please visit www.veithondemand.com or call (800) 987-9314, select option 3.

HOTEL AND TRAVEL

A block of rooms has been reserved at the conference rate of \$359 plus taxes per night. This rate is available until the block is filled or until October 10, 2023. *Please request the VEITH rate when reserving your accommodations.*

New York Hilton-Midtown (Symposium Site)

1335 Avenue of the Americas

New York, NY 10019

(212) 586-7000 or 1-800-HILTONS (toll free U.S. only)

American Express Global Business Travel at The Cleveland Clinic

Phone: (216) 444-2564, Extension 62134971 E-mail: Judy.M.Kraut@amexgbt.com



SAVE THE DATE

Tuesday - Saturday, November 19-23, 2024



Symposium Chairman Frank J. Veith, MD

Executive Co-Chairman Enrico Ascher, MD

Symposium Co-Chairmen Kenneth Ouriel, MD, MBA Sean P. Lyden, MD

Sponsored by







TUESDAY, NOVEMBER 14, 2023

General Registration - Rhinelander Gallery, 2nd Floor 6:00 A.M. 6:00 A.M. Faculty Registration — Gramercy Suite West, 2nd Floor 6:15 A.M. Continental Breakfast - Rhinelander Gallery, 2nd Floor

CONCURRENT TUESDAY PROGRAMS

PROGRAM A: (SESSIONS 1-8)

Progress In The Treatment Of Diseases Of The Coronary Arteries, Heart Valves And The Thoracic And Abdominal Aorta 6:45 A.M. - 6:02 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM B: (SESSIONS 9-16)

Progress In Vascular Robotics, Guidance Systems, Laparoscopy, Simulation And COVID; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; New Technology Concepts And Artificial Intelligence (AI); Vascular Surgery Identity, Training, Manpower And Mentorship; Updates On Open And Hybrid Vascular Surgery, **And Treatment Of Aortic Coarctation**

6:40 A.M. - 5:59 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM C-1: (SESSIONS 17-18)

Management Of Pulmonary Embolism: The Ultimate

Team Approach

7:00 A.M. - 12:00 P.M. Trianon Ballroom, 3rd Floor

Course Leader: Michael R. Jaff, DO

PROGRAM C-2: (SESSIONS 19-22)

Interesting Topics Related To Lower Extremity Occlusive Disease **And Its Treatments**

1:00 P.M. - 6:06 P.M.

Trianon Ballroom, 3rd Floor

PROGRAM A (SESSIONS 1-8)

PROGRESS IN THE TREATMENT OF DISEASES OF THE CORONARY ARTERIES, HEART VALVES AND THE THORACIC AND ABDOMINAL AORTA

Grand Ballroom East, 3rd Floor

6:45 - 6:50Opening Remarks

Frank J. Veith, MD

SESSION 1 (Grand Ballroom East, 3rd Floor) PROGRESS IN CORONARY ARTERY STENTING,

TRANSCATHETER VALVE REPLACEMENT, AND TREATMENT OF ASCENDING AORTIC DISEASE

Moderators: Roxana Mehran, MD Hazim J. Safi, MD

Tilo Kölbel, MD, PhD

CORONARY STENTS

6:50 - 6:55What Is New In Coronary Artery Stenting: What Is The Role For Bare Metal Stents Roxana Mehran, MD

6:56 - 7:01What Is New With Treatment Outcomes For Left Main Coronary Artery Disease: Advantages And Limitations Of PCI And CABG: Which Has Better Long-Term Survival

Gregg W. Stone, MD

TRANSCATHETER HEART VALVES

7:02 - 7:07Update On The Status Of Transcatheter Mitral Valve Replacement/Repair (TMVR) Juan F. Granada, MD

- 7:08 7:13**DEBATE:** Update On Current State Of TAVR: A Cardiac Surgeon's View: What Is The Role Of Surgery In Aortic Valve Disease Ali B. Khovnezhad, MD, PhD
- 7:14 7:19**DEBATE:** What Is New With Transcatheter Aortic Valve Replacement (TAVR): What Are Its Limitations: A Cardiologist's View Torsten Vahl, MD

THE ASCENDING AORTA

- 7:20 7:25Progress In Endovascular Graft Treatment Of Ascending Aortic Lesions: What New Grafts Are Being Developed: What Problems Exist: Will They Be Overcome And Will This Segment Of The Aorta Be Conquered Endovascularly Rodney A. White, MD
- 7:26 7:31Endovascular Treatment Of Type A Aortic Dissections (TAADs) In 2023: What Is Here And What Is Coming: **Experience With Ascending Aortic Endografting** Eric E. Roselli, MD
- 7:32 7:37Current Status Of Endo Bentall Procedures In Patients: Review Of Early Clinical Experiences: How Can It Be Done Without Left Ventricular Access Yazan Duwayri, MD, MBA Bradley G. Leshnower, MD
- 7:38 7:43Current And Future Status Of Ascending Aortic Endograft Repairs: Devices And Experience With Endo-Wheat And Endo-Bentall Procedures Nimesh D. Desai, MD, PhD
- 7:44 7:50**Panel Discussion**

SESSION 2 (Grand Ballroom East, 3rd Floor) PROGRESS IN THE TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS

- Moderators: Ali B. Khoynezhad, MD, PhD Alan B. Lúmsden, MD Christoph A. Nienaber, MD, PhD
- 7:50 7:55Current Status Of Open Aortic Arch Repair: What Is The Benchmark That Endo And Hybrid Techniques Must Compete With Anthony L. Estrera, MD
- 7:56 8:01Update On Hybrid Repair Of Aortic Arch And Thoracic Aortic Aneurysms Using ThoraFlex (Hybrid) And Relay Devices For Frozen Elephant Trunk (FET) And TEVAR: Indications And Results Joseph S. Coselli, MD (PowerPoint Presentation With Synched Audio) Ourania Preventza, MD
- 8:02 8:07Update On Endovascular Arch Repair With Cook 2- Or 3-Branched Device For Lesions Involving The Entire Aortic Arch: Retrograde Versus Antegrade Insertion Of Arch Branches: Advantages Of A Fully Percutaneous Approach Stephan Haulon, MD

8:08 — 8:13	Long-Term Results With 2-Branched Endograft (Relay – Terumo Aortic) And Single Branched Device (Nexus – Endospan) For Treatment Of Zone 0 Arch Lesions Toru Kuratani, MD, PhD
8:14 — 8:19	Update On The Terumo Relay Branched Endograft Device For Aortic Arch Lesion Repairs: Advantages, Limitations And Results Vicente Riambau, MD, PhD Ciro Ferrer, MD Martin Czerny, MD
8:20 - 8:25	A New Device For Endovascular Repair Of A ortic Arch Aneurysms: Advantages And Early Clinical Experience Qingsheng Lu, MD Zaiping Jing, MD
8:26 — 8:31	Update On Total And Partial Aortic Arch Lesion Repairs With The Gore TAG Single Branch Endograft: An Off-The-Shelf (OTS) Device For Revascularizing Arch Branches: Experience To Date, Advantages And Limitations Michael D. Dake, MD Himanshu Patel, MD Joseph E. Bavaria, MD
8:32 — 8:37	How Best To Treat TBADs Extending Into The Arch Or Ascending Aorta; When Open, When Endo, When Hybrid I-Hui Wu, MD, PhD
8:38 — 8:43	A New Device For Endovascular Aortic Arch Reconstruction: Characteristics, Advantages And Early Clinical Results Chang Shu, MD
8:44 — 8:49	How Best To Treat Aortic Arch Lesions: Customized Versus Off-The-Shelf (Chimney) Versus Physician Modified Endografts: Is Open Repair Ever Necessary Nicola Mangialardi, MD
8:50 — 8:55	Value Of Ascending Aortic Banding As Primary Or Adjunctive Treatment For Aortic Arch Lesions Chun Che Shih, MD, PhD
8:56 — 9:02	Panel Discussion
PROGRES OF AORT	(Grand Ballroom East, 3rd Floor) SS IN THE ENDOVASCULAR TREATMENT TC DISSECTIONS: REPORTING RDS, CLASSIFICATION SYSTEMS, STABILISE, DRE
	Michael D. Dake, MD Joseph V. Lombardi, MD Hazim J. Safi, MD
9:02 — 9:07	Guideline Update On The SVS-STS Aortic Dissection Reporting Standards And Classification System: How Do They Help In Precisely Determining High Risk TBAD Patients Joseph V. Lombardi, MD
9:08 — 9:13	Important Bullet Points Regarding Aortic Dissections From The European Association For Cardiothoracic Surgery: What Is New About Them Martin Czerny, MD

9:14 - 9:19

	Stent-Graft Designed Specifically For Aortic Dissections Weiguo Fu, MD
9:20 - 9:25	New Findings Regarding The STABILISE Concept For Treating Acute And Chronic TBADs By Disrupting The Intimal Flap By Overdilating The Distal Bare Stent: How It Works, Precautions, And Should It Be The Treatment Of Choice Jean-Marc Alsac, MD, PhD
9:26 — 9:31	Updated Experience With The STABILISE Technique For Acute And Subacute TBADs: Indications, Technical Tips, Precautions And Results Andrea Kahlberg, MD Germano C.G. Melissano, MD Roberto L.V. Chiesa, MD
9:32 — 9:37	Dual Lumen Interventions To Promote False Lumen Thrombosis In Chronic Aortic Dissections: The FLIRT Procedure: What Is It; When Is It Useful; How To Do It <i>Christoph A. Nienaber, MD, PhD</i>
9:38 — 9:43	There Will Always Be A Need For Open Repair For Post-Dissection TAAAs: In What Circumstances <i>Hazim J. Safi, MD</i>
9:44 — 9:49	Distal Stent-Graft Induced New Entry Tears (SINEs) With TEVAR Treatment Of TBADs: Prevention By Avoiding Oversizing And Ballooning And Using Tapered Endografts Ludovic Canaud, MD, PhD
9:50 - 9:55	The Impact Of Distal Stent-Graft Induced New Entry Tears (SINEs) On Aortic Remodeling Of Chronic TBADs: How To Prevent And Treat Them Chun Che Shih, MD, PhD
9:56 — 10:01	Highlights From The New SVS, AATS, AHA, ACC, ACR, STS, SVM, SCAI, SCA Aortic Disease Guidelines: What Are The Key Differences <i>James H. Black</i> , <i>III</i> , <i>MD</i>
10:02-10:07	International Experience With Endovascular Treatment Of Complex Aortic Diseases In Patients With Connective Tissue Disease (CTD) Including Loeys-Dietz And Ehlers-Danlos Syndromes: What Is Its Role Anders Wanhainen, MD, PhD (PowerPoint Presentation With Synched Audio)
10:08-10:14	Panel Discussion
10:14-10:24	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
MORE NE OF TBAD THORAC	(Grand Ballroom East, 3rd Floor) EW DEVELOPMENTS IN THE TREATMENT IS, THORACIC AORTIC DISEASE AND OABDOMINAL ANEURYSMS (TAAAs)
moaerators:	Jean M. Panneton, MD Eric L.G. Verhoeven, MD, PhD

Michael J. Jacobs, MD

Margaret Tracci, MD, JD

When Should Fully Open Repair Be First Line Treatment For TAAAs And When Should A Hybrid (Endograft Proximal + Open Distal) Be The Preferred

Treatment: How To Do The Latter

Imperfect TEVAR Stent-Graft Performance As A Cause Of Aortic Remodeling: How It Can Be Prevented And Treated With The Chinese Fabulous® Thoracic Aortic

10:24-10:29

10:30-10:35	New Strategies And Indications For Open TAAA Repair Including Failed EVAR And F/B/EVAR: Technical Tips And Results Andrea Kahlberg, MD Germano C.G. Melissano, MD Roberto L.V. Chiesa, MD
10:36-10:41	Update On Aortic Arch Repairs With Frozen Elephant Trunk (FET) Followed By Open Or Endo Extensions For TAAA Repairs: Techniques And Outcomes; Importance Of Staging Michael J. Jacobs, MD Barend M.E. Mees, MD, PhD Geert Willem H. Schurink, MD, PhD
10:42-10:47	New Findings From The STABLE I And II Trials: What Are The Short And Long-Term Benefits And Limitations Of A Distal Bare Stent Combined With A Proximal Covered Stent (The Petticoat Procedure): Update On Aortic Remodeling Joseph V. Lombardi, MD
10:48-10:53	25 Years Of Data From The IRAD Registry (International Registry of Acute Aortic Dissection): How Has Treatment Evolved; What Lessons Have Been Learned: What Key Questions Remain Santi Trimarchi, MD, PhD
10:54-10:59	F/B/EVAR For TAAAs Degenerative And Post TBAD: The Good, Bad And Ugly: Complications And How To Prevent Them: Value Of The BeBack Catheter To Cross The Dissection Flap Eric L.G. Verhoeven, MD, PhD Athanasios Katsargyris, MD
11:00-11:05	Experience With Inner And Outer Branched Endografts And The t-Branch OTS Device (Cook) To Treat TAAAs After TBADs: Technical Tips And Results Marcelo Ferreira, MD (PowerPoint Presentation With Synched Audio)
11:06-11:12	Panel Discussion
11:12-11:17	Update On The Endovascular Treatment Of Ascending Aortic Disease With The Gore Ascending Aortic Endograft: Advantages, Limitations And Results From The ARISE Trial Ali Azizzadeh, MD
11:18-11:23	Unitary Manifold Endograft System For Complex Type 4 TAAAs, Aneurysms With Chronic TBADs, Ruptured Complex AAAs And Failed Prior EVAR Repairs: How Does It Work And Up To 10-Year Results Patrick W. Kelly, MD (PowerPoint Presentation With Synched Audio)
11:24-11:29	With Acute Type A Aortic Dissection (TAAD) And End-Organ Ischemia, Which Should Come First – Aortic Repair Or Restoration Of Branch Perfusion: How To Accomplish The Latter David M. Williams, MD (PowerPoint Presentation With Synched Audio)
11:30-11:35	Improved Aortic Remodeling With TEVAR And A Distal Bare Metal Stent In Acute Complicated TBAD Christoph A. Nienaber, MD, PhD
11:36-11:41	Endovascular Thermal Septotomy Of The Dissection Flap With An Electrocautery Activated Guidewire To Eliminate And Prevent Enlargement Of The False Lumen To Treat Chronic TBADs: Is There A Downside Carlos H. Timaran, MD.

11:42-11:47	Current Status Of A Catheter Aortic Septotomy Device For Treating Aortic Dissections By Cutting The Septum From Below: Yes, There Is A Downside To Other Septotomies That Cut The Septum From Above Ramon Berguer, MD, PhD
11:48-11:53	With Acute Type B Aortic Intramural Hematomas (IMHs): When Is TEVAR Indicated: How Long Should Treatment Be Delayed For Optimal Outcomes: Earlier TEVAR Has More Adverse Events <i>Jean M. Panneton, MD</i>
11:54-12:00	Panel Discussion
12:00- 1:00	Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors)
NEW DEV	(Grand Ballroom East, 3rd Floor) VELOPMENTS IN ABDOMINAL AORTIC SM (AAA) ETIOLOGY AND TREATMENT, D EVAS (ENDOVASCULAR ANEURYSM
	Caron B. Rockman, MD Michel Makaroun, MD Grace J. Wang, MD, MSCE
1:00 — 1:05	Failing EVARs Are An Enlarging Epidemic: Etiology And How Best To Prevent And Treat The Problem: Can Cloud Based Fusion Help $Murray\ L.\ Shames,\ MD$
1:06 — 1:11	What Evidence Really Matters In Evaluating EVAR Results: What Is The Best Type Of Evidence To Compare EVAR With Open Repair: RCTs May Not Reflect Reality As Well As Other Methods: The NICE Guidelines Prove It
1:12 – 1:17	Matt M. Thompson, MD Are There Registry Differences In Neck Behavior And AAA Sac Shrinkage After Excluder And Endurant Endografts: Why We Need A Head-To-Head Randomized Comparison After EVAR With The 2 Endografts: The ADVANCE RCT Marc L. Schermerhorn, MD Hence J.M. Verhagen, MD, PhD
1:18 — 1:23	Observation Of Small AAAs (<5.0 cm) Is Safe, Predictable And Does Not Reduce EVAR Options: Are There Exceptions And Does AAA Volume Matter Jon S. Matsumura, MD
1:24 — 1:29	Update On A Novel New Endovascular Technology (Nectero) To Slow AAA Growth; How Does It Work And 3-Year Clinical Results: Status Of The STAAABLE RCT And Recent Approval Of FDA Fast Track Designation Venkatesh G. Ramaiah, MD Daniel G. Clair, MD Andrew Holden, MBChB
1:30 — 1:35	Why And When EVAR Is NOT The Best Treatment For All AAAs Even With Favorable EVAR Anatomy: When Open And When No Treatment Is Better Fabio Verzini, MD, PhD
1:36 - 1:42	Panel Discussion

A Note Of Caution Regarding Nellix Endografts And

	EVAS From The European Society for Vascular Surgery (ESVS) Guidelines Committee Jonathan R. Boyle, MD Nikolaos Tsilimparis, MD, PhD Isabelle Van Herzeele, MD, PhD Anders Wanhainen, MD, PhD
1:48 — 1:53	Short And Long-Term Results For Endovascular Therapy For Infected Aortic Aneurysms At Various Levels: A 17-Year, 163-Case Experience: EVAR Can Work Boonprasit Kritpracha, MD
1:54 — 1:59	Sac Dynamics After EVAR Influence Long-Term Survival: What Can Be Done To Improve AAA Sac Shrinkage: Filling The Sac With Polymer Plugs From Shape Memory Medical Promotes Sac Shrinkage: Update On The AAA-SHAPE Study Michel M.P. Reijnen, MD, PhD Andrew Holden, MBChB
2:00 — 2:05	Update On Long-Term Results From The DREAM RCT Comparing EVAR With Open Repair For AAAs Suitable For Both: Adverse Neck Anatomy (Short, Wide, Angulated) Was Associated With Increased Reintervention And Mortality Rates Equally After Open And Endo Repairs: How Should This Influence Treatment Jan B. Blankensteijn, MD
2:06 — 2:11	Management Of The Internal Iliac Artery With Extensive Aorto-Iliac Aneurysms In The Era Of Iliac Branched Devices: Is There Any Role For Open Surgery Heron E. Rodriguez, MD
2:12 - 2:17	Danger Of Performing EVAR In Patients With Visceral Artery (SMA) Occlusive Disease: What Can Happen And How Should It Be Avoided Karan Garg, MD Neal S. Cayne, MD Carlos H. Timaran, MD Frank J. Veith, MD
2:18 — 2:23	Which AAA Patients Should Get Open Repair (OR) In 2023: Young Healthy Patients With Large AAAs Do Better With OR: But EVAR Outcomes Are Improving While OR Outcomes Are Not Marc L. Schermerhorn, MD
2:24 - 2:30 2:30 - 2:40	Panel Discussion Break - Visit Exhibits And Pavilions (2nd and 3rd
2.00 2.40	Floors)
MORE AE AND COI GUIDELIN	(Grand Ballroom East, 3rd Floor) BOUT AAAS AND EVAR, STANDARD MPLEX: UPDATES ON THE UK NICE AAA NES AND OTHER AORTIC PATHOLOGY Maarit Venermo, MD, PhD Dittmar Böckler, MD Mark A. Adelman, MD
2:40 — 2:45	The Safe-AAA Study Emphasizes The Importance Of Ongoing Surveillance And Continuing EVAR Device Risk: Some EVAR Endografts Have Been Found To

Have More Late Risks Than Others Philip P. Goodney, MD, MS Eric A. Secensky, MS, MSc

1:42 - 1:47

	Support Or Refute The NICE AAA Guidelines Andrew W. Bradbury, MD
2:52 — 2:57	How Have The NICE AAA Guidelines Influenced The Performance Of EVAR In The UK: Are The Guidelines Wrong And Can They Be Fixed Michael P. Jenkins, MBBS, BSc, MS
2:58 — 3:03	Why The NICE AAA Guidelines Are The Way They Are: Bias Has Played A Role As It Does In Many Things: Randomized Controlled Trials (RCTs) Can Be Misleading Frans L. Moll, MD, PhD
	TOPICS RELATED TO INFRARENAL AORTIC LESIONS AND AAAs
3:04 — 3:09	Spontaneous Infrarenal Acute Aortic Syndrome: What Is It And Why Is It Best Treated With A Unibody Stent-Graft Felice Pecoraro, MD
3:10 — 3:15	Diabetes Versus COVID-19: How Should Both Modify AAA Treatment Or Its Planning Ronald L. Dalman, MD
3:16 — 3: 21	How Does Metformin Work To Slow AAA Growth: Is It The Reason For Decreased AAA Incidence In Diabetes Kak Khee Yeung, MD, PhD
3:22 - 3:27	The Metformin For AAA Growth Inhibition (MAAGI) Multicenter Trial: Design And Preliminary Results: Will The Drug Help In The Treatment Of Small AAAs Anders Wanhainen, MD, PhD (PowerPoint Presentation With Synched Audio)
	TOPICS RELATED TO COMPLEX AORTIC PATHOLOGY
3:28 — 3:33	Value Of IVUS In Treating Complex Aortic Pathology Andres Schanzer, MD
3:34 — 3:39	Early Experience With Off-The-Shelf Inner Branch Stent Grafting For Suprarenal AAAs And TAAAs
	Dittmar Böckler, MD
3:40 — 3:45	With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It Successfully
3:40 - 3:45 3:46 - 3:56	With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It
3:46 – 3:56 SESSION 7 MORE NE OF AORT PREVENT	With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It Successfully Andres Schanzer, MD
3:46 – 3:56 SESSION 7 MORE NE OF AORT PREVENT	With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It Successfully Andres Schanzer, MD Panel Discussion (Grand Ballroom East, 3rd Floor) EW DEVELOPMENTS IN THE TREATMENT TIC AND THORACIC PATHOLOGY; STROKE TION WITH TEVAR Mark A. Farber, MD Manju Kalra, MBBS
3:46 – 3:56 SESSION 7 MORE NE OF AORT PREVENT Moderators:	With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It Successfully Andres Schanzer, MD Panel Discussion (Grand Ballroom East, 3rd Floor) EW DEVELOPMENTS IN THE TREATMENT IC AND THORACIC PATHOLOGY; STROKE ION WITH TEVAR Mark A. Farber, MD Manju Kalra, MBBS Thomas L. Forbes, MD How To Predict Failed Proximal EVAR Fixation With Short Necked AAAs So Initial Treatment Should Be With F/EVAR Or Ch/EVAR

2:46 – 2:51 Review Of All Recent AAA Guidelines: Do They

4:08 — 4:13	High Risk Features In Uncomplicated TBAD Patients: How Do We Know They Justify Elective TEVAR Joseph V. Lombardi, MD Jeffrey P. Carpenter, MD
4:14 - 4:19	Current Role Of Physician Modified Endografts (PMEGs) For Total Endovascular Aortic Arch Repair Carlos H. Timaran, MD
4:20 — 4:25	How To Prevent Bird Beaking And Type I Endoleaks With TEVAR In The Aortic Arch: How To Size TEVAR Grafts Optimally And Does It Matter <i>Thomas L. Forbes, MD</i>
4:26 — 4:31	How Best To Treat TBADs Extending Into The Aortic Arch Or Ascending Aorta: When Open, When Endo, When Hybrid: Technical Tips <i>I-Hui Wu, MD, PhD</i>
4:32 — 4:37	Endovascular Aortic Arch Interventions: Hybrid Options Versus Total Endovascular Repair Cherrie Z. Abraham, MD
4:38 — 4:43	Long-Term (>5 Years) Good Results Of The Medtronic Valiant Captiva Endografts For TEVAR In TBAD Patients: Advantages And Disadvantages Nimesh Desai, MD, PhD Joseph E. Bavaria, MD
4:44 — 4:49	How To Treat Aortic Dissections With An Entry Tear In The Aortic Arch: Can Ancillary Techniques Help Santi Trimarchi, MD, PhD
4:50 — 4:56	Panel Discussion
MORE NE AND TEV TIMING O TBADs	(Grand Ballroom East, 3rd Floor) EW DEVELOPMENTS REGARDING TBADS 'AR: NATURAL HISTORY; NEED FOR AND OF TEVAR FOR ACUTE UNCOMPLICATED
Moderators.	Benjamin W. Starnes, MD Jon S. Matsumura, MD William D. Jordan, Jr., MD
4:56 — 5:01	Celiac Artery Orifice Coverage During TEVAR Is Not Always Benign: It Is Often Associated With Visceral Ischemia And Other Poor Outcomes Richard G.J. Gibbs, FRCS
5:02 — 5:07	What Does Endovascular Aortic Repair Do To Cardiac And Coronary Artery Function: Does The Position Of The Graft Make A Difference: Do We Need A Compliant Endograft Rachel E. Clough, PhD, FRCS
	DEBATE ON TREATMENT OF ACUTE UNCOMPLICATED TBADs
5:08 — 5:13	DEBATE: With Uncomplicated Acute TBADs, The Case For Waiting 2-6 Weeks From Onset For TEVAR And Then Limiting Aortic Coverage <i>Mark A. Farber, MD</i>
5:14 — 5:19	DEBATE : With Uncomplicated TBADs, The Case For Early TEVAR With Extensive Aortic Coverage In Most Patients William D. Jordan, Jr., MD
	Bradley G. Leshnower, MD

How To Prevent Abdominal Extension Of The False Lumen And TAAAs With TBADs: Does Early TEVAR

Help: What Other Techniques Show Promise

Rodney A. White, MD

5:20 - 5:25

	Its Timing In Predicting Outcomes With Acute Uncomplicated TBAD Patients: When Is Medical Treatment Alone Indicated Ali Azizzadeh, MD
5:32 - 5:37	With TBADs, Is True Lumen Compression Ever So Severe That It Negatively Influences TEVAR Deployment Or Performance: How Can It Be Managed Sara L. Zettervall, MD, MPH (PowerPoint Presentation With Synched Audio)
	Benjamin W. Starnes, MD
5:38 — 5:43	With TBADs, Distal Fenestrations Are Important: How Should They Be Treated <i>Frank R. Arko, MD</i>
5:44 — 5:49	Hybrid Surgical And Endovascular Staged Approaches For The Treatment Of Complex Aneurysmal Lesions Involving The Thoracic Aorta Francesco Setacci, MD
5:50 — 5:55	Re-Entry Specific Endovascular Therapy (RESET), i.e. TEVAR Plus Dealing With Re-Entry Tears: It Promotes False Lumen Thrombosis, Aortic Remodeling And Improves Outcomes: How To Do It <i>Jean M. Panneton, MD</i>
5:56 — 6:02	Panel Discussion End of Program A
PROGRAM B (SESSIONS 9-16) PROGRESS IN VASCULAR ROBOTICS, GUIDANCE SYSTEMS, LAPAROSCOPY, SIMULATION AND COVID; NEW DEVELOPMENTS IN CAROTID DISEASE AND ACUTE STROKE TREATMENT; ABDOMINAL AORTIC BRANCH TREATMENT; NEW TECHNOLOGY CONCEPTS AND ARTIFICIAL INTELLIGENCE (AI); VASCULAR SURGERY IDENTITY TRAINING, MANPOWER AND MENTORSHIP; UPDATES ON OPEN AND HYBRID VASCULAR SURGERY AND TREATMENT OF AORTIC COARCTATION Grand Ballroom West, 3rd Floor 6.47 – 6.50 Opening Remarks Enrico Ascher, MD	
PROGR LAPARO SIMULA	9 (Grand Ballroom West, 3rd Floor) ESS IN VASCULAR ROBOTICS, DSCOPY, GUIDANCE SYSTEMS AND ATION ors: Willem Wisselink, MD Barry T. Katzen, MD
6:50 — 6:55	How Can Ex Vivo Training With Simulators Decrease Vascular Complications And Improve Outcomes Michael E. Barfield, MD
6:56 — 7:01	Laparoscopic Aortic Surgery: How I Did It Routinely And Why I Stopped After More Than 150 Cases <i>Laurent Chiche, MD</i>
7:02 — 7:07	25 Years Of Robotic Vascular Surgery: If It Is So good, Why Isn't It Mainstream Now Willem Wisselink, MD

5:26 – 5:31 The Indication For TEVAR Is More Important Than

7:08 - 7:13	Focus On Radiation Protection During Simulation-
	Based Training Improves Both Correct Behavior And
	Procedural Performance: Proven By A Randomized
	Comparison
	Lars R Lann MD PhD (Dawar Daint Dragget ation With Synchol Audia)

Lars B. Lonn, MD, PhD (PowerPoint Presentation With Synched Audio)

7:14 – 7:19 Inside Out: Next Generation Technology That
Transmits Physical Intelligence And Parameters
Continuously From Within The Patient: How Will It
Help In Vascular Treatment
Barry T. Katzen, MD

RADIATION REDUCING IMAGING GUIDANCE TECHNIOUES

- 7:20 7:25 True Radiation Reduction Strategies For Complex Endovascular Procedures: FORS, Digital Zooming, IVUS, And Live Fusion Guidance Carlos H. Timaran, MD
- 7:26 7:31 Updated Experience With The Fiberoptic 3D Endovascular Guidance With The Fiberoptic RealShape (FORS) System (From Philips): Advantages And Limitations

 Joost A. van Herwaarden, MD, PhD
- 7:32 7:37 Update On The 3D Radiation Free Electromagnetic Intraoperative Positioning System (IOPS) From Centerline For Endovascular Guidance: Advantages And Limitations

 Francis Caputo, MD

 Matthew J. Eagleton, MD
- 7:38 7:43 New Findings Related To The Incidence Of Cancer After EVAR: What Causes It And How Can It Be Reduced

 Dittmar Böckler, MD

7:44 – 7:50 Panel Discussion

SESSION 10 (Grand Ballroom West, 3rd Floor)
NEW DEVELOPMENTS IN CAROTID DISEASE
AND ITS TREATMENT; DIFFERING VIEWS ON
TREATMENT OF ASYMPTOMATIC CAROTID
STENOSIS (ACS) AND CAROTID SCREENING

Moderators: Ali F. AbuRahma, MD Bruce A. Perler, MD, MBA

- 7.50 7.55 Update On International Variations In Carotid Stenosis
 Treatment Within Countries And Between Countries Is
 Huge Despite All The RCTs On Which They Are Based
 Being The Same: What Are The Implications
 Maarit Venermo, MD, PhD
- 7.56 8.01 Current Optimal Treatment For Carotid Artery
 Dissection: When Best Medical Therapy (BMT), When
 Open Surgery, When Carotid Stenting (CAS) With
 Proximal Embolic Protection
 Felice Pecoraro, MD
- 8:02 8:07 Intracranial Imaging For Strokes With A Newly Developed Imaging Platform Using Artificial Intelligence To Integrate All Forms Of Imaging To Facilitate Patient Care: The Viz.ai System Allan L. Brook, MD
- 8.08 8.13 Value Of Advanced Imaging In The Diagnosis And Treatment Of Near Total Occlusions And String Signs Of The Internal Carotid Artery (ICA): How Are They Best Treated: When Conservatively; When Invasively By CEA; By CAS

 Christos D. Liapis, MD

8:14 - 8:19

	Best Treated Currently: Conservatively, CEA, CAS In Symptomatic Patients: In Asymptomatic Patients Weiguo Fu, MD
8:20 — 8:26	Panel Discussion
	DIFFERING VIEWS ON TREATMENT OF ACS AND REIMBURSEMENT POLICY
8:26 — 8:31	DEBATE: ALL Asymptomatic Carotid Stenosis (ACS) Patients Are Best Treated Medically: Invasive Treatment Causes More Harm Than Good And Should Not Be Reimbursed <i>Anne L. Abbott, MD, PhD</i>
8:32 — 8:37	DEBATE: Not So: About 25% Of ACS Patients Can Benefit From CEA Or CAS And Should Be So Treated And Reimbursed Accordingly Bruce A. Perler, MD, MBA
8:38 — 8:43	DEBATE: Both Views Are Wrong: Severe Carotid Stenosis Has Declined As A Cause Of Ischemic Stroke To <1% Per Year: So <5% Of ACS Patients Should Be Treated Invasively <i>Robert W. Chang, MD</i>
	DIFFERING VIEWS ON CAROTID SCREENING
8:44 — 8:49	A Tribute To George S. Lavenson, MD (1932-2023) And His Case For Widespread Carotid Screening Benjamin W. Starnes, MD
8:50 — 8:55	The Case Against Carotid Screening: It Leads To Unneeded And Possibly Harmful Treatment Anne L. Abbott, MD, PhD
8:56 — 9:01	Screening For ACS And Common Femoral Artery Disease: How Can It Guide Lipid Treatment: How Low Should LDL-Cholesterol (LDL-C) Be Pushed And What Will It Do To Carotid Plaques Stavros Kakkos, MD Andrew N. Nicolaides, MS, FRCS
9:02 — 9:07	What Are The Effects Of A Minor Stroke With Apparent Full Recovery: Minor Strokes Are By No Means Minor: Why Is This Important In Evaluating The Conclusions Of RCTs Emmanuel M. Houdart, MD
9:08 — 9:15	Panel Discussion
9:15 — 9:30	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
	SOUT CAROTID AND VERTEBRAL DISEASE: ON INVASIVE TREATMENT FOR ACUTE
	Klaus D. Mathias, MD Allan L. Brook, MD
9:30 — 9:35	Carotid Artery Aneurysms: What Etiologies Cause Them; When Is Endovascular Treatment Best And Technical Tips For Doing So Successfully Peter L. Faries, MD
9:36 — 9:41	When After An Acute Stroke With Thrombolysis Treatment, Or Without, Should Carotid Endarterectomy (CEA) Be Performed: Delay Has Consequences: But CEA Within 48 Hours Of Symptom Onset Has A Higher Complication Rate <i>Maarit Venermo</i> , MD, PhD

What Is Carotid Near Occlusion: When And How Is It

	Thrombectomy For An Acute Stroke In Patients With Carotid Stenosis, Which Invasive Treatment (CEA Or CAS) Is Best And When Should It Be Performed Laura Capoccia, MD, PhD
	1
9:48 — 9:53	With Acute Strokes, What Is New With Endovascular Intracranial Techniques For Arterial Clot Removal: How Can Artificial Intelligence (AI) And Intraarterial Thrombolysis With Alteplase (Genentech) Help – What Is Happening With The CHOICE RCT Adnan H. Siddiqui, MD, PhD L. Nelson Hopkins, MD
9:54 — 9:59	How Does Temporal Access And A Through And Through Femoral Wire Facilitate CAS With A Difficult Aortic Arch: Technical Tips And Results Piotr Myrcha, MD, PhD
10:00-10:05	Update On Acute Stroke Interventions: Challenging Cases And Tips For Treating Them Successfully Kolja Sievert, MD Horst Sievert, MD
10:06-10:11	How Best To Treat An ICA Occlusion With Distal Embolization: Sequence And Timing Of Treatment: Site Of Treatment (OR Versus Angio Suite Versus Hybrid Room): Technical Tips Adnan H. Siddiqui, MD, PhD L. Nelson Hopkins, MD
10:12-10:17	Outcomes Of Carotid Interventions (CEA And CAS) In Women And Younger Patients: How And Why Do They Differ From Those In Men And Older Patients Caron B. Rockman, MD
10:18-10:23	Update On Endovascular Interventions In The Vertebrobasilar System For Acute Strokes: A New Horizon, What Is Involved And Results Ivo Petrov, MD, PhD
10:24-10:30	Panel Discussion
PROGRES AORTO-I	(Grand Ballroom West, 3rd Floor) SS IN THE TREATMENT OF AORTIC AND LIAC OCCLUSIVE DISEASE Daniel G. Clair, MD Wayne W. Zhang, MD Zhong Chen, MD
10:30-10:35	Life Altering Events After Endovascular Aortic Repairs Include Death, Dialysis, Paralysis Or Stroke: The Incidence Of These Events Varies Markedly Depending On The Level Of Repair Marc L. Schermerhorn, MD
10:36-10:41	Hidden Tricks For Diagnosing Iliac Endofibrosis In Professional Cyclists: Diagnosis Can Be Challenging And Require Unusual Techniques Gabriel Szendro, MD (PowerPoint Presentation With Synched Audio)
10:42-10:47	5-Year Update On The Value Of VBX Balloon Expandable Covered Stents In Treating Complex Aorto- Iliac Occlusive Disease: Advantages And Limitations: When And How Does Shockwave Lithotripsy Help Andrew Holden, MBChB
10:48-10:53	Value And Limitations Of The iCast Balloon Expandable Covered Stent (From Getinge) Recently FDA Approved For Treating Iliac Artery Lesions Jean M. Panneton, MD

9:42 – 9:47 After Thrombolysis And/Or Mechanical

COVERED ENDOVASCULAR RECONSTRUCTION OF THE AORTIC BIFURCATION (CERAB) PROCEDURE

- 10:54-10:59 Long-Term Outcomes Of The CERAB Procedure With Covered Stents For Complex Aorto-Iliac Occlusive Disease: Why It Is Better Than Kissing Bare Stents: Which Stent Should We Use

 Michel M.P. Reijnen, MD, PhD

 Peter C.J. Goverde, MD, PhD
- 11:00-11:05 The CERAB Technique: From A Niche Procedure To A Better General Solution For Complex Aorto-Iliac Occlusive Disease Based On The 2-Year Results Of The Multicenter BeGlory Registry

 Maria A. Ruffino, MD
- 11:06-11:11 Value Of Shockwave Intravascular Lithotripsy (IVL)
 For Calcified Aorto-Iliac Occlusive Disease Treatment
 And For Facilitating Large Bore Access With Narrowed
 Calcified Iliac Arteries
 Daniel G. Clair, MD
- 11:12-11:17 Panel Discussion
- 11:18-11:23 Impact Of Female Gender On Outcomes Of Endovascular Treatment Of Aorto-Iliac Occlusive Disease: When Is Open Repair Indicated Franco Grego, MD
- 11:24-11:29 Treatment Of Infrarenal And Pararenal Aortic Stenosis: When Stents; When Stent-Grafts; When Open Bypass: Why Results Are Worse In Women Sigrid Nikol, MD
- 11:30-11:35 Endovascular Treatment Of Aorto-Iliac Occlusions With Impotence (Leriche Syndrome): Long-Term Results: Is Open Repair Ever Needed Sonia Ronchey, MD, PhD
- 11:36 -11:41 **DEBATE:** How To Treat Chronic Flush Juxtarenal Aortic Occlusions Endovascularly With Safety: Endo Is The Way To Go

 David Minion, MD
- 11.42 -11.47 **DEBATE:** Not So: Open Or Hybrid Repairs Are Best For Complex Juxtarenal Aorto-Iliac Occlusive Disease: Technical Tips

 Yamume Tshomba, MD
- 11:48-11:53 What Is New In The Treatment Of External Iliac Artery Endofibrosis In Committed Cyclists: Is There A Role For Endovascular Treatment

 Margaret Tracci, MD, JD

 Kenneth J. Cherry, MD
- 11:54-12:00 Panel Discussion
- 12:00 1:00 Lunch Break Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 13 (Grand Ballroom West, 3rd Floor)
NEW CONCEPTS, MACHINE LEARNING AND
ARTIFICIAL INTELLIGENCE (AI)
(SEE ALSO SESSION 87)

Moderators: Barry T. Katzen, MD Kak Khee Yeung, MD, PhD

1:00 – 1:05 What Is Big Data In Vascular Surgery: How Can It Be Used With Artificial Intelligence (AI) In Evidence Based Medicine: How Can It Replace Randomized Controlled Trials (RCTs)

Jean-Baptiste Ricco, MD, PhD

	And Treatment With AI: How Can It Help With Prediction Of AAA Growth, Endoleaks And Spinal Cord Ischemia Kak Khee Yeung, MD, PhD
1:18 — 1:23	Update On How Vascular Treatment Will Intersect With Other New Technologies: Wearable Trackers, AI, And Using CT Scans To Predict Plaque Histology (ElucidVivo) David H. Deaton, MD
1:24 — 1:29	How Does An AI Based Prediction Of Rupture Risk Compare With Size Based Predictions Jes S. Lindholt, MD
1:30 — 1:35	Is Image Fusion Guidance For Complex And Simple Aortic Procedures Really Worthwhile And Cost Effective: Why Is It A Question And Do We Need A Trial Rachel E. Clough, PhD, FRCS
1:36 — 1:41	How Can AI Facilitate Assessment After EVAR And F/B/EVAR: Are Volume Measurements Before And After Endo Repairs Necessary Stephan Haulon, MD
1:42 — 1:47	High Fidelity Computational Modeling To Help With Decision Making In Carotid Stenosis Santi Trimarchi, MD, PhD
1:48 — 1:53	Update On Siemens I-Flow: A New Intelligent Technology To Improve The Endo Treatment Of Lower Extremity Occlusive Disease Ravi K. Veeraswamy, MD
1:54 — 1:59	For The Novice, How In Simple Terms Do The FORS, IOPS And Cydar Guidance Systems Work To Improve Endovascular Procedures And Reduce Radiation

Will Big Data Enhance Vascular Care

Enhancing Clinical Decision Making In AAA Diagnosis

Michael R. Jaff, DO

Peter C.J. Goverde, MD (PowerPoint Presentation With Synched Audio)
2:06 – 2:12 Panel Discussion

2.00 - 2.05

Mark A. Adelman, MD

Occlusive Disease

1:06 - 1:11

1:12 - 1:17

SESSION 14 (Grand Ballroom West, 3rd Floor)
PART 1: VASCULAR SURGERY'S NUMBERS AND
IDENTITY AND HOW TO MEET THE SPECIALTY'S
NEEDS FOR ITS SERVICES; THE IMPORTANCE OF
MENTORSHIP IN VASCULAR SURGERY
PART 2: LATE BREAKING DEVELOPMENTS IN
COVID RELATED VASCULAR DISEASE ISSUES

How Can AI Help In The Treatment Of Aorto-Iliac

Moderators: Dawn M. Coleman, MD Jerry Goldstone, MD

> PART 1 – VASCULAR SURGERY'S NUMBERS AND IDENTITY AND HOW TO MEET THE SPECIALTY'S NEEDS FOR ITS SERVICES; THE IMPORTANCE OF MENTORSHIP IN VASCULAR SURGERY

2:12 – 2:17 What Makes Vascular Surgery Different, Are There Insufficient Numbers Of Vascular Trainees And Surgeons: How To Improve Our Identity And Recognition And Expand Our Numbers Evan C. Lipsitz, MD, MBA

2:18 — 2:23	Update On Applicants For 0+5 And 5+2 Vascular Surgery Training Programs: The Number Of Applicants Is Up: What About Their Quality: Do We Need More Programs Peter L. Faries, MD Dawn M. Coleman, MD
2:24 — 2:29	Increased Diversity In Vascular Surgery And Will It Improve The Shortage Of Vascular Surgeons Dawn M. Coleman, MD
2:30 — 2:35	How To Improve Vascular Surgery Stature And Well-Being Within An Institution By Transforming It Into Its Own Freestanding Department: What Benefits Accrue Jeffrey $H.\ Hsu,\ MD$
2:36 — 2:41	Progress Made By The American Board Of Vascular Surgery (ABVS) In The Last Several Years: Do We Still Need An Independent Board And How Should We Achieve It Alan M. Dietzek, MD
2:42 — 2:47	The Importance Of Mentorship In Vascular Surgery: How Best To Achieve It <i>Malachi Sheahan</i> , <i>MD</i>
2:48 - 2:53	Panel Discussion
	PART 2 – LATE BREAKING DEVELOPMENTS IN COVID RELATED VASCULAR DISEASE ISSUES
2:54 — 2:59	Current Developments In COVID-19 Prevention And Treatment: How Effective Are Current Vaccines, Boosters And Antiviral Therapies: Status Of Intranasal Vaccines And Antivirals: What Is New And What Is In The Pipeline Clayton J. Brinster, MD
3:00 — 3:05	Timing Of A Major Operative Intervention After A Positive COVID-19 Test Affects Postoperative Mortality: When To Retest And When Best To Intervene Panos Kougias, MD, MSc
3:06 — 3:11	COVID-19 Associated Arterial Events Are Worse In Non-Vaccinated Individuals: What Is The Role And Effectiveness Of Endovascular Therapy Michel Makaroun, MD
3:12 — 3:17	Is The COVID-19 Pandemic Behind Us: What We Know About Herd Immunity And The Lasting Effects Of Long COVID Clayton J. Brinster, MD
3:18 — 3:23	Panel Discussion
3:24 — 3:36	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
PROGRES RENAL A	(Grand Ballroom West, 3rd Floor) SS IN THE TREATMENT OF VISCERAL AND RTERY DISEASE James C. Stanley, MD Michael C. Dalsing, MD
3:36 — 3:41	DEBATE: All Visceral And Renal Artery Aneurysms Can Be Treated Endovascularly: Bare Stent Flow Diverters Are The New Frontier In Their Treatment Maria A. Ruffino, MD
3:42 - 3:47	DEBATE: Open Treatment Of Visceral And Renal

Artery Aneurysms Is Sometimes Best: When Is This So

Timur P. Sarac, MD

3:48 - 3:53Optimal Current Treatment Of Renal Artery Aneurysms: When Endo; When Open; Technical Tips Fred A. Weaver, MD, MMM 3:54 - 3:59The Vascular Low Frequency Consortium: What Is It And What Management Changing Information Does It Tell Us About The Size When Renal Artery Aneurysms Become Dangerous: It Is >3 cm In Diameter Peter F. Lawrence, MD 4:00 - 4:05Best Endovascular Techniques To Exclude Large Renal And Visceral Aneurysms Jacques Busquet, MD 4:06 - 4:11Update On The New SVS Practice Guidelines For Treating Visceral Artery Aneurysms; When Endo; When Open Rabih A. Chaer, MD 4:12 - 4:17Retrograde Open Mesenteric Stenting (ROMS): It Is Indicated With Peritoneal Signs And When Prograde Stenting Is Not Possible: Tips To Gain Retrograde Access To The SMA Richard I. Powell, MD 4:18 - 4:23With Acute Mesenteric Ischemia With Necrotic Bowel, Open Treatment With SMA Bypass Using A Deep Vein Conduit Is An Option Patrick A. Stone, MD 4:24 - 4:29Technical Tips For Recanalizing Long Complex Visceral Artery (SMA) Occlusions Armando Mansilha, MD, PhD 4:30 - 4:36Panel Discussion SESSION 16 (Grand Ballroom West, 3rd Floor) UPDATE ON OPEN VASCULAR SURGICAL AND HYBRID PROCEDURES: PROGRESS IN THE TREATMENT OF AORTIC COARCTATIONS Moderators: Linda M. Harris, MD Keith D. Calligaro, MD OPEN AND HYBRID VASCULAR SURGERY 4:36 - 4:41Open Conversion For Failing Suprarenal And Thoracic Endovascular Repairs: When Is Endo Rescue Not Possible And Open Conversion Necessary: Technical Francis J. Caputo, MD 4:42 - 4:47 When Is Open Treatment Of Complex Aorto-Iliac Occlusive Disease Best: Tips And Tricks For Doing It Safely In The Endovascular Era Timur P. Sarac, MD 4:48 - 4:53Technical Tips For Open Retroperitoneal Exposure Of The Aorta And All Its Abdominal Branches; How To Do A Retroperitoneal Aorto-Bifemoral Bypass Kamphol Laohapensang, MD Use Of Minimal Incisions For Retroperitoneal Aorto-4:54 - 4:59Bifemoral Bypass And Other Procedures: Technical Tips And Limitations Robert M. Proczka, MD, PhD 5:00 - 5:05Duplex Surveillance Should Be Used After All Open Aorto-Bifemoral Bypasses: How Does It Improve Outcomes

Keith D. Calligaro, MD

5:06 — 5:11	Open Treatment Of Infected Aortic Grafts And Endografts By Replacing ThemWith Rifampkin Soaked Dacron Or Cryopreserved Aortic Conduits: When Is Which Treatment Appropriate, And Results Manju Kalra, MBBS
5:12 — 5:17	Update On Renal Consequences Of Left Renal Vein Division During Open AAA Repair: It Is Not Always Benign Kimihiro Komori, MD, PhD
5:18 — 5:23	Open And Endovascular Treatment Of Intestinal, Renal, And Lumbar Artery Aneurysms In Children James C. Stanley, MD
5:24 - 5:30	Panel Discussion
	UPDATE ON COARCTATION TREATMENT
5:30 — 5:35	Endovascular Repair Of Aortic Coarctation: Balloon Angioplasty Versus Bare Stents Versus Covered Stents And When Is Open Repair Necessary Tilo Kölbel, MD, PhD
5:36 — 5:41	Update On The Experience With BeGrafts (From Bentley), A Balloon Expandable Covered Stent For Treating Aortic Coarctations: Advantages And Limitations Elchanan Bruckheimer, MBBS (PowerPoint Presentation With
	Elemantari Bruckneimer, MBBS (PowerFoint Presentation With Synched Audio)
5:42 — 5:47	Positive Remodeling In The Ascending Aorta As Well As Distally After TEVAR Treatment Of Aortic Coarctations Frank R. Arko, MD
5:48 — 5:53	Axillo-Unifemoral And Axillo-Bifemoral Bypasses Have Equal Patency For More Than A Year: Why The Bilateral Procedure Should Only Be Used When Bilateral Ischemia Exists Jeffrey J. Siracuse, MD, RPVI
5:54 - 5:59	Panel Discussion
	End of Program B
PROGRAM C-1 (SESSIONS 17-18) MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE TEAM APPROACH Trianon Ballroom, 3rd Floor Course Leader: Michael R. Jaff, DO	
MANAG THE ULT	(Trianon Ballroom, 3rd Floor) EMENT OF PULMONARY EMBOLISM: IMATE TEAM APPROACH — PART 1 Michael R. Jaff, DO
7:00 — 7:05	Introduction To The Symposium Frank J. Veith, MD
7:05 — 7:15	Welcome And Introduction Michael R. Jaff, DO
7:15 — 7:25	The Basics Of Pulmonary Embolism Diagnosis: What Is The Role Of The History, Exam, Biomarkers <i>Ido Weinberg, MD, MSc</i>
7:25 — 7:35	Do We Need An Echocardiogram To Manage Acute Submassive PE David M. Dudzinski, MD
7:35 — 7:45	Advanced Imaging For PE: How To Interpret The CT PE On The Run Brian B. Ghoshhajra, MD, MBA

7:45 — 7:55	Testing For Cancer And Other Hypercoagulable States In PE: Why, When, And What Tests Rachel Rosovsky, MD, MPH
7:55 — 8:10	Medical Treatment Of PE: When, Why, For How Long, And How Can I Remember <i>Luis H. Eraso, MD</i>
8:10 — 8:20	Intravenous Thrombolytic Therapy For PE: Does This Replace Catheter-Based Therapies Jay Giri, MD, MPH
8:20 — 8:35	An Overview Of Technologies For Management Of High-Risk PE
8:35 — 8:45	Eric A. Secemsky, MD, MSc Ultrasound-Assisted Pharmacomechanical Thrombectomy: Does This Really Work Kush R. Desai, MD
8:45 — 8:55	Percutaneous Mechanical Thrombectomy Without Lytics: The Indigo System Robert A. Lookstein, MD, MHCDL
8:55 — 9:05	Percutaneous Mechanical Thrombectomy Without Lytics: The Flowtriever System Mitchell D. Weinberg, MD
9:05 — 9:15	Large Bore Aspiration Thrombectomy: Tips, Tricks And Pearls Ripal T. Gandhi, MD
9:15 — 9:25	The Big Trials In PE: What's Running, What's Starting, What Will They Tell Us <i>Gary M. Ansel, MD</i>
9:25 — 9:40	Panel Discussion
Moderator:	Michael R. Jaff, DO
Panelists:	Gary M. Ansel, MD Kush R. Desai, MD Luis H. Eraso, MD Brian B. Ghoshhajra, MD, MBA Jay Giri, MD, MPH Raghu Kolluri, MD Robert A. Lookstein, MD, MHCDL Rachel Rosovsky, MD, MPH Eric A. Secemsky, MD, MSc Ido Weinberg, MD, MSc Mitchell D. Weinberg, MD
9:40 - 10:10	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
MANAGE THE ULTI	(Trianon Ballroom, 3rd Floor) EMENT OF PULMONARY EMBOLISM: MATE TEAM APPROACH — PART 2 Michael R. Jaff, DO
10:10-10:20	Contemporary Endovascular Strategies For Treatment Of Massive PE Christopher J. Kwolek, MD, MBA
10:20-10:30	ECMO-Assisted Pulmonary Embolectomy In Massive PE: Can It Replace Open Surgical Thrombolectomy Animesh Rathore, MD
10:30-10:40	Is There Anything New In Vena Cava Filters In PE Treatment John A. Kaufman, MD, MS
10:40-10:55	Your Referring Docs Think Heparin Is All They Need To Offer For PE – How To Tell The Intervention Story

Patrick Troy, MD

10:55-11:10 Pulmonary Denervation: A New Frontier In The Treatment Of Pulmonary Hypertension Mark G. Davies, MD 11:10-11:25 Balloon Pulmonary Angioplasty For Chronic Thromboembolic Pulmonary Hypertension: Has This Become Mainstream Kenneth Rosenfield, MD 11:25-11:35 The Team Approach To PE Management: The National PERT Consortium William B. Keeling, MD Challenging The Experts: Interactive Q&A 11:35-12:00 Moderator: Michael R. Jaff, DO Panelists: Mark G. Davies, MD Kush R. Desai, MD Jay Giri, MD, MPH Robert A. Lookstein, MD, MHCDL John A. Kaufman, MD, MS William B. Keeling, MD Christopher J. Kwolek, MD, MBA Animesh Rathore, MD Kenneth Rosenfield, MD Eric A. Secemsky, MD, MSc Patrick Troy, MD Ido Weinberg, MD, MSc 12:00 - 1:00Lunch Break - Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) **End of Program C-1** PROGRAM C-2 (SESSIONS 19-22) INTERESTING TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS Trianon Ballroom, 3rd Floor SESSION 19 (Trianon Ballroom, 3rd Floor) HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS

Moderators: Cynthia K. Shortell, MD Joseph L. Mills, MD

1:00 – 1:05 Key Points From The SVS Appropriate Use Criteria For Management Of Intermittent Claudication: Are Invasive Treatments Being Overused And Will These Criteria Help Jessica P. Simons, MD, MPH Karen Woo, MD, PhD

1:06 – 1:11 What Are The Dangers Of Working In An Office Based Lab (OBL): Why I Chose Not To Work There Dipankar Mukherjee, MD

1:12 – 1:17 Real Five-Year Single Center Results With Atherectomy
For De Novo Lower Extremity Lesions And In Stent
Restenosis: How Good Or Bad Are They
Russell H. Samson, MD

1:18 – 1:23 Intravascular Lithotripsy (From Shockwave) For Peripheral Arterial Occlusive Lesions: What Are The New Systems (L6 And M5+) For Delivering And What Are The Advantages

Andrew Holden, MBChB

1:24 – 1:29 How Do SoundBite Wires (From SoundBite Medical) Help To Cross Calcified Lesions, Especially BTK: Updated Experience

Marianne Brodmann, MD

1:30 — 1:35	Alternate Anatomic Approaches To Lower Extremity Arteries When Standard Approaches Are Prevented By Scarring Or Infection Neal S. Cayne, MD
1:36 — 1:41	Updated Status And Prospects For Sirolimus Coated Devices And Bioresorbable Stents ATK And BTK Marianne Brodmann, MD
1:42 — 1:47	Advances In Deep Venous Arterialization Techniques: Better Access, Procedure Maintenance And Wound Care Matter For Limb Salvage In No Option CLTI Patients Anahita Dua, MD, MS, MBA
1:48 — 2:04	Panel Discussion
MORE HO	(Trianon Ballroom, 3rd Floor) DT NEW TOPICS RELATED TO LOWER TY OCCLUSIVE DISEASE AND ITS
TREATME Moderators:	. N Vincent I. Rowe, MD Marianne Brodmann, MD
2:04 — 2:09	How To Train Vascular Surgeons In Distal Bypass Procedures In 2023: How Many Cases Are Needed To Achieve Competence Francesco Spinelli, MD
2:10 — 2:15	Novel Uses Of Selective Superficial Venous Arterialization To Achieve Lower Limb Salvage: Techniques, Indications, Precautions And Results John M. Felder, MD Patrick J. Geraghty, MD
2:16 — 2:21	Coagulation Testing To Allow Optimal Thromboprophylaxis And Decrease Thrombosis Rates In Lower Extremity Grafts And Stents Anahita Dua, MD, MS, MBA
2:22 — 2:27	Fractional Flow Reserve (FFR) In Claudicants And CLTI Patients: The Value Of Physiology Over Anatom In The Fempop Segment Konstantinos Katsanos, MD, PhD, MSc
2:28 - 2:33	Pedal Acceleration Time (PAT): What Is It And Its Feasibility And Utility As An Assessment Tool For Limb Ischemia And Adequacy Of Revascularization Procedures Vincent I. Rowe, MD
2:34 — 2:39	What Are The Best Ways To Evaluate CLTI Treatment Outcomes: Physiology (ABIs And PVRs), Wound Healing, Anatomy (Angiography Or Ultrasound), MACE Or MALE: Why It Matters <i>Ido Weinberg, MD, MSc Mitchell D. Weinberg, MD</i>
2:40 — 2:45	For Intermittent Claudication, What Endovascular Revascularization Strategies Are Currently Justified For Aortoiliac And Femoropopliteal Artery Disease: From A Meta-Analysis *Iris Baumgartner*, MD**
2:46 — 2:52	Panel Discussion
2:52 — 3:00	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

HOT NEV EXTREMI	(Trianon Ballroom, 3rd Floor) V TOPICS RELATED TO LOWER TY OCCLUSIVE DISEASE Neal S. Cayne, MD Gary M. Ansel, MD
3:00 — 3:05	Pillars For Success With Radial Artery Access For Remote Visceral, Renal Or Lower Extremity Lesion Treatment Marcelo Guimaraes, MD, MBA
3:06 — 3:11	Value And Technical Tips To Make The Supera Stent Work In Tortuous And Angulated Non-SFA Lesion Locations Rajiv Parakh, MBBS, MS
3:12 — 3:17	Non-Aspiration Based Mechanical Thrombo- Embolectomy With The Pounce (From Surmodics) Or Rotarex (From BD) Devices: How Do They Work And What Will Their Role Be In Treating Acute Limb Ischemia Gary M. Ansel, MD
3:18 — 3:23	Pedal Bypass As A Bail Out After Failed Or Compromised Retrograde Access: Rescuing A Threatened Limb After Bridges Burned Palma M. Shaw, MD, MBA
3:24 — 3:29	Technical Tips For A Successful BTK Intervention In Patients With CLTI Including How To Perform An Antegrade Femoral Artery Puncture And Pass The Guidewire Into The SFA Ali Amin, MD, RVT
3:30 — 3:35	Tips And Tricks To Make Distal Bypasses Work In The Endo Era: When If Ever Might In Situ Techniques Be Worth The Effort Kellie R. Brown, MD
3:36 — 3:41	Local Anesthetic Injection Into Lesion Site Facilitates PTA And Stent Placement: How To Do It (Video Presentation) Andrej Schmidt, MD
3:42 - 3:47	Panel Discussion
3:47 - 3:52	Does Atherectomy Still Have Value After Shockwave Lithotripsy Treatment Of A Calcified Occlusive Lesion Lawrence A. Garcia, MD
3:53 — 3:58	When Should Common Femoral Occlusive Disease Be Treated Endovascularly Based On The CONFESS Trial Hany Zayed, MD
3:59 — 4:04	The Deeper Limus Trial Using A Limus Coated Temporary Spur Balloon (From Reflow Medical): How Does The Device Work And Preliminary Results <i>Marianne Brodmann</i> , <i>MD</i>
4:05 — 4:10	Heel Ulceration And Ischemic Gangrene Involving The Achilles Tendon Should Not Be An Indication For A BTK Amputation: Revascularization And Appropriate Local Treatment Can Save Such A Limb Mark G. Davies, MD
4:11 — 4:16	Popliteal Artery-To-Distal Bypass For Limb Salvage; Status In 2023: Technical Tips And Value: When Is It Better Than Endovascular Treatments Francesco Spinelli, MD
4:17 - 4:23	Panel Discussion

SESSION 22 (Trianon Ballroom, 3rd Floor) MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND CHRONIC LIMB THREATENING ISCHEMIA (CLTI) Moderators: Brian G. DeRubertis, MD Caitlin W. Hicks, MD, MS 4:24 - 4:29CLTI Is A Global Epidemic; How Can A CLTI Program Decrease Its Morbidity Barry T. Katzen, MD 4:30 - 4:35Open And Endo Revascularization In Young Patients With PAD: What Works, What Doesn't, What Factors Impact Outcomes And How Should Treatment Be Modified William P. Robinson, MD 4:36 - 4:41 Is BEST-CLI Best For CLTI Patients And Interventional Treatments Lawrence A. Garcia, MD 4:42 - 4:47 Intravascular Lithotripsy And DCB Versus DCB Alone In The Treatment Of Infrapopliteal Lesions In Diabetics: Rationale And Design Of The DEBATE-BTK SHOCK RCT And Early Results Francesco Liistro, MD 4:48 - 4:53How To Size Lower Extremity Target Arteries For Endo Treatments Accurately Using Intravascular Ultrasound (IVUS): How Does It Help Jos C. van den Berg, MD, PhD 4:54 - 4:59Lower Extremity Interventions (PTA, Stents, Atherectomy) Under IVUS Guidance: Its Costs, Advantages And Limitations Ignacio Escotto, MD 5:00 - 5:06 **Panel Discussion** 5:06 - 5:11Overuse, Misuse, And Just Plain Inappropriate Use Of Lower Extremity And Other Endovascular Procedures: How Should The Vascular Community Police Itself To Prevent Such Procedures Michael S. Conte, MD 5:12 - 5:17Experience With >1500 Retrograde Recanalization For Chronic Total Occlusions (CTOs); What Predicts Technical Success And What Predicts Periprocedural Complications: Are Reentry Devices Ever Helpful Erwin Blessing, MD 5:18 - 5:23How To Avoid Or Manage Unexpected Catastrophes When Treating CLTI In The Operating Room Or Angio Robert B. McLafferty, MD, MBA 5:24 - 5:29Tibial Interventions For Intermittent Claudication: An Ethical And Professional Challenge For All Vascular Specialists And The Vascular Community Michael S. Conte, MD 5:30 - 5:35A New Technology (From AOTI) Combining Local Oxygen Therapy With Cycled Compression And Humidification Enhances Healing Of Diabetic Wounds And Ischemic Ulcers After Revascularization Anil P. Hingorani, MD Enrico Ascher, MD

TUESDAY/WEDNESDAY SESSION 22

5:36 – 5:41 Contemporary Comparative Results Of BTK Open Bypass Revascularization: Heparin Bonded PTFE Grafts Versus In Situ Or Reversed Vein Grafts: When Are PTFE Grafts To Tibial/Peroneal Arteries Worthwhile Carlo Pratesi, MD Giovanni Pratesi, MD

5:42 – 5:47 Nerve Block Without General Anesthesia Allows Safer Bypass Surgery For CLTI Even With High Risk Patients Nobuyoshi Azuma, MD

Nobuyoshi Azuma, MD

5:48 – 5:53

Techniques For Overcoming Problems With Subintimal Angioplasty For Chronic Total Occlusions (CTOs):
Like Inability To Re-Enter The True Lumen: Fancy Gadgets (Outback, Pioneer, Enteer, OffRoad) Are Almost Never Needed

Ali Amin, MD, RVT

5.54 – 5.59 How To Do Bypass Surgery To Heavily Non-Compressible Calcified Target Arteries Enrico Ascher, MD Frank J. Veith, MD

6:00 - 6:06 Panel Discussion End of Program C-2

WEDNESDAY, NOVEMBER 15, 2023

6:00 A.M. General Registration — Rhinelander Gallery, 2nd Floor 6:00 A.M. Faculty Registration — Gramercy Suite West, 2nd Floor 6:15 A.M. Continental Breakfast — Rhinelander Gallery, 2nd Floor

CONCURRENT WEDNESDAY PROGRAMS

PROGRAM D (SESSIONS 23-30)

Progress In Lower Extremity Occlusive Disease And Its Treatment 6:40 A.M. – 6:20 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM E (SESSIONS 31-38)

New Developments In Medical Treatments And New Drugs; Progress In Anti-Atherogenic And Anti-Hypertensive Treatments; Management Of Endoleaks; Recorded Live Cases From Leading Centers In The US And EU; Issues Of Interest; Outpatient And Office Based Vascular Treatment; Topics Related To Government, Reimbursement, The SVS, VQI, FDA, Guidelines, Trials And Evidence Based Medicine

6:40 A.M. - 6:30 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM F (SESSIONS 39-46)

More New Developments In Thoracic Aortic Disease, TEVAR, Aortic Dissections, TAAAs, Juxta- And Pararenal AAAs, Parallel Grafts, Fenestrated And Branched EVAR (F/B/EVAR), Multilayer Bare Stents, Infrarenal AAAs And Standard EVAR, And Hot New Aortic And Carotid Topics

6:50 A.M. - 6:30 P.M.

Trianon Ballroom, 3rd Floor

PROGRAM D (SESSIONS 23-30)

PROGRESS IN LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT

Grand Ballroom East, 3rd Floor

SESSION 23 (Grand Ballroom East, 3rd Floor)
GENERALITIES IN THE ENDOVASCULAR AND OPEN
TREATMENT OF LOWER EXTREMITY OCCLUSIVE
DISEASE AND CLTI

Moderators: Enrico Ascher, MD Andrej Schmidt, MD

- 6:40 6:45 How Do Prior Endovascular Interventions Affect Future Lower Extremity Bypass Outcomes For CLTI: Why Do The Results Of The BEST-CLI Trial Make This More Important

 Matthew T. Menard, MD
- 6:46 6:51 Do Diabetic Patients With CLTI And Extensive Foot Necrosis Have Time For An Endovascular First Strategy: Primary Open Bypass Is Better Treatment In This Setting Katariina M. Noronen, MD, PhD
- 6:52–6:57 Presenting Symptoms Of Lower Extremity Occlusive
 Disease And Intermittent Claudication Are Different In
 Women Than In Men: Why Is This Important
 Linda M. Harris, MD
- 6:58 7:03

 Selective Coronary Revascularization Based On
 Preop CT Fractional Flow Reserve (FFR_{CT}) Improves
 Long-Term Survival Of CLTI Patients After Lower
 Extremity Revascularization: When Should Coronary
 Revascularization Be Performed Before Or After The
 Lower Extremity Procedure
 Christopher K. Zarins, MD
 Dainis K. Krievins, MD
- 7:04 7:09 Why Does Medial Artery Calcification (MAC) Lead To Small Artery Disease (SAD): A Computational Based Analysis Of Lower Limb Blood Flow Reveals That Increasing Vascular Stiffness May Be Causative: Can Anything Be Done About It Roberto Ferraresi, MD

OPTIMAL TECHNIQUES FOR VESSEL PREP FOR ENDOVASCULAR TREATMENTS

- 7:10 7:15 Optimal Different Techniques Of Vessel Prep For Plain Old Balloon Angioplasty (POBA), Drug Coated Balloon (DCB) Treatment And Drug Eluting Stent (DES) Treatment Fabrizio Fanelli, MD
 - 7:16 7:21 Technical Tips For Vessel Prep For DCBs And DESs: It Is Different And Not Simple: Is Vessel Prep Currently Overrated

 Erwin Blessing, MD
- 7:22 7:27 New Devices And A New Paradigm For Treating Lower Extremity Arterial Lesions Via A Radial Approach: Can Lesions Below The Knee Be Treated Craig M. Walker, MD
- 7:28 7:33 What Are The Downsides To Trans-Radial Or Pedal Access

 Gary M. Ansel, MD

TECHNICAL TIPS ON GUIDEWIRE CHOICE AND USAGE

7:34 – 7:39 Tips For Treating Difficult BTK/BTA Lesions: How To Get A Guidewire Across A Long Calcified Occlusion, Getting A Resistant Balloon To Go Over The Wire And Tips For Retrograde Access

Marco G. Manzi, MD

7:40 - 7:45Guidewire Tips For Treating Lesions Below The Ankle (BTA): Sliding, Piercing, Dissecting, Retrograde Maneuvers

Roberto Ferraresi, MD

7:46 - 7:53**Panel Discussion**

SESSION 24 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN ATHERECTOMY, STENTS (UNCOATED, COATED AND BIORESORBABLE)

Moderators: Craig M. Walker, MD Iris Baumgartner, MD

PROGRESS IN ATHERECTOMY

- 7:53 7:58New Developments In Laser Atherectomy And Lithotripsy: What Progress Has Been Made And Are Their Benefits Proven George L. Adams, MD (PowerPoint Presentation With Synched Audio)
- 7:59 8:04Which Vascular Specialists Are Performing Tibial Atherectomies And Angioplasties For Intermittent Claudication And Are There Suboptimal Outcomes Caitlin W. Hicks, MD, MS
- 8:05 8:10Update On Optical Coherence Tomography (OCT) Guided Intraluminal Crossing Catheters (Avinger) For SFA Occlusions: Intraluminal Patency Superiority And New Data On The TigerEye Catheter Todd R. Vogel, MD, MPH
- 2-Year Experience With The Rotarex Atherectomy 8:11 - 8:16And Thrombectomy System (From BD) For Arterial Occlusive Disease And In Stent Restenosis (ISR): How Does It Work And Advantages Michael K.W. Lichtenberg, MD

UPDATE ON THE SUPERA STENT

- 8:17 8:23Update On The Advantages Of The Supera Vasculomimetic (VMI) Stent For Treating Long Complex Fempop Occlusive Lesions: Is There Value To DCB Vessel Prep First Peter C.J. Goverde, MD (PowerPoint Presentation With Synched Audio)
- 8:24 8:29 Update On The Supera Interwoven Stent: When Is It The Best Treatment And How To Optimally Deploy This Unique Stent D. Christopher Metzger, MD Craig M. Walker, MD

DRUG ELUTING STENTS (DESs) FOR BTK LESIONS

- 8:30 8:35Updated Experience With Everolimus And Other Nonabsorbable DESs To Treat Infrapopliteal BTK Lesions - Long And Short - Causing CLTI: What Are The Stents And How Are They Doing Robert A. Lookstein, MD, MHCDL
- 8:36 8:41Update On Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5 Years: From The DISAPEAR Registry And A Meta-Analysis Of Other Bioresorbable BTK Stent Results Steven Kum, MD Ramon L. Varcoe, MBBS, MS, PhD

8:42 - 8:47 Progress In And 1-Year Results Of The LIFE-BTK Randomized Controlled Comparison Of Abbott's Esprit Drug-Eluting Resorbable Stent With Plain Balloon Angioplasty (POBA) Ramon L. Varcoe, MBBS, MS, PhD Sahil A. Parikh, MD Brian G. DeRubertis, MD

8.48 – 8.53 Updated Results With A 3-French Compatible Microstent (From Micro Medical) For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: From The STAND RCT And The HEAL Registry Robert E. Beasley, MD Marco G. Manzi, MD

8:54 – 9:00 Panel Discussion

SESSION 25 (Grand Ballroom East, 3rd Floor)
LOWER EXTREMITY TOPICS RELATED TO DRUG
COATED BALLOONS (DCBs) AND DRUG ELUTING
STENTS (DESs)

Moderators: Kenneth Ouriel, MD, MBA Sahil A. Parikh, MD

- 9.00 9.05

 Older And More Recent Meta-Analyses Reveal
 Increased Mortality And Amputation Rates In Patients
 Receiving Paclitaxel Coated Devices Compared To
 Uncoated Devices: Are These Increased Rates Still
 Valid In View Of The Many Recent Studies That Do Not
 Confirm Them
 Konstantinos Katsanos, MSc, MD, PhD
 - 9.06 9.11 Large Population Based German Multicenter Study
 Of Paclitaxel Coated BTK DCBs And DESs Indicates
 Decreased Mortality And Amputation Rates Compared
 To Uncoated Devices
 Christian A. Behrendt, MD
 - 9.12 9.17 The Final Word On The Safety Of Paclitaxel Coated Balloons And Stents: Putting Together Observation, Randomized Trial And Meta-Analysis Derived Data Eric A. Secensky, MD, MSc Peter A. Schneider, MD
 - 9.18 9.23

 2-Year Results With The Sundance DCB (Surmodics)
 To Treat BTK Occlusive Lesions: From The SWING
 Trial
 Ramon L. Varcoe, MBBS, MS, PhD
 - 9.24 9.29 Update On DCBs For BTK Angioplasty: RCT
 Comparing A Paclitaxel DCB (Litos From Acotec)
 Versus A Sirolimus DCB (Magic Touch From Concept
 Medical): Rationale Of The Studies, Update On
 Enrollment And Interesting Cases In The DEBATE
 BTK DUELL RCT
 Francesco Liistro, MD
 Edward T. Choke, MD, PhD
 - 9.30 9.35 Progress With A Sustained Release Sirolimus DCB:
 Results With The Magic Touch DCB Compared To A
 Paclitaxel DCB: From The SIRONA Study
 Thomas Zeller, MD
 Andrej Schmidt, MD
 Dierk Scheinert, MD
 Marianne Brodmann, MD
 - 9.36 9.41 Adventitial Drug Delivery With The BullFrog Device (From Mercator Medical) And The Spur Device (From Reflow): How Do They Work And How Will We Know They Improve Results William A. Gray, MD
 - 9.42 9.47 The Light And Darkness Of Fluoropolymer-Based Limus DESs In The Treatment Of Femoropopliteal Lesions

 Osamu Iida, MD

9.48 – 9.53 Lower Extremity Endovascular Treatments: Who Is Performing Most Of Them And Where: Are They Overutilized And Why: How To Fix The Problem Russell H. Samson, MD

9.54 – 9.59 Are DESs Ever Associated With Aneurysmal Degeneration: Is It Related To The Drug (Paclitaxel Or Limus) Or To The Fluoropolymer Excipient To Which The Drug Is Attached Osamu Iida, MD

10:00-10:08 Panel Discussion

10:08-10:18 Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 26 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN DRUG COATED
BALLOONS (DCBs) AND DRUG ELUTING STENTS
(DESs): UPDATES ON RANDOMIZED CONTROLLED
TRIALS (RCTs) AND BTK LESION TREATMENTS
WITH DCBs AND DESs

Moderators: Joseph L. Mills, MD John R. Laird, MD

NEW INFORMATION ON DCBs AND DESS FOR FEMPOP LESIONS: UPDATES ON RCTs

10:18-10:23 DCB Treatment Of Femoropopliteal Lesions Causing CLTI (From Boston Scientific) Is Cost Effective: Based On A 2-Year Study Of Patients Treated With Ranger DCBs: Advantages Of An .018 Device Often Suitable For Radial Access

Ignacio Escotto, MD

10:24-10:29 Stellarex (Philips) DCBs With Low Dose Paclitaxel Is Safe And Has Higher Patency Rates Than POBA With De Novo Or Recurrent Fempop Lesions At 5 Years In The ILLUMENATE US And European RCTs

Sean P. Lyden, MD Marianne Brodmann, MD Sahil A. Parikh, MD William A. Gray, MD

10:30-10:35

3-Year Results Of A RCT Comparing SurVeil DCBs (Surmodics) With In.Pact DCBs (Medtronic) For Treating Fempop Lesions: From the TRANSCEND Trial

Peter A. Schneider, MD

10:36-10:41 New Findings From The DRASTICO Study Comparing DESs To DCBs For Fempop Lesions: 5-Year Results With TASC A/B Lesions Versus TASC C/D Lesions Francesco Liistro, MD

10.42-10.47 Value Of In.Pact DCBs (Medtronic) For Long Complex SFA-Pop Lesions Including ISR And CTOs: Technical Tips And Contraindications: From The Global Registry: What Is The Best Endo Treatment For These Lesions

Gunnar Tepe, MD Marianne Brodmann, MD

10.48-10.53 Update On The Randomized Head To Head
 Comparison Of In.Pact (Medtronic) And Ranger
 (Boston Scientific) DCBs For Complex SFA Lesions:
 3- And 4-Year Results Of The COMPARE RCT: Similar
 Results With Different Paclitaxel Dosages
 Dierk Scheinert, MD

Dierk Scheinert, ML Sabine Steiner, MD 10:54-10:59 Below The Ankle Endo Interventions In 2023: Techniques, Devices And Should Balloons Be Drug Coated Or Not Marianne Brodmann, MD New Information On The Safety And Effectiveness 11:00-11:05 Of The Cook Zilver PTX DES Based On An Updated Meta-Analysis And Global Data: When Is It The Best DES; When Is It The Best Treatment: Is Distal Microembolization A Concern Peter A. Schneider, MD William A. Gray, MD Sahil Parikh, MD Michael D. Dake, MD 11:06-11:11 Updated 5-Year Results Of The IMPERIAL RCT Head To Head Comparison Of The Eluvia DES (Boston Scientific) With The Zilver PTX DES (Cook): Both Are Safe And Effective: What Are The Differences Stefan Müller-Hülsbeck, MD William A. Gray, MD Thomas Zeller, MD 11:12-11:18 **Panel Discussion** NEW INFORMATION ON BTK DCBs AND DESs 11:18-11:23 Advances In BTK Drug Delivery Technology And DCBs: What Have We Learned From The In.Pact Deep BTK DCB Trial And New Challenges With Treating CLTI Patients Thomas Zeller, MD 11:24-11:29 5-Year Results From The AcoArt II BTK DCB RCT Show Safety With No Increased Mortality And Improved Patency Versus POBA To Treat BTK Lesions Wei Guo, MD (PowerPoint Presentation With Synched Audio) Francesco Liistro, MD 11:30-11:35 Orbital Atherectomy Vessel Preparation To Maximize DCB Efficacy In Calcified BTK Lesions: OPTIMIZE BTK RCT 2-Year Results Thomas Zeller, MD 11:36-11:41 The Sirolimus DCB BTK Era Begins: The SELUTION DCB (From MedAlliance And Cordis): Why The FDA Considered It A Breakthrough Device: Results From Singapore And Europe Are Promising And Justified The Ongoing SELUTION4BTK IDE Trial: Preliminary Results Patrick J. Geraghty, MD George L. Adams, MD Michael K.W. Lichtenberg, MD 11:42-11:47 Why Some BTK DCB Trials Have Not Shown Uniformly Better Results: Technical And Balloon Factors Matter Francesco Liistro, MD 11:48-11:53 Three-Year Results For The BioMimics 3D Swirling Flow Stent Show Why It Is The Most Cost-Effective Stent Of Choice For CLTI Patients Michael K.W. Lichtenberg, MD Bret Wiechmann, MD Amy Yip, PhD Peter A. Gaines, MD

11:54-12:00

12:00- 1:35

Panel Discussion

Celebratory Lunch Break - Rhinelander Gallery, 2nd Floor -Visit Exhibits & Pavilions (2nd and 3rd Floors)

SESSION 27 (Grand Ballroom East, 3rd Floor)
PROGRESS IN EXOTIC AND EXTREME NEW
TREATMENTS FOR VERY DISTAL LOWER
EXTREMITY DISEASE CAUSING ADVANCED
CLTI: OPTIONS TO SAVE THE "NO OPTION FOR
TREATMENT" LIMB AND THE "DESERT FOOT"

Moderators: Michael S. Conte, MD Marco G. Manzi, MD

- 1:35 1:40 DEBATE: IVUS Is Useful In The Majority Of Lower Extremity Interventional Treatments Eric A. Secensky, MD, MSc
- 1:41 1:46

 DEBATE: Not So: Peri-Procedural Duplex Scanning
 May Be Better And Cheaper Than IVUS For Improved
 Imaging In Most Lower Extremity Intervention
 Enrico Ascher, MD
 Natalie A. Marks, MD, RPVI, RVT
- 1.47 1.52 No Option CLTI: Why Is It A Misnomer: Hybrid And Other Actual Options For Treatment And Limb Salvage Hisham Rashid, FRCS

VALUE OF PROSTHETIC (PTFE) TIBIAL BYPASSES

- 1:53 1:58 What Are The Best Options For Limb Salvage When A Single Autologous Vein Is Inadequate: Does The BEST-CLI RCT Help

 Joseph L. Mills, MD
- 1:59 2:04

 PTFE Bypasses To Infrapopliteal Target Arteries Can Save Limbs In Patients Facing Imminent Amputation With No Other Therapeutic Option: They Can Have Worthwhile Long-Term Patency And Limb Salvage Rates: A Multicenter Experience

 Hasan D. Dosluoglu, MD
- 2:05 2:10 For Patients Facing Amputation With No Endo Options Or Useable Vein, PTFE Tibial Bypasses Are A Worthwhile Option That Yields Acceptable Mid-Term Patency And Long-Term Limb Salvage Rates R. Clement Darling III, MD
- 2:11 2:16

 Current Outcomes With PTFE Bypasses To
 Infrapopliteal (Tibial) Targets: Why Is There Variability
 Between Surgeons And Institutions: How Does The
 BEST-CLI Trial Help
 Matthew T. Menard, MD

UPDATE ON FOOT VEIN ARTERIALIZATION FOR CLTI

- 2:17 2:22 Long-Term View Of The Role And Value Of Vein Arterialization: Best Way To Do It And Late Results: From The First To Make It Work Pramook Mutirangura, FRCS
- 2:23 2:28 Endovascular And Surgical Venous Arterialization For REAL No Option Patients Facing Amputation From CLTI: Does Neo-Angiogenesis Occur Roberto Ferraresi, MD
- 2.29 2.34

 Pivotal US Trial (PROMISE II), US Feasibility Study (PROMISE I) And European 2-Year Registry Results With Deep Vein Arterialization Using The LimFlow Device For CLTI With Gangrene Shows Reasonable Limb Salvage And Wound Healing Daniel G. Clair, MD Andrej Schmidt, MD Daniela Branzan, MD

2:35 - 2:40What's New In Gene And Stem Cell Therapy For No Option CLTI In 2023 Richard J. Powell, MD

2:41 - 2:46Importance Of Open Surgical Procedures In A Limb Preservation Practice: What Are They And When Should They Be Used: It Is No longer About In Situ Vein Bypasses Richard F. Neville, MD

2:47 - 2:53**Panel Discussion**

SESSION 28 (Grand Ballroom East, 3rd Floor) NEW DEVELOPMENTS IN STENTS; PROSTHETIC GRAFTS; ENDOVASCULAR BYPASSES: STENT GRAFTS AND TREATMENT OF IN STENT RESTENOSIS (ISR)

Moderators: Timothy M. Sullivan, MD Mark A. Adelman, MD Anahita Dua, MD, MS, MBA

ARTERIAL PTFE BYPASSES

- Value Of Heparin Bonded PTFE Grafts For Femoral 2:53 - 2:58To Below-The-Knee Bypasses: A Systematic Review And Meta-Analysis: Are There Advantages To Propaten Grafts: Value To Crural Targets Yann Gouëffic, MD, PhD
- 2:59 3:04Improved Method For Restoring Patency To Occluded PTFE Bypasses Using A Fluoroscopically Guided Adherent Clot Remover (From Edwards): It's Less Invasive And More Effective Neal S. Cayne, MD Frank J. Veith, MD

PERCUTANEOUS BYPASSES

3:05 - 3:10Percutaneous (PQ) Transvenous Fempop PTFE Bypasses With The Torus 2 Device (Now From Endologix): How It Works And Updated Status Of The DETOUR And TORUS Trials In The US With 2-Year Results Sean P. Lyden, MD Daniel G. Clair, MD

Peter A. Schneider, MD

- 3:11 3:16Updated Late European Results Of The Detour PQ Fempop Arterial Bypass Routed Through The Femoral Vein From The DETOUR 1 Trial: Which Open Bypasses Will Be Made Obsolete Dainis K. Krievins, MD Peter A. Schneider, MD
- 3:17 3:22A Novel Technique For Percutaneous Extravascular Fempop Bypass - Routing A PTFE Graft Through The Soft Tissue Of The Thigh: It Is A Transcatheter Technique That Is Clampless, Sutureless, And Without External Exposure: How Is It Done; Advantages And Results Pierre Sarradon, MD

Jean-Pierre Becquemin, MD

3.23 - 3.28**Panel Discussion**

NEW INFORMATION ON STENT-GRAFTS

Can Viabahn Stent-Grafts Be Used Safely And 3:28 - 3:33Effectively In The SFA For CLTI: From Pooled Multicenter Data: What Are The Limitations Of These Devices Michel M.P. Reijnen, MD, PhD

3:34 – 3:39 Performance Of A New Generation Balloon
Expandable Stent-Graft (VBX from Gore) For
Peripheral Aneurysmal And Occlusive Disease As Well
As A Bridging Stent For F/B/EVAR
Rocco Giudice, MD
Ciro Ferrer, MD

TREATMENT OF IN STENT RESTENOSIS (ISR)

- 3:40 3:45 Update On The Excimer Laser For Treating ISR: It Has A Role In Crossing And Debulking Difficult Lesions: Technical Tips

 Craig M. Walker, MD
- 3.46 3.51 How Best To Treat Long Difficult Complex SFA Lesions Including Those From ISR

 Sonia Ronchey, MD, PhD
- 3.52 4:03 Panel Discussion And Break
 (Visit Exhibits And Pavilions 2nd and 3rd Floors)

SESSION 29 (Grand Ballroom East, 3rd Floor)
LOWER EXTREMITY TRIALS; GUIDELINES; FOOT
PERFUSION EVALUATION METHODS AND VALUE
OF ANGIOSOMES

Moderators: Brian G. DeRubertis, MD Mark K. Eskandari, MD Frank J. Veith, MD

- 4:03 4:08 The Japanese SPINACH Registry Confirms That Open Bypasses Are Superior To Endovascular Treatments In CLTI Patients When Ischemia And Infection Are Advanced Nobuyoshi Azuma, MD
- 4:09 4:14 The Global Vascular Guidelines And WIff Staging For CLTI Are Better Than Obsolete TASC Guidelines Because Treatment Recommendations, Revascularization Strategies And Needs For The Future Are Not Solely Based On Lesion Anatomy But Are Nuanced By Other Factors: What Are They Michael S. Conte, MD
- 4:15 4:20 Ancillary Outcomes Of The BEST-CLI RCT
 Comparing Endovascular And Open Treatment For
 CLTI When Both Treatments Are Feasible; What
 Are The Deficiencies In BEST-CLI And Why Might
 Interventionalists Claim It Is Misleading
 Alik Farber, MD
 Matthew T. Menard, MD
 Kenneth Rosenfield, MD
- 4:21 4:26 Why Many Interventionalists Believe The Conclusions Of BEST-CLI (Which Involved Mostly Fempop Treatments) Are Misleading Sahil A. Parikh, MD
- 4:27 4:32 Key Findings From The Just Completed BASIL 2 RCT Comparing Open And Endovascular Treatments For Severe Leg Ischemia From Mostly BTK Disease: How Do They Mesh With BEST-CLI Results

 Andrew W. Bradbury, MBChB, MD, MBA
- 4:33 4:38 Panel Discussion

METHODS FOR EVALUATING FOOT PERFUSION

4:39 – 4:44 How And Why To Measure Foot Perfusion During And After Endo Treatments: Hyperspectral Imaging, O₂ Sensors, Etc: When Is The Angiosome Concept Helpful; When Not Marianne Brodmann, MD

- 4:45 4:50 New Methods For Evaluating The Significance Of
 Lower Extremity Arterial Lesions And Foot Perfusion
 Using Fractional Flow Reserve (FFR) And MRI; How
 They Work And Their Value In Assessing Therapeutic
 Success
 Bijan Modarai, PhD
- 4.51 4.56 What Are The Best Methods For Measuring Foot Perfusion: They Are Invaluable In CLTI For Assessing Treatment Success And Predicting Healing Werner Lang, MD
- 4:57 5:02 Panel Discussion

SESSION 30 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN THE TREATMENT OF
INTERMITTENT CLAUDICATION (IC) AND ACUTE
LIMB ISCHEMIA (ALI)

Moderators: Matthew T. Menard, MD Marianne Brodmann, MD

INTERMITTENT CLAUDICATION (IC)

Synched Audio)

- 5:02 5:07 An RCT After 2 Years Showed That Stent Treatment For Intermittent Claudication (IC) Improves Quality Of Life More Than Medical Treatment And Exercise: Do The Long-Term Results Refute Or Negate The 2-Year Results

 Hans Lindgren, MD, PhD (PowerPoint Presentation With
- 5:08 5:13 At 2 Years After Endovascular Interventions For IC, Only 32% Of Patients Were Free From Recurrent IC: From A VQI Multicenter Study: What Are The Implications Peter F. Lawrence, MD Karen Woo, MD, PhD
- 5:14 5:19 When Are Invasive Vascular Treatments Justified For IC And When Are They Not: What Is The Evidence Caitlin W. Hicks, MD, MS

 James H. Black, III, MD
- 5:20 5:25 With Critical ALI, Catheter Based Aspiration
 Techniques Should Be Considered First-Line Therapy:
 When Should Other Treatments Be Used
 Matthew D. Wooster, MD, MBA
- 5:26 5:31 Panel Discussion

ACUTE LIMB ISCHEMIA (ALI) (See Also Session 63)

- 5:31 5:36 Key Points In The Diagnosis And Treatment Of ALI In The Lower Limbs: When To Use Endovascular Treatments And When To Use Open Treatments With Thrombectomy Or A Bypass Because Such ALI Is Always Associated With Chronic Occlusive Disease Martin Björck, MD, PhD
- 5:37 5:42 The PROMOTE-ALI Study Shows That Open Surgery Is Still Number One In The Treatment Of ALI Katariina M. Noronen, MD, PhD
- 5.43 5.48 Endovascular Mechanical Thrombectomy Is Obviating The Need For Thrombolytics In ALI: Which Device Is Best – When And Why Patrick E. Muck, MD

- 5:49 5:54

 Percutaneous Vacuum Thrombectomy For ALI:
 Devices And Techniques: In 2023 When Is There A
 Role For Thrombolytics, Angioplasty, Open Balloon
 Catheter Thrombectomy Or A Bypass
 Scott L. Stevens, MD
- 5.55 6.00 What Is New With Penumbra Indigo Clot Aspiration Systems: What Makes Them Different: Indications And Contraindications

 James F. Benenati, MD
- 6:01 6:06 Update On How To Treat ALI Under Duplex Ultrasound Guidance: Advantages And Limitations Natalie A. Marks, MD, RPVI, RVT Enrico Ascher. MD
- 6:07 6:12 The STRIDE Multicenter Trial Showed That Mechanical Suction Thrombectomy With The Indigo Aspiration System (Penumbra) For Lower Limb ALI Had A Low Complication Rate And Excellent Limb Salvage: When Was Angioplasty, Stenting Or A Bypass Necessary Thomas S. Maldonado, MD
- 6:13 6:20 Panel Discussion End of Program D

PROGRAM E (SESSIONS 31-38)
NEW DEVELOPMENTS IN MEDICAL TREATMENTS
AND NEW DRUGS; PROGRESS IN ANTIATHEROGENIC AND ANTI-HYPERTENSIVE
TREATMENTS; MANAGEMENT OF ENDOLEAKS;
RECORDED LIVE CASES FROM LEADING CENTERS
IN THE US AND EU; ISSUES OF INTEREST;
OUTPATIENT AND OFFICE BASED VASCULAR
TREATMENT; TOPICS RELATED TO GOVERNMENT,
REIMBURSEMENT, THE SVS, VQI, FDA, GUIDELINES,
TRIALS AND EVIDENCE BASED MEDICINE
Grand Ballroom West, 3rd Floor

SESSION 31 (Grand Ballroom West, 3rd Floor)
ADVANCES IN MEDICAL TREATMENTS, NEW ANTIATHEROGENIC DRUGS, VALUE OF RIVAROXABAN
AND PREVENTING MIS IN VASCULAR SURGERY
PATIENTS

Moderators: Peter Henke, MD Ido Weinberg, MD, MSc

- 6:40 6:45 When, Why And How To Lower High Triglyceride Levels: Value Of Vascepa To Decrease Cardiac Risk In Vascular Patients: Based On The REDUCE-IT RCT Jeffrey S. Berger, MD
- 6:46 6:51 New Strategies On How To Avoid And Treat Periprocedural Myocardial Infarctions (MIs) In Open Endo Vascular Surgery Patients Peter Henke, MD
- 6:52 6:57

 DEBATE: LDL Cholesterol (LDL-C) Lowering
 And Statins For Prophylaxis Of Vascular Events Are
 Dangerous And Not Helpful: What Does The Latest
 Evidence Show
 Sherif A.H. Sultan, MD

- 6:58 7:03 DEBATE: Not So: Update On LDL-C Lowering
 With Statins And Other Drugs Stabilizes And Shrinks
 Plaques And Decreases Morbid Vascular Events:
 Stopping Statins Increases Patients' Risk Of MI And
 Death
 Ron Waksman, MD
- 7:04 7:09 Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured

 J. David Spence, MD
- 7.10 7.15 LDL-C Lowering Should Be Maximized With High Dose Statins And Ezetimibe (Zetia) To Minimize Risks From Atherosclerotic Lesions: The LDL-C Level Cannot Be Too Low And Side Effects Are Minor: LDL-C Levels Must Be Monitored And Treated To A Target Level Anne Abbott, MD, PhD
- 7:16 7:21 New Findings From The VOYAGER PAD And COMPASS Trials With Low Dose Rivaroxaban (Xarelto From Janssen And J&J) And Aspirin: How Do These Drugs Lower Major Adverse Limb And Cardiac Event Rates After Lower Extremity Revascularization (Endo And Open) For PAD

 Marianne Brodmann, MD

 Sebastian E. Debus. MD
- 7:22 7:27 How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials Anthony I. Comerota, MD
- 7.28 7.33 New Adjunctive Drugs (Plus Statins) To Lower LDL-Cholesterol (LDL-C) In Vascular Patients: Inclisiran, Bempedoic Acid And Ezetimibe: How Do They Work And When And How To Use Them: Level Of LDL-C To Strive For: The CLEAR RCT Show That Bempedoic Acid Really Works

 Richard Bulbulia, MA, MD

7:34 - 7:42 Panel Discussion

SESSION 32 (Grand Ballroom West, 3rd Floor)
CATHETER-BASED TREATMENTS OF RESISTANT
HYPERTENSION; MANAGEMENT OF CARDIAC
PROBLEMS, SMOKING AND TRANSFUSION IN
VASCULAR SURGERY PATIENTS; MORTALITY RISK
IN STROKE PATIENTS; PREVENTING VASCULAR
AND CARDIAC COMPLICATIONS

Moderators: Ron Waksman, MD Michael R. Jaff, DO

UPDATE ON RENAL DENERVATION FOR HYPERTENSION

7:42 – 7:47 Update On The Status Of Renal Denervation For Hypertension: It Is Here To Stay: Where Is It Going: Status Of The Radiofrequency Denervation SPYRAL HTN-OFF MED RCT (vs Sham) And Other Catheter-Based Ablative And Ultrasound Methods (The RADIANCE II RCT Findings)

Eric A. Secemsky, MD, MSc

How To Do It Kolja Sievert, MD Horst Sievert, MD

7:48 - 7:53

7:54 - 7:59A Precision Medicine Approach To Managing Pediatric Renovascular Hypertension: How Can Medical And Open Surgical Treatment Control It Dawn M. Coleman, MD OTHER TOPICS RELATED TO VASCULAR DISEASE AND ITS TREATMENT 8:00 - 8:05How Does The Female Sex Impact The Occurrence Of Lower Extremity Atherosclerosis, Its Treatment And Results Of Treatment Katherine A. Gallagher, MD 8:06 - 8:11How And Why Do Thoracic Endografts For TEVAR Negatively Affect The Blood Pressure And The Heart: Can A Compliant Endograft Prevent The Problem Frans L. Moll, MD, PhD 8:12 - 8:17When Should Smoking Be Stopped Before AAA Repair; Before Lower Extremity Bypass: At Least 4 Weeks: Why Does The Duration Of Cessation Matters Jeffrey J. Siracuse, MD 8:18 - 8:23Update On Limiting Transfusion And Permitting Anemia After Major Vascular Operations Increases Mortality And Serious Adverse Events Especially In Patients With Cardiac Co-Morbidities Panos Kougias, MD, MSc 8:24 - 8:29How To Quantitate Late Mortality Risk In Asymptomatic Carotid Stenosis (ACS) Patients: Why It's Important In Deciding To Treat ACS Patients Non-Invasively Stavros Kakkos, MD Andrew N. Nicolaides, MS, FRCS 8:30 - 8:35Secondary Prevention Of Vascular Disease And Its Complication With PCSK9 Inhibitors; When They Should Be Used And When Not: How Well Does The New Oral PCSK9 (Inhibitor MK-01616 Work) Roxana Mehran, MD (PowerPoint Presentation With Synched Audio) 8:36 - 8:41How Important Is Inflammation As Determined By C-Reactive Protein (CRP) Levels In Predicting Adverse Cardiac Events: What Drugs Can Lower This Risk Ron Waksman, MD

Multiorgan Denervation For Treatment Of Hypertension, Diabetes And Metabolic Syndrome:

TO TREAT OR NOT TO TREAT TYPE 2 ENDOLEAKS

Break - Visit Exhibits And Pavilions (2nd and 3rd

9:06 – 9:11 Active AAA Sac Management With Polymers: This Is
The Missing Link To Improve Outcomes After EVAR:
Technique And Results From The SHAPE AAA Trial
(From Shape Memory)
Michel M.P. Reijnen, MD, PhD
Andrew Holden, MBChB

UNDERSTANDING THEIR CONSEQUENCES AND PREDICTING, PREVENTING AND TREATING THEM

8:42 - 8:50

8:50 - 9:06

Panel Discussion

SESSION 33 (Grand Ballroom West, 3rd Floor)
PROGRESS IN MANAGING ENDOLEAKS:

Peter L. Faries, MD

Floors)

Moderators: Timur P. Sarac, MD

Fibrin Glue Sac Filling Technique During EVAR To Prevent All Endoleaks: It Should Be Routine And Is A Game Changer Based On A Multicenter Trial: How To

TREATING TYPE 1 ENDOLEAKS

	71.E. (111 (G 7 7 7 E 7 E 1 7 E 6 E E 7 11 G
9:18 — 9:23	Post EVAR Type 1A Endoleaks Are Predictable And Preventable: Strategies To Prevent Them Or Treat Them Michael J. Singh, MD
9:24 — 9:29	Embolization Of Type 1 Endoleaks Post EVAR: Longer Term Outcomes; Who To Select For The Procedure And Tips And Tricks For Doing It Robert A. Morgan, MD
9:30 — 9:35	When And How To Use Embolization Coils To Treat Type 1A Endoleaks Successfully: When Won't Coils Work: How To Diagnose Type 1A Endoleaks Accurately Sigrid Nikol, MD
9:36 — 9:41	How To Minimize Gutter Type 1A Endoleaks With Chimney EVAR (Ch/EVAR): How Does A Standard Protocol Help; How To Treat Them When They Occur David J. Minion, MD
9:42 — 9:48	Panel Discussion
	PREVENTION OF TYPE 2 ENDOLEAKS AFTER EVAR
9:49 — 9:54	A RCT Shows The Advantages Of Inferior Mesenteric Artery (IMA) And Lumbar Embolization: The Next Generation Of EVAR Endografts Must Prevent Endoleaks: How Can It Be Done Dominique Fabre, MD
0.55 10.00	Stephan Haulon, MD
9:55-10:00	Preventing Threatening Type 2 Endoleaks By IMA Embolization When AAA Sac And IMA Are Large: Indications And Technical Tips And Evidence Toru Kuratani, MD, PhD
10:01-10:06	With A Large IMA (> 3mm), When Should It Be Embolized; Or When Should It Be Revascularized: How And Why Piotr M. Kasprzak, MD
10:07-10:12	Reduction Of Type 2 Endoleaks By Pre-Emptive Coiling Of Aortic Side Branches >3 mm: How Do We Know Based On A Mid-Term Analysis Götz M. Richter, MD, PhD
10:13-10:19	Panel Discussion
	TREATMENT OF TYPE 2 ENDOLEAKS AND ENDOTENSION AFTER EVAR
10:20-10:25	Transcaval Approach To Treat Type 2 Endoleaks After EVAR: Indications: Technique; Precautions And Results Ross Milner, MD
10:26-10:31	Glue Embolization Is Effective Treatment For Most Threatening Type 2 Endoleaks: When And How Best To Do It: Limitations Neal S. Cayne, MD
10:32-10:37	New Concepts In Post EVAR Endoleaks And Endotension: The Role Of Fabric Fatigue, Concealed Or Positional Endoleaks And AAA Sac Hygromas: How Can These Be Detected And Best Treated Sherif A.H. Sultan, MD, PhD

9:12 - 9:17

Do It

Qingsheng Lu, MD

10:38-10:43 How To Use 3D Fusion Software (GE) To Get Into The Nidus And Treat Type 2 Endoleaks: Best Embolic Agent And Alternate Approaches (Transgraft Or Transcaval) For Access: How To Seal The Graft Puncture Site Mark W. Mewissen, MD 10:44-10:49 Laser Assisted Transgraft Onyx Embolization Of Type 2 Endoleaks: Indications, Equipment And Technique: How Is The Graft Puncture Site Revealed Zvonimir Krajcer, MD Most Type 2 Endoleaks After EVAR Should Be Left 10:50-10:55 Alone Because Treatments Have Poor Results, Have Complications And Do Not Improve Outcomes: Are There Exceptions Hence K. M. Verhagen, MD, PhD 10:56-11:01 With Type 2 Endoleaks And Sac Expansion, Open Sacotomy And Branch Ligation Is Often The Best Treatment: What Precautions Are Needed In Case There Is An Occult Type 1 Leak Zachary M. Arthurs, MD 11:02-11:11 **Panel Discussion** SESSION 34 (Grand Ballroom West, 3rd Floor) TCT AND PLINIO ROSSI RECORDED LIVE COMPLEX AND CHALLENGING ENDOVASCULAR CASES TCT RECORDED LIVE CHALLENGING ENDOVASCULAR **CASES** Moderators: Juan F. Granada, MD Sahil A. Parikh, MD PROGRAM TO BE DETERMINED 11:12-11:36 (Visit www.veithsymposium.org for updates.) PLINIO ROSSI'S RECORDED LIVE COMPLEX AND CHALLENGING ENDO CASES Moderators: Fabrizio Fanelli, MD Andrew Holden, MBChB Carlo Setacci, MD 11:36-11:43 Renal Bridging Stent Rescue After EVAR Nicola Mangialardi, MD 11:43-11:48 11:48-11:55 BTK Angioplasty In A CLTI Patient: Never Give Up Roberto Ferraresi, MD 11:55-12:00 12:00- 1:35 Celebratory Lunch Break - Rhinelander Gallery, 2nd Floor -Visit Exhibits And Pavilions (2nd and 3rd Floors) SESSION 35 (Grand Ballroom West, 3rd Floor) RECORDED LIVE CHALLENGING CASES AND INNOVATIVE TECHNIQUES FROM THE LINC **GROUP** Moderators: Dierk Scheinert, MD Andrej Schmidt, MD Daniela Branzan, MD 1.35 - 1.46Presentation: Calcium In BTK: What Are The Options Andrej Schmidt, MD 1:46 - 1:57Recorded Case: Long Segment BTK Revascularization With Orbital Atherectomy And DCB 1:57 - 2:07Recorded Case: Reconstruction Of The Tibioperoneal Trifurcation With DES

SESSION 36 (Grand Ballroom West, 3rd Floor)
ISSUES IMPORTANT IN VASCULAR SURGERY:
PRACTICE PATTERNS, HISTORY, EFFICIENCY,
MALPRACTICE, SCIENCE, TRAINING AND
HUMAN BEHAVIOR

Moderators: Dawn M. Coleman, MD Kim J. Hodgson, MD

- 2.08 2:13 Care Fragmentation In Vascular Treatment: What Is It; What Are Its Causes And What Is Its Impact On Outcomes After Vascular Procedures

 Olamide Alabi MD

 William D. Jordan, Jr., MD
- 2:14 2:19 History Of Women In Surgery And Vascular Surgery: What Does The Future Hold Within The Next 10 Years *Cynthia K. Shortell, MD*
- 2.20 2.25 How To Improve Operating Room Efficiency For Vascular Surgical Operations: Why Is Inefficiency In This Setting So Widespread And Hard To Fix Panos Kougias, MD, MSc
- 2.26 2.31 Why Non-Compete Clauses In Contracts Should be Eliminated By Law: The SVS Position In Favor Of Such Law Contrasts With The AHA Position Against Margaret Tracci, MD, JD
- 2:32 2:37 Why Systematic Reviews, Meta-Analyses And RCTs Can Be Misleading: What To Do About It: Does Current Wisdom Help Janet T. Powell, MD, PhD
- 2.38 2.43 Why Endovascular Treatments Are Overutilized: Who Is Responsible: How Can The Problem Be Remedied Kim J. Hodgson, MD
- 2:44 2:49 Lifeline Proprietary Carotid Screening: Who Profits: Is It A Good Thing Or A Hoax; What Can It Tell Us About The Prevalence Of Asymptomatic Carotid Stenosis William A. Gray, MD

ISSUES IN VASCULAR TRAINING

- 2:50 2:55 Optimal New Training Paradigm For Vascular Surgeons: 0+5 Vascular Surgery Residency Followed By 2 Years Of Cardiac Surgery Residency Training: Why Is It Better Than 2 Extra Years Of Laboratory Research Alan B. Lumsden, MD
- 2:56 3:01 Integrated (0+5) Vascular Residency Plus CT Surgery Fellowship How Many Are There; Are They Over Trained And Underutilized: How Has It Helped Me *Jennifer L. Perri*, MD, MBA
- 3:02 3:07 Is Vascular Surgery Facing A Looming Decline Because Of Inadequate Numbers Of Both 5+2 And 0+5 Training Programs: What Should And Can Be Done About It: What Are The Impediments

 Michael B. Silva, Jr., MD
- 3:08 3:13 How To Remedy The Deficiency Vascular Fellows And Residents Have In Their Numbers Of Open Vascular Surgical Operations: When Should They Get Additional Subspecialty Training In Another Institution

 Malachi Sheahan. MD
- 3:14 3:19 How Human Behavior Even With Vascular Specialists Is Controlled By Biases And Rationalizations: How To Overcome These And Perform Better

 Scott L. Stevens, MD

3:20 - 3:33	Panel Discussion And Break
	Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 37 (Grand Ballroom West, 3rd Floor)
MORE ISSUE-RELATED TOPICS IMPORTANT
TO VASCULAR SURGEONS AND VASCULAR
SPECIALISTS; ISSUES RELATED TO OUTPATIENT
CENTERS OR OFFICE BASED LABS (OBLS)

Moderators: Sean P. Roddy, MD Krishna Jain, MD

- 3.33 3.38 How COVID And Changes In The Economy Have Caused Hospitals To Run Out Of Money; What Is The Resulting Impact On Vascular Care And Vascular Doctors; What Can Be Done About It Samuel R. Money, MD, MBA
- 3.39 -3.44 DEBATE: How Heart And Vascular Centers Are Attracting Private Equity Investment Leading To Benefits For All Concerned Including Vascular Surgeons And Their Patients

 Jean Bismuth, MD
- 3.45 3.50 DEBATE: Heart And Vascular Centers Are Artificial Entities That Disadvantage Vascular Surgeons And Don't Improve Patient Care

 Malachi Sheahan, MD
- 3.51 3.56

 Vascular Spinoff Revenue In Tertiary Healthcare
 Systems: Substantially More Downstream Benefits
 From Vascular Surgeons: How To Make Hospital
 Administrators Appreciate The Value Of Vascular
 Surgeons And Reward Them Appropriately
 Joseph V. Lombardi, MD

ISSUES RELATED TO OUTPATIENT CENTERS AND OBLS

- 3.57 4.02 The Ever Changing Reimbursement For Lower Extremity Endovascular Therapies In Hospitals And OBLs: Why It's Happening And Where Is It Going Sean P. Roddy, MD Robert M. Zwolak, MD, PhD
- 4:03 4:08 Strategies To Succeed In An OBL Despite Continuing Cuts In CMS Reimbursement

 Clifford M. Sales, MD, MBA
- 4:09 4:14 Panel Discussion

MORE ISSUES RELATED TO OUTPATIENT CENTERS AND OBLS

- 4:15 4:20 **DEBATE:** OBLs Are Bad: Why I Choose Not To Work In An OBL

 Dipankar Mukherjee, MD
- 4:21 4:26 DEBATE: Not True! How Can OBLs Provide Good Vascular Care With Excellent Results, Be Profitable And Still Allow Vascular Surgeons To Only Work From 8 AM To 5 PM Mark A. Mattos, MD
- 4:27 4:32 How To Make Out-Patient Vascular Treatment Facilities (OBLs, ASCs) Safe, Effective And Profitable Without Doing Unjustified Procedures

 Christopher J. Kwolek, MD, MBA
- 4:33 4:38 Comparison of Arterial Closure Devices In An OBL Setting: Which Is Best Based On An Experience With 19,000 Cases

 Sam S. Ahn, MD, MBA

4:39 – 4:44 Tips For Performing High-Risk Lower Extremity
Endovascular Procedures Including Redos Safely And
Effectively In An OBL
Anil P. Hingorani, MD
Enrico Ascher, MD

4:45 – 4:50 OBL Audits: What Are They Looking For And How To Avoid Civil And Criminal Penalties: Do Practice Guidelines Help Or Harm O. William Brown, MD, ID

4:51 – 4:56 Panel Discussion

SESSION 38 (Grand Ballroom West, 3rd Floor)
UPDATES AND ISSUES IMPORTANT TO ALL
VASCULAR SURGEONS AND SPECIALISTS: FUTURE
REIMBURSEMENT; VASCULAR REGISTRIES AND THE
VQI, VALUE OF GUIDELINES AND RCTs:
THE FDA: STATISTICS; EVIDENCE BASED MEDICINE;
MISCELLANEOUS

Moderators: Jack L. Cronenwett, MD Sean P. Roddy, MD

- 4.57 5.02 What Obstacles And Blows Are Vascular Surgeons And Other Vascular Specialists Facing In 2023: Will Planned Increased Reimbursement For Office And Hospital Visits Cause More Decreases In Procedural Reimbursements Sean P. Roddy, MD
- 5:03 5:08 VQI Collaboration With The International Consortium of Vascular Registries (ICVR): How Can It Better Evaluate Aortic Endograft Performance Adam Beck, MD
- 5.09 5:14 The Role And Value Of Guidelines And RCTs In Vascular Practice; Why Guidelines And RCTs Can Be Misleading: What To Do About The Problem Anders Wanhainen, MD, PhD (PowerPoint Presentation With Synched Audio)

REGULATORY AND FDA ISSUES

- 5:15 5:20 How Can A Device Qualify With The FDA For BREAKTHROUGH Status And How Does It Differ From SAFER Status

 Valerie M. Merkle, PhD
- 5:21 5:26 Past, Present And Future Collaboration Between Industry, Clinicians And The FDA To Address Unmet Clinical Needs: We Should Not Be Adversaries Dorothy B. Abel, BSBME

EVIDENCE-BASED MEDICINE ISSUES

- 5:27 5:32 Improved And Simplified Clinical Trial Statistics For Dummies: Why p Values Are Decreasing In Importance And Bayesian Statistics Are Increasing In Importance: What Is The Latter

 Charles C. Miller, PhD
- 5:33 5:38 Registry Based RCTs (RBRCTs): What Are They, How Do They Work And Why Are They Better Than Other Evidence-Based Techniques

 Jens Eldrup-Jorvisitgensen, MD

 Jack L. Cronenwett, MD
- 5:39 5:44 Panel Discussion

MISCELLANEOUS

- 5:45 5:50 Managing Various Specialties And Generations Of Specialists In A Multi-Specialty Vascular Institute Or Center: How To Satisfy Everyone And Optimize Patient Outcomes

 Gary M. Ansel, MD
- 5.51 5.56 Despite What The New York Times And Others Say, Close Relationships Of Vascular Surgeons With Industry Are Mostly Ethical And Beneficial To Patients And Society: Pitfalls To Avoid Bruce A. Perler, MD, MBA
- 5.57 6.02 Innovation In Vascular Surgery: Ideas, Funding,
 Partners And Intellectual Property: How To Turn
 Fantasy Into Reality
 Jeffrey H. Lawson, MD, PhD
- 6:03 6:08

 Current Quality Analysis For Vascular Surgeons And Vascular Specialists Does Not Reflect Quality Of Care: Why And What Can Be Done About It

 Richard F. Neville, MD
- 6:09 6:14 Editorial Update On The JVS And All Its Progeny: Its Status And How It Will Be Improved
 Ronald L. Dalman, MD
 Thomas L. Forbes, MD
- 6:15 6:20 Effects Of The Affordable Care Act (ACA) On Vascular Surgical Outcomes: Does The Medicaid Expansion Of The ACA Improve Outcomes Or Not Mohammad H. Eslami, MD, MPH
- 6:21 6:30 Panel Discussion End of Program E

PROGRAM F (SESSIONS 39-46)
MORE NEW DEVELOPMENTS IN THORACIC
AORTIC DISEASE, TEVAR, AORTIC DISSECTIONS,
TAAAS, JUXTA- AND PARARENAL AAAS, PARALLEL
GRAFTS, FENESTRATED AND BRANCHED
EVAR (F/B/EVAR), MULTILAYER BARE STENTS,
INFRARENAL AAAS AND STANDARD EVAR, AND
HOT NEW AORTIC AND CAROTID TOPICS
Trianon Ballroom, 3rd Floor

SESSION 39 (Trianon Ballroom, 3rd Floor)
MORE TOPICS RELATED TO THE THORACIC
AORTA, AORTIC DISSECTIONS, INTRAMURAL

HEMATOMAS (IMHs), INFLAMMATORY ANEURYSMS AND THEIR TREATMENT

Moderators: Ramon Berguer, MD, PhD
Paulo E. Ocke-Reis, MD, PhD

- 6:50 6:55 What Is Best Medical Treatment For TBAD Patients: How Best To Control Blood Pressure And To Get Patients To Comply: They Don't Colin D. Bicknell, MD
- 6:56 7:01 Requirement For Adjunctive Branch Stents After TEVAR For Complicated TBADs Is An Indicator Of Poor Prognosis: What Can Be Done To Offset It Mark K. Eskandari, MD
- 7:02 7:07 Current Optimal Management Of Intramural Hematomas (IMHs): Which Ones Should Be Treated With TEVAR And What Is The Best Extent Of Aortic Coverage

 Frank J. Criado, MD

Outer/Inner/Upward Branches Or Fenestrations: Strategies For Complex Aortic Repair For Patients With Chronic TBADs: What Are The Unmet Needs

7:08 - 7:13

	Bijan Modarai, MD, PhD	
7:14 — 7:19	Current Advances In The Treatment For Inflammatory Aneurysms: How Effective Are EVAR And TEVAR Furuzan Numan, MD	
7:20 - 7:25	Panel Discussion	
7:25 — 7:30	DEBATE: The STABILISE Technique Will Lead To Paradigm Shift In The Treatment Of TBADs And Will Replace Most False Lumen Occlusion Devices And F/B/EVAR Treatments: It Relaminates The Aorta And Eliminates The False Lumen: How To Do It And Precautions Igor A. Laskowski, MD Josh B. Goldberg, MD Heepeel Chang, MD	
7:31 – 7:36	DEBATE : Not So Fast! A Multimodular Approach To Treating Chronic TBADs With TAAAs: Who Needs A F/B/EVAR; Who Needs A Candy-Plug Or Other Occlusion Technique <i>Tilo Kölbel, MD, PhD Fiona Rohlffs, MD, PhD</i>	
7:37 — 7:42	When Are Thoracic Endografts Valuable Treatments For Genetic Aortopathies Cherrie Z. Abraham, MD	
7:43 — 7:48	What Are The Knowledge Gaps In The Treatment Of TBADs: How Can And Will They Be Resolved Colin D. Bicknell, MD	
7:49 — 7:54	A Recently Funded Multicenter NIH Grant (IMPROVE-AD) To Evaluate Unknowns In The Treatment Of Acute And Subacute TBADs: What Will It Tell Us And Why Was It So Hard To Get It Approved: Are There Other Similar RCTs Outside The US Gustavo S. Oderich, MD Firas F. Mussa, MD	
7:55 — 8:00	Panel Discussion	
SESSION 40 (Trianon Ballroom, 3rd Floor) MORE ADVANCES RELATED TO TREATING PATHOLOGY INVOLVING THE ASCENDING AORTA AND THE AORTIC ARCH; AORTIC DISSECTIONS AND THEIR TREATMENT Moderators: Rodney A. White, MD Thomas S. Maldonado, MD		
8:00 — 8:05	When In Addition To TEVAR And F/BEVAR Are False Lumen (FL) Occlusion Procedures Needed To Reduce FL Pressure And Promote Aortic Remodeling <i>Götz M. Richter, MD, PhD</i>	
8:06 — 8:11	With TAAD When And How Should The Distal Aorta Be Treated By TEVAR Before Repairing The Ascending Aorta Ourania Preventza, MD Joseph S. Coselli, MD	
8:12 — 8:17	Fenestrated TEVAR Devices For The Treatment Of Post Dissection Aortic Arch False Lumen Aneurysms: What	

Devices Are Available, How Do They Work And Results

Nicola Mangialardi, MD

0:10 — 0:23	Dissection Membrane Creates A Single Lumen TEVAR Landing Zone: How Is The Technique Performed And Early Results Nuno V. Dias, MD, PhD (PowerPoint Presentation With Synched Audio) Björn Sonesson, MD, PhD
8:24 — 8:29	Continuing Experience For Precise TEVAR Placement In Or Near The Arch By Valsalva And PEEP (Munich Valsalva Maneuver): It Is Safe And Effective And Better Than Adenosine, Rapid Pacing And Caval Occlusion: How To Do It And Results Nikolaos Tsilimparis, MD, PhD
8:30 - 8:35	Panel Discussion
8:35 — 8:40	Single, Double Or 3-Branched Endograft Devices For Arch Lesion Repairs: When Is Each Best And Why: How To Do It From A Totally Femoral Approach Gustavo S. Oderich, MD
8:41 — 8:46	An Off-The-Shelf Combined Valve+Fenestrated Endograft For Treating Acute TAADs – An Endo Bentall: Device Description, Indications And Clinical Status Stephan Haulon, MD
8:47 — 8:52	Percutaneous Endovascular Arch Repair Is Feasible With The Use Of Adjuncts: The "Innominate Approach" Avoids The Need To Get Open Exposure Of The Carotid Arteries For Access: How Is It Done <i>Timothy A. Resch, MD, PhD</i>
8:53 — 8:58	Physician Modified Double Fenestrated Stent-Grafts (PMEGs) For Total Aortic Arch Repair: Technique, Precautions And Results In 150 Cases <i>Ludovic Canaud, MD, PhD</i>
8:59 — 9:04	Zone 0 Aortic Arch Branched Endograft Repair Is Feasible With A Mechanical Aortic Valve: Tips And Tricks For Performing It Without Impairing Valve Function Nikolaos Tsilimparis, MD, PhD
9:05 — 9:11	Panel Discussion
9:11 — 9:24	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
OPEN AN AAAs (JU: TAAAs; N	(Trianon Ballroom, 3rd Floor) ND ENDO TREATMENT OF COMPLEX XTA, PARA- AND SUPRA-RENAL) AND NEW DEVICES FOR THEIR TREATMENT Christopher J. Kwolek, MD, MBA Gilbert R. Upchurch, MD
	COMPLEX AAAs AND TAAAs
9:24 — 9:29	Aortic Neck Dilatation And AAA Sac Shrinkage After F/EVAR Is Better Than After Standard EVAR Thomas S. Maldonado, MD
9:30 — 9:35	Recent Progress In Prevention Of Spinal Cord Ischemia (SCI) Especially Paraplegia After Complex AAA And TAAA Endovascular Repairs Adam Beck, MD Matthew J. Eagleton, MD
9:36 — 9:41	Complete Aortic Endovascular Repairs (Zones 0-10) Using Parallel Endografts With A Docking Station: How And Why To Make Them Work Effectively Despite Doubts About Parallel Grafts Manish Mehta, MD, MPH

8:18 – 8:23 With Chronic TBADs Laser Assisted Resection Of The

9.42 – 9.47 Value Of Ch/EVAR For Juxtarenal AAAs: They Are As Safe And Effective As Any Other Procedure And Simpler: Based On A Meta-Analysis Of Mid-Term Outcomes Joost A. van Herwaarden, MD, PhD

9.48 – 9.53 Key Findings From The UK-Complex Aneurysm Study (UK-COMPASS) Comparing Outcomes Of Off-Label EVAR, Open Repair And F/EVAR For Short Necked AAAs

S. Rao Vallabhaneni, MD Michael P. Jenkins, MBBS, BSc, MS

9.54 – 9.59 Comparison Of Endo And Open Repair Of Post Dissection TAAAs: Which Procedure Is Best And When

Fabio Verzini, MD, PhD
10:00-10:05 What Is A Hybrid Repai

10:00-10:05 What Is A Hybrid Repair Of A TAAA (Proximal Endograft + Distal Open Repair - The Upchurch Procedure): When Is It Indicated; What Are The Advantages And Results

Gilbert R. Upchurch, MD

Salvatore T. Scali, MD

Dean Arnaoutakis, MD

10:06-10:12 Panel Discussion

TOPICS RELATED TO INTERESTING NEW DEVICES

10:12-10:17 Update On The Incraft Endograft (From Cordis) For Standard Infrarenal EVAR: Is Its Low Profile An Advantage Or Limitation

Giovanni B. Torsello, MD

Matteo Orrico, MD

Nicola Mangialardi, MD

10:18-10:23 How To Prevent Patch Aneurysms After Open TAAA
Repair With Long Antegrade Grafts: How To Treat
Them When They Occur
Manju Kalra, MBBS

10:24-10:29 Can EVAR And F/EVAR Be Done Under Local
Anesthesia: Can They Become Outpatient Procedures
Or Office Based Lab Procedures: What Are The
Contraindications
Michael C. Stoner, MD

10:30-10:35 WeFlow Device For Juxtarenal AAA, TAAA And Arch Repairs: A New Inner Branch And Outer Branch Approach: How Does It Work And Promising Results Wei Guo, MD (PowerPoint Presentation With Synched Audio)

10:36-10:40 Panel Discussion

SESSION 42 (Trianon Ballroom, 3rd Floor)
PROGRESS IN TREATING ILIAC LESIONS;
ILIAC BRANCHED DEVICES (IBDs); UPDATE ON
MULTILAYER FLOW MODULATING (MLFM) AND
OTHER BARE STENTS FOR TREATING ANEURYSMS
AND DISSECTIONS

Moderators: Thomas S. Maldonado, MD Rodney A. White, MD

TREATMENT OF ILIAC ANEURYSMS AND IBDs

10.40-10.45 Surprisingly Occlusion Of 1 Or Both Hypogastric Arteries During EVAR Does NOT Result In Serious Adverse Events: From A Large VQI Study Heepeel Chang, MD

10:46-10:51	Update On The Gore IBE Excluder For Treating Iliac Aneurysms And Preserving Hypogastric Artery Flow: Why It Should Be Preserved Whenever Possible: When Can It Not Be Michel M.P. Reijnen, MD, PhD
10:52-10:57	Updated Experience With Cook IBD For The Treatment Of Common Iliac Aneurysms: Including After Previous EVAR Giovanni B. Torsello, MD Carlos H. Timaran, MD Andres Schanzer, MD
10:58-11:03	Long-Term Comparison Of The Cook Zenith And Gore Excluder IBDs: Advantages And Limitations Of Both: What Is Currently The Best Bridging Stent <i>Giovanni Pratesi, MD</i>
11:04-11:09	An Iliac Customized Fenestrated Device (From Terumo Aortic): When And How Can It Work In Anatomies Unsuitable For Branched Endografts: Advantages And Limitations Afshin Assadian, MD Fadi Taher, MD
11:10-11:15	Update On The Advantages Of The Artivion (Formerly CryoLife/Jotec) IBD Device For Treating Common And Internal Iliac Artery Aneurysms: When Bell Bottom Technique; When IBD: From The PLIANT II Study Lee Bouwman, MD, PhD, MSc
11:16-11:21	Covered Endovascular Reconstruction Of The Iliac Bifurcation (CERIB) For Preservation Of Pelvic Flow During Treatment Of Aortoiliac Occlusive Disease: How And When To Do It <i>Joshua D. Adams, MD</i>
11:22-11:30	Panel Discussion
	UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS
11:30-11:35	Is There A Role For Bare Stents (Allay From Intressa, Formerly Cardiatis) In The Treatment Of Type A Aortic Dissections (TAADs) Rodney A. White, MD
11:36-11:41	8-Year Clinical Experience With Bare Stent And Chimney Graft Treatment Of TAADs Ivo Petrov, MD, PhD Victor S. Costache, MD, PhD
11:42-11:47	3-Year Experience With Bare Stents (Allay From Intressa, Formerly Cardiatis) For The Treatment Of TAADs Claude A. Vaislic, MD
11:48-11:53	Role Of Bare Metal AMDS Stents From Artivion (Formerly CryoLife/Jotec) For Repair Of Acute Type A Dissections: Indications And Results Wilson Y. Szeto, MD Grayson H. Wheatley, MD
11:54-12:00	Panel Discussion
12:00- 1:35	Celebratory Lunch Break – Rhinelander Gallery, 2nd Floor -Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 43 (Trianon Ballroom, 3rd Floor)

MORE NEW DEVELOPMENTS IN AAA TREATMENT AND STANDARD EVAR: A NEW DEVICE TO SLOW AAA GROWTH; AAA NECK DILATATION AFTER EVAR; VALUE OF LOW PROFILE AAA ENDOGRAFTS; IMPROVED ULTRASOUND SURVEILLANCE AND ALL AAAs ARE NOT TIME BOMBS WAITING TO **EXPLODE**

Moderators: Michael L. Marin, MD Fred A. Weaver, MD, MMM

1:35 - 1:40Should Saccular AAAs Be Repaired At A Smaller Diameter Than Fusiform AAAs: How To Measure Saccular AAA Diameter: Should It Include The Normal Aorta Or Not Frans L. Moll, MD, PhD

1:41 - 1:46Decreasing Frequency Of Elective And Ruptured AAA Repairs Is Due To Epidemiology Rather Than Other Factors Like Screening Ian Loftus, MD Pete Holt, MD, PhD

AAA NECK BEHAVIOR AFTER EVAR

- 1:47 1:52 Optimal Stent Design And Optimal Degree Of Oversizing To Avoid Neck Dilatation And Why It Matters Carlos Bechara, MD
- 1:53 1:58Major Aortic Neck Dilatation Occurs Equally After EVAR And Open Repair: From The DREAM RCT: This ONLY Occurs After EVAR With Self-Expanding **Endografts** Jan D. Blankensteijn, MD
- 1:59 2:04What Should Be The Role Of Physician Modified Endografts (PMEGs) For the Treatment Of Short Or No Neck AAAs When Industry Made F/EVAR Devices Are Available: Why PMEGs Are Only Good In Some Centers: New Computer 3D Modeling Adjuncts (From Terumo) To Make PMEGs Better And Simpler Benjamin W. Starnes, MD
- 2:05 2:10**DEBATE**: Low Profile Devices For EVAR Are Failing: Their Future Is Questionable Based On Results Of Other Devices Like The Endurant Endograft At 10 Years (From The ENGAGE OUS Registry) Hence J.M. Verhagen, MD, PhD
- 2:11 2:16**DEBATE**: Not So: Ovation Stent-Grafts (From Endologix) Have Good 5-Year Results With No Neck Dilatation Or Migration Even With Challenging Neck Anatomy: Based On A Multicenter International Study Of A Low Profile Endograft Mahmoud B. Malas, MD, MHS
- 2:17 2:22Is AAA Thrombus More Dangerous In Women Than In Men: What Are The Dangers Of Such Thrombus Janet T. Powell, MD, PhD
- 2:23 2:28How Well Does Non-Fluoroscopic Guidance Using The IOPS System From Centerline Work For Performance Of Standard EVAR: Findings From The MOTION Trial Frank J. Caputo, MD
- 2:29 2:34Despite Great Advances With AAA Management, Little Progress Has Been Made In 2 Important Areas: Improving Indications For Treatment And Precision Of Measurement: AAAs ≤6.0 cm Rarely Rupture Frank J. Criado, MD

2:35 - 2:41Panel Discussion

SESSION 44 (Trianon Ballroom, 3rd Floor) MORE NEW DEVELOPMENTS IN AAAs: HOW DOES THROMBUS LOAD EFFECT PROGNOSIS AFTER EVAR AND EVAS; OTHER RELATED AAA **TOPICS**

Moderators: Evan C. Lipsitz, MD, MBA Janet T. Powell, MD, PhD

AAA SAC THROMBUS LOAD

- 2:41 2:46Impact Of Thrombus In AAA Sac And Neck On AAA Behavior And EVAR Outcomes: How To Quantitate Thrombus Load And Distribution Nicos Labropoulos, BSc (Med), PhD, DIC
- 2:47 2:52 **DEBATE**: Large Amount Of AAA Sac Thrombus Promotes Morbidity Without Rupture And With Rupture: By What Mechanisms Is Thrombus Harmful And How Can Thrombus Load Be Quantitated David H. Deaton, MD
- 2:53 2:58**DEBATE**: Large Flow Luminal Space In An AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective Hence J.M. Verhagen, MD, PhD

OTHER AAA RELATED TOPICS

- 2:59 3:04Graft Infolding: A Unique EVAR Complication: How To Prevent It And How To Treat It Ashraf Mansour, MD
- 3:05 3:10With Aneurysmal Disease What Causes The Aorta To Rotate: What Is The Impact Of Counterclockwise Rotation Of The Aneurysmal Aorta Nicos Labropoulos, BSc (Med), PhD, DIC
- 3:11 3:16Observation For Small AAAs (<5.0 cm) Is Safe And Does Not Impair Future EVAR Options Jon S. Matsumura, MD
- 3:17 3:22Update On Median Arcuate Ligament Syndrome (MALS): Current Status Of Its Etiological Concepts And Optimal Diagnosis And Treatment Wilhelm Sandmann, MD
- 3:23 3:28Update On Technical Tips To Perform SAFE Large Sheath Percutaneous Femoral Access And Closure For Complex AAA EVAR In Obese Or Scarred Groins - Even With Calcified Arteries: It Is Almost Always Possible Barend M.E. Mees, MD, PhD
- 3:29 3:34Increased Inflammatory Biomarkers And Increased 18F FDG Uptake On PET CT In AAA Patients Are Associated With Rapid Growth And Worse Long-Term Survival: Should These Markers Be Tested Routinely And How Should AAA Treatment Be Modified If They Are Elevated Natzi Sakalihasan, MD, PhD

Panel Discussion

3:41 - 3:50Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 45 (Trianon Ballroom, 3rd Floor)

HOT AORTIC TOPICS

Moderators: Timothy A.M. Chuter, MD Peter Gloviczki, MD

3:35 - 3:41

3:50 — 3:55	Aorto-Enteric Fistulas Associated With Infected EVARs Or Open Prosthetic Grafts; What Are The Differences Between Them And What Are the Implications For Treatment Salvatore T. Scali, MD
3:56 — 4:01	International Experience With 1,000 Physician Modified Endografts For Complex Aortic Aneurysms: When Is The Procedure A Good Thing And When Is It A Bad Thing Nikolaos Tsilimparis, MD, PhD
4:02 — 4:07	Impact Of COVID, The NICE Guidelines And Changing Disease Patterns On AAA Practice In The UK: Which Is Most Important Ian Loftus, MD Pete Holt, MD, PhD
4:08 — 4:13	TEVAR For Acute Complicated TBAD: Improved Outcomes When The Endograft Is Extended To Zone 2 Versus Zone 3: Why Is This So And What To Do About The Subclavian Artery <i>Jean M. Panneton, MD</i>
4:14 - 4:19	Safe Anticoagulation In F/B/EVAR Patients Requiring Spinal Fluid Drainage Afshin Assadian, MD
4:20-4:25	Panel Discussion
4:25 — 4:30	Are We Overtreating AAAs: The Current Diameter Threshold For AAA Repair Is No Longer Relevant: Based On New Scrutiny Of Old Trials And A Meta- Analysis Of AAA Rupture Risk Timothy A. Resch, MD, PhD
4:31 — 4:36	What Is "Failure To Rescue" After Endovascular TAAA Repairs: What Factors Are Responsible And Why Is It Important Jade S. Hiramoto, MD
4:37 — 4:42	Laser In Situ F/EVAR As An Off-The-Shelf Option For Ruptured Complex Or Short Necked AAAs And Failed EVAR: Experience And Technical Tips Timothy A. Resch, MD, PhD
4:43 — 4:48	10-Year Experience Shows The Safety And Effectiveness Of Endoanchors For F/EVAR: They Support A Shortened Main Endograft Length And A Reduced Procedural Complexity Jörg Tessarek, MD (PowerPoint Presentation With Synched Audio)
4:49 — 4:54	Risk Factors And Late Clinical Consequences Of AAA Neck Dilatation After EVAR With Self-Expanding Endografts: What Are The Differences In Neck Behavior After Excluder And Endurant Endografts: Based On 10-Year Results From The ENGAGE Registry Hence J.M. Verhagen, MD, PhD
4:55-5:00	Panel Discussion
MORE SH AORTO-I TREATME	(Trianon Ballroom, 3rd Floor) HORT HOT NEW TOPICS RELATED TO LIAC AND CAROTID DISEASE AND THEIR ENTS; ANTI-ATHEROSCLEROSIS VACCINE Andres Schanzer, MD Peter F. Lawrence, MD
5:01 — 5:06	Are Low Profile Devices For EVAR And TEVAR

Improving Or Worsening Outcomes Naoki Fujimura, MD, PhD

5:07 — 5:12	Why Is It Important To Avoid "Lost To Follow Up" In AAA Studies: What Measures Can Do So Matthew W. Mell, MD, MS
5:13 — 5:18	Single Access Retrograde Iliac Branch Endograft Device (IBD) Implantation: Technique, Advantages And Limitations Mario L. Lachat, MD
5:19 — 5:24	Treo Endograft From Terumo Aortic For EVAR: Advantages And 5-Year Results From The US IDE Trial Michael C. Stoner, MD
5:25 — 5:30	Isolated Iliac Artery Aneurysms Do NOT Rupture And Need To Be Treated Until They Are At Least 4 Centimeters In Diameter Christopher J. Smolock, MD
5:31 — 5:36	How To Safely Stent The Large Fenestration Of A ZFEN Endograft When It Is Crossed By Struts: Indications For Doing So And Late Results Luis A. Sanchez, MD
5:37 — 5:42	The Mega-Aortic Syndrome: What Is It: When And How Should It Be Treated <i>Martin Czerny, MD</i>
5:43 - 5:49	Panel Discussion
	CAROTID RELATED TOPICS
5:49 — 5:54	Transcarotid Artery Revascularization (TCAR) Versus Carotid Endarterectomy (CEA): In A Single Center Experienced In Both, Which Is Best And When Zachary AbuRahma, DO Ali F. AbuRahma, MD
5:55 — 6:00	Intracranial Angiography During TCAR: Technique And Value Peter L. Faries, MD Michael L. Marin, MD
	MORE AORTA RELATED TOPICS
6:01 — 6:06	Improved Survival After Implementation Of A Large Scale Dedicated Network For Aortic Emergencies: Why The French SOS Aorta System Works Jean-Marc Alsac, MD, PhD
6:07 — 6:12	How Can The Gore Recapturable C3 Excluder Endograft Be Modified As A PMEG For F/EVAR And TAAA Repair: Technique And Results Wayne W. Zhang, MD
6:13 — 6:18	The Sandwich-Periscope Technique For Left Subclavian Revascularization With Zone 2 TEVAR: It May Be The Best Way And How To Do It: Technique $Sukgu\ Han,\ MD$
	ANTI-ATHEROSCLEROSIS VACCINE
6:19 — 6:24	An Interesting New Anti-Atherosclerosis Vaccine (AntheroVax): How It Works And Current Status Nicholas Kipshidze, MD, PhD, DSc
6:25 — 6:30	Panel Discussion End of Program F

THURSDAY, NOVEMBER 16, 2023

6:00 A.M. General Registration - Rhinelander Gallery, 2nd Floor 6:00 A.M. Faculty Registration — Gramercy Suite West, 2nd Floor 6:15 A.M. Continental Breakfast - Rhinelander Gallery, 2nd Floor

CONCURRENT THURSDAY PROGRAMS

PROGRAM G (SESSIONS 47-54)

Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAAs; More About New Devices, Techniques Or Concepts; **Progress In Radiation Safety**

6:50 A.M. - 5:58 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM H (SESSIONS 55-63)

New Or Improved Devices For: Standard EVAR, EVAS And More Complex AAAs; Repairs Of T AAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels

7:00 A.M. - 5:52 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM I (SESSIONS 64-73)

Superficial Venous Disease

7:00 A.M. - 6:40 P.M.

Trianon Ballroom, 3rd Floor

PROGRAM J (SESSIONS 74-78)

Multidisciplinary Acute Stroke Management

8:00 A.M. - 12:30 P.M.

Murray Hill Suites, 2nd Floor

PROGRAM G (SESSIONS 47-54)

EXCITING NEW OR REDISCOVERED TECHNIQUES, CONCEPTS OR DEVICES; PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs; TRIBUTE TO OUR MILITARY; PROGRESS IN THE TREATMENT OF RUPTURED AAAs; MORE ABOUT NEW DEVICES, TECHNIQUES OR CONCEPTS: PROGRESS IN RADIATION SAFETY

Grand Ballroom East, 3rd Floor

SESSION 47 (Grand Ballroom East, 3rd Floor)

EXCITING NEW OR REDISCOVERED TECHNIQUES, DEVICES, CONCEPTS, TRIBUTE TO ROGER M.

GREENHALGH

Moderators: Caron B. Rockman, MD Richard F. Neville, MD Frank J. Veith, MD

6:50 - 6:55Combating Bias In Medical And Vascular Studies And Therapeutic Decision Making: Why It Is Such A Big Deal And What To Do About It

Matthew T. Menard, MD

6:56 — 7:01	Function And Other Parameters: Where Is It At And Where Is It Going Richard F. Neville, MD
7:02 — 7:07	New Wearable Technologies For Telemonitoring Vascular Diseases And Their Treatments: What Are The Current UK Research Priorities: How Will They Improve Patient Care Celia Riga, BSc, MBBS, MD
7:08 — 7:13	A New Core Outcome Set For Evaluating AAA Repairs: This Will Reflect What Is Currently Most Valued By Patients, Surgeons, Nurses, Industry And Others Involved In Patient Care Janet T. Powell, MD, PhD
7:14 — 7:19	Update On Tissue Engineered Biological Arterial Grafts (Humacyte) In Various Vascular Beds: How Well Are They Working In Patients: 6-Year Durability Data Todd E. Rasmussen, MD Alexander Kersey, MD Jeffrey H. Lawson, MD, PhD
7:20 — 7:25	Progress In Developing A Curved Angioplasty Balloon: How It Works And Why It's Important Timothy A. M. Chuter, MD
7:26 - 7:31	Panel Discussion
7:31 — 7:36	Relining Occluded Vein Grafts With Viabahn (Gore) Stent-Grafts Or Supera (Abbott) Bare Stents Can Restore Patency And Avoid Thrombolysis Or Clot Removal: Techniques And Results Hans Lindgren, MD, PhD (PowerPoint Presentation With Synched Audio)
7:37 — 7:42	Measuring Aortic Diameters Is Inaccurate And Subjective: Even With Newer Imaging Technology, One Can Make The Diameter What You Want: How Does It Invalidate Many Studies And Trials Janet T. Powell, MD, PhD
7:43 — 7:48	Provider Skill Is Not Getting Appropriate Attention In The Health Care Value Equation Of Value = Outcome/ Cost: Even Within A Specialty All Doctors Are Not Equal: What To Do About It Lars B. Lonn, MD, PhD
7:49 — 7:54	Performing Transplants In Ukraine During The Russian Invasion: Limitations And Gratification Robert A. Montgomery, MD, DPhil
7:55 — 8:00	Pediatric Vascular Surgery – A New Subspecialty Within Vascular Surgery: What Pathologies Are Involved; Why Is It Necessary And What Resources Are Needed To Optimize Care Alexander Fairman, MD
8:01 — 8:06	A Tribute To Roger M. Greenghalgh (1941-2023) Janet T. Powell, MD, PhD
8:07 — 8:12	Panel Discussion
PROGRES (F/B/EVA AAAs AN	(Grand Ballroom East, 3rd Floor) SS IN FENESTRATED AND BRANCHED EVAR R) AND PARALLEL GRAFTS FOR COMPLEX ID TAAAs; AND RELATED TOPICS Timothy A.M. Chuter, MD Andres Schanzer, MD James F. McKinsey, MD
	✓ •

The "Shaggy Aorta": What Is It; How Is It Determined

And Quantitated; How Shaggy Does It Have To Be To

8:12 - 8:17

	Matter
	Germano C.G. Melissano, MD
8:18 — 8:23	The US Aortic Research Consortium (US-ARC): What Is It And How Do Multicenter Systematic Studies Like It With F/B/EVAR Better Answer Clinical Questions: Is There Still Value To Single Center Studies Andres Schanzer, MD
8:24 — 8:29	Value Of Parallel Endografts In The Management Of TAAAs And Other Aorto-Iliac Pathology: Why Do They Fail And How To Make Them Work David J. Minion, MD
8:30 — 8:35	Branched EVAR For TAAA Repair Can Be Performed With Only Transfemoral Access Using Steerable Sheaths: How To Stabilize The Distal End Of The Sheath Tilo Kölbel, MD, PhD
8:36 — 8:41	With Steerable Sheaths Upper Extremity Access With B/EVAR Is Rarely Necessary: Which Sheath Is Best And Pitfalls To Be Avoided Eric L.G. Verhoeven, MD, PhD
8:42 — 8:47	Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A US Perspective On The Advantages Of The Gore VBX Stent Graft Mark A. Farber, MD
8:48 — 8:53	Updated Advantages And Disadvantages Of The BeGraft, BeGraft Plus (Bentley) And Advanta (iCAST™ – Getinge) Bridging Stents For F/B/EVAR: Experience With >2000 Target Vessels Eric L.G. Verhoeven, MD, PhD Athanasios Katsargyris, MD
8:54 — 8:59	Advantages Of The Cook Inner Branched Endograft For Repair Of TAAAs: Which Is The Best Covered Stent For The Branches Martin J. Austermann, MD (PowerPoint Presentation With Giovanni B. Torsello, MD Synched Audio)
9:00 — 9:05	New Cook Endograft With Bidirectional Inner Branches For B/EVAR: Advantages And Early Results Nuno V. Dias, MD, PhD (PowerPoint Presentation With Synched Audio)
9:06 — 9:11	With Complex AAAs, When F/B/EVAR; When Parallel Grafts; When Open Repair: All Have Their Pros And Cons Chang Shu, MD
9:12 — 9:17	How To Deal With Bad Necks Or No Necks In AAAs: We Need All Options: Chimneys, Endoanchors, Fenestrated And Branched Solutions: Case Selection Is The Key: How To Do It Götz M. Richter, MD, PhD
9:18 — 9:26	Panel Discussion
9:26 — 9:38	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
SESSION 49	(Grand Ballroom East, 3rd Floor)

MORE PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAS; AND

Timothy A. Resch, MD, PhD Frank J. Veith, MD

RELATED TOPICS

Moderators: Gustavo S. Oderich, MD

9:38 - 9:43

9:44 - 9:49

9:50 - 9:55

9:56 -10:01

10):02 - 10:07	DEBATE: The Case Against Ch/EVAR And Parallel Grafts For Complex AAA And TAAA Repairs: F/B/EVAR Is Much Better <i>Adam Beck, MD</i>
10):08-10:13	DEBATE : Nonsense! Ch/EVAR And Parallel Grafts If Done Right Are As Safe And Effective As F/B/EVAR And In Some Cases Better And Cheaper David J. Minion, MD
10):14-10:19	Parallel Endografts For Aorto-Iliac Lesions: The Good, The Bad And The Ugly: A Balanced View <i>Grace J. Wang, MD, MSCE</i>
10):20-10:25	Pros And Cons Of Inner Versus Outer Branches In Off- The-Shelf Endovascular TAAA Repair Timothy A. Resch, MD, PhD
10):26 -1 0:31	Technical Tips To Deploy F/EVAR Endografts Precisely With Tortuous Anatomy: How To Compensate For Endograft Rotation And Still Match Fenestrations To Branch Orifices Perfectly Neal S. Cayne, MD Björn Sonesson, MD, PhD
10):32 -10:37	Advantages Of Steerable (Variable Curve) Sheaths For Complex AAA And TAAA Repairs And TBADs: Which One Is Best And Why: Pitfalls And How To Prevent Them W. Anthony Lee, MD
10):38-10:43	Although Some Recommend That F/EVAR Always Include 3 Vessels, 2 Vessel F/EVAR Is Effective And Durable In Some Anatomies: Which Ones, Based On A Single Center Experience And Systematic Review Geert Willem H. Schurink, MD, PhD
10):44-10:52	Panel Discussion
A Pl T V H	TRIBUT HYSICIA REATME ASCULA IEMORR UPPORT	(Grand Ballroom East, 3rd Floor) TE TO OUR MILITARY AND MILITARY ANS: SOME MILITARY HISTORY; ENT OF MILITARY AND CIVILIAN AR INJURIES AND CONTROL OF CHAGE; INNOVATIVE TECHNOLOGIES TED BY THE DEFENSE DEPARTMENT Todd E. Rasmussen, MD Wayne F. Yakes, MD

Update On Aortic Neck Dilatation Occurring After F/ EVAR: What Causes It And Is It Harmful To Patients

Percutaneous Femoral And Axillary Access For Complex Endovascular AAA Repair: How To Do It Safely And To Safely Downsize Femoral Sheaths To More Rapidly Restore Lower Extremity Flow: Why Is It

Use Of Parallel Grafts To Treat Common Iliac Aneurysms And Preserve Hypogastric Flow:

Techniques, Advantages Over IBDs, Long-Term Results

Advantages And Short-Comings Of Off-The-Shelf Endografts (Industry Made And Parallel) For Complex AAAs And TAAAs: When Are They Helpful And When

Michael P. Jenkins, MBBS, BSc, MS

Important

Not

Darren B. Schneider, MD

Mark A. Farber, MD

Armando C. Lobato, MD, PhD

Battle of Takur Ghar: 20 US Army Airborne Rangers Go To Rescue 7 Navy Seals And 1 Air Force Spotter Attacked By Over 400 Al-Qaeda Forces And 2 Congressional Medal Of Honor Winners Later In That 17-Hour Battle (10-Minute Talk) Wayne F. Yakes, MD 11:03-11:13 Can The US Military Avoid The Damage Of The "Peace Time Effect" And Recent Wokeness Changes To Maintain Real Combat And Surgical Readiness To Win And Avoid Needless Loss Of Life When The Next War Starts (10-Minute Talk) Todd E. Rasmussen, MD 11:14-11:24 A Vascular Surgeon's Impressions About The Terrible War In The Ukraine: Analysis Of Vascular Trauma And Late Outcomes Of Vascular Reconstructions In 70 Wounded Soldiers (10-Minute Talk) Andriy Nykonenko, MD 11:25-11:30 Humanitarian Vascular Surgery: A Report On The War In Ukraine And The Role Of Non-Governmental Organizations (NGOs) To Deploy Talent To Combat Zones Charles J. Fox, MD Update Of Endovascular Resuscitation And Trauma 11:31-11:36 Management: Use Of Catheter Based Treatments, **Endografts And Other Devices** Tal M. Hörer, MD, PhD 11:37-11:42 Updated Progress And Precautions With REBOA (Resuscitative Endovascular Balloon Occlusion Of The Aorta): How Will They Make It Worthwhile For Battlefield Hemorrhage And Other Conditions Johnathan J. Sexton, MD Brandon Propper, MD How Will We Train The Next Generation Of Surgeons 11:43-11:48 To Treat Vascular Trauma: For Military Practice: For Civilian Practice: What Issues Complicate It Paul W. White, MD Update On Isolated Limb Perfusion To Enable 11:49-11:54 Traumatically Amputated Limb Reimplantation Zachary M. Arthurs, MD 11:55-12:00 Unique Aspects Of Major Vascular Injury And Its Treatment In The Ukraine War: From An Experience With Over 700 Major Arterial And Venous Injuries Yuliia Nahaliuk, MD Lunch Break - Rhinelander Gallery, 2nd Floor 12:00- 1:00 Visit Exhibits And Pavilions (2nd and 3rd Floors) SESSION 51 (Grand Ballroom East, 3rd Floor) PROGRESS IN THE TREATMENT OF RUPTURED INFRARENAL AAAs, COMPLEX AAAs, TAAAS AND **RELATED TOPICS** Moderators: Thomas L. Forbes. MD Timur P. Sarac, MD Frank J. Veith, MD 1:00 - 1:05Complications After EVAR For Ruptured AAAs: How To Prevent Them And How To Treat Them Tal M. Hörer, MD, PhD

The Frequency Of Ruptured AAAs Is Plummeting:

What Is The Reason And Why Is It A Challenge To

Training And Treatment Ian Loftus, MD Peter Holt, MD, PhD

1:06 - 1:11

10:52-11:02

Only One-Third Of Ruptured AAA Patients Were Randomized In The 3 RCTs Comparing EVAR With Open Repair: Why Does That Invalidate The Conclusion Of The RCTs That EVAR Is No Better Than Open Repair Thomas L. Forbes. MD
Thomas L. Forbes, MD

- 1:18 1:23 Long-Term Results Of The AJAX RCT Comparing
 EVAR With Open Repair For Ruptured AAAs: Despite
 Its Flaws, EVAR Wins In The End Especially In
 Patients >80
 Willem Wisselink, MD
- 1:24 1:29 Variation In Use Of EVAR Versus Open Repair For Ruptured AAAs Depends On Training And Bias Rather Than Data, Logic Or Facts: EVAR Is Clearly The Best Treatment If It Can Be Done

 Martin Malina, MD, PhD
- 1:30 1:35

 EVAR Should Be The Standard Of Care For Most Ruptured AAAs: Reasons Why It Is Not So And How To Overcome Them

 Hans-Henning Eckstein, MD, PhD (PowerPoint Presentation With Christoph Knappich, MD Synched Audio)
- 1:36 1:41

 A New System For Estimating AAA Wall Weakness From Gated Dynamic CT Scans: A Better Way To Predict Rupture Risk (From ViTAA Medical): How Does It Work And Where Does It Stand Randy D. Moore, MD Mark A. Farber, MD
- 1:42 1:47 Outcomes Of Ruptured AAA Repair Are Better In High Volume Institutions Both For EVAR And Open Repair: From A Meta-Analysis With >120,000 Cases George A. Antoniou, MD, PhD, MSc
- 1.48 1.53 Aortic Endograft Diameter Sizing With Ruptured Aneurysms: Why Is It Different And How To Do It Zoran Rancic, MD, PhD
- 1.54 1.59 With Ruptured Complex AAAs And TAAAs Parallel Grafts Are The Best Treatment: They Are Simpler, More Effective And Less Costly Than Other Treatments Manish Mehta, MD, MPH

2:00 - 2:06 Panel Discussion

SESSION 52 (Grand Ballroom East, 3rd Floor)
MORE NEW DEVELOPMENTS IN RUPTURED
AAAS AND TAAAS; WHAT IS AND SHOULD BE
HAPPENING WITH AAA SCREENING

Moderators: Keith D. Calligaro, MD Mario L. Lachat, MD Benjamin W. Starnes, MD

NEW DEVELOPMENTS IN EVAR SURVEILLANCE AND AAA SCREENING

- 2:06 2:11 Why We Are Doing More EVAR Surveillance Than
 Is Needed: The EVAR Surveillance Paradox: From A
 Meta-Analysis Of 23,000 EVAR Patients
 George A. Antoniou, MD, PhD, MSc
- 2.12 2.17 Update On Current Screening For AAAs In The US:
 Most Ruptured AAAs Occur In Patients Not Being
 Screened: How Should US PSTF Recommendations
 Be Changed And How Should Screening Groups Be
 Expanded

Marc L. Schermerhorn, MD Thomas F.X. O'Donnell, MD 2.18 – 2.23 New Developments In AAA Screening: Is It Overused Or Underused: Has It Decreased Rupture Rates In Denmark Or Elsewhere: Should We Change Who Is Being Screened

Jes S. Lindholt, MD

MORE ABOUT AAA RUPTURES AND THEIR TREATMENT

- 2.24 2.29 AAA Rupture After EVAR: Endovascular Treatment Is Best In This Setting And How To Do It David T. McGreevy, MD
- 2.30 2.35 AAA Rupture After EVAR Behaves Differently From De Novo Rupture: How Should Treatment Be Modified In Patients With Post EVAR Ruptures Piotr Szopinski, MD, PhD
- 2.36 2.41 Update On Treating All (100%) Ruptured Thoracic And Abdominal Aneurysms Endovascularly: A 13-Year Experience Shows It Is The Best Treatment And Lowers The Turndown Rate

 David T. McGreevy, MD

 Thomas Larzon, MD, PhD

 Mario L. Lachat, MD

 Tal M. Hörer, MD, PhD
- 2:42 2:47 Applicability And Results Of Cook t-Branch OTS Endograft In Complex Aortic Aneurysms (Ruptured And Elective) With Narrow Internal Aortic Lumens: Advantages And Limitations

 Ciro Ferrer, MD

 Rocco Giudice, MD
- 2.48 2.53 In Situ Laser Fenestration To Facilitate Endograft
 Treatment Of Ruptured TAAAs: When Is It Needed;
 How To Do It And Results
 Stephan Haulon, MD
 Dominique Fabre, MD
- 2.54 2.59 Role Of In Situ F/EVAR For Treating Ruptured Complex AAAs: How To Do It And Results Sukgu Han, MD Fred A. Weaver, MD, MMM
- 3.00 3.05 How Can The Turndown Rate For Invasive Treatment Of Ruptured AAAs Be Decreased And Is It Worthwhile Matthew W. Mell, MD, MS
- 3:06 3:11 Urgent And Emergent Treatment Of Symptomatic And Ruptured Aortic Pathologies Using Physician Modified Endografts (PMEGs) Based On 3D Aortic Models: Is This A Limited Or Generalizable Technique Benjamin W. Starnes, MD
- 3:12 3:17 Update On Advances In Treatment Of Abdominal Compartment Syndrome Associated With Ruptured AAAs: When And How To Treat Medically And When And How To Treat With Opening The Abdomen Martin Björck, MD, PhD
- 3:18 3:30 Panel Discussion And Break
 Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 53 (Grand Ballroom East, 3rd Floor)
EXCITING NEW OR UPDATED CONCEPTS,
TECHNIQUES AND TREATMENTS

Moderators: Luis A. Sanchez, MD Reese A. Wain, MD

3:30 - 3:35	The CHOCO-CABANA RCT Shows The Chocolate
	PTA Balloon (From Medtronic) Sustained Increased
	Lumen Gain Compared To POBA For BTK Lesions
	Gunnar Tepe, MD
	Andrew Holden, MBChB
	Thomas Zeller, MD

- 3:36 3:41 Novel Application Of Polymer Technology To Create Endogenous Tissue With Host Collagen And Endothelium Compatible With Flowing Blood: 1-Year Clinical Results Of The aXess Graft (From Xeltis) Frans L. Moll, MD, PhD
- 3:42 3:47 Progress With The Retrievable Rescue Stent-Graft To Control Massive Aortic Or Caval Bleeding: How Does It Work, How Is The Device Retrieved And When Will It Be Widely Available

 Bryan W. Tillman, MD, PhD
- 3.48 3.53

 Value And Limitations Of The 355 nm Auryon
 B-Laser™ (From AngioDynamics) For The Treatment
 Of Infrainguinal Atherosclerotic Disease: Results
 And How It Can Help Facilitate The Safe Crossing Of
 Otherwise Uncrossable Lesions
 Luis R. Leon, Jr., MD (PowerPoint Presentation With Synched Audio)
- 3.54 3.59 Transradial Approaches With The Terumo R2P System Enable Endovascular Treatment Of Complex Renal, Visceral, And Lower Extremity Stenotic And Occlusive Lesions Including CTOs: Do They Work For Lesions Below The Knee

 David O'Connor, MD
- 4:00 4:05 Improving The Function Of A Hybrid Room: What Are The Elements And How Does The "OR Black Box System" Help To Improve Operator Performance And Decrease Radiation Exposure

 Isabelle Van Herzeele, MD, PhD
- 4.06 4:11 Update On A Clampless Sutureless Technique For Performing Difficult Arterial Anastomoses Using Endograft Connectors: The VORTEC Technique Useful When Arterial Dissection, Control And Suturing Are Challenging Or Impossible As With Heavily Calcified Arteries

 Mario L. Lachat, MD
- 4:12 4:17 IVUS Studies Before And After PTAs With The Ultrascore Scoring Balloons (From BD) Show The Benefits Of Such Balloons And How They Work Robert E. Beasley, MD
- 4:18 4:23 Femoral Vein Grafts For Arterial Procedures: How
 To Harvest Them Safely And Expeditiously Without
 Consequences To The Donor Limb: When Can They Be
 Uniquely Beneficial
 Timur P. Sarac, MD

4:24 – 4:31 Panel Discussion

SESSION 54 (Grand Ballroom East, 3rd Floor)
PROGRESS IN RADIATION SAFETY AND MORE
NEW CONCEPTS, DEVICES AND TECHNIQUES

Moderators: Lindsay Machan, MD Glenn Jacobowitz, MD

WHAT'S NEW IN RADIATION SAFETY

4:32 – 4:37 Myths And Facts Regarding Radiation Protection And Safety: Imperfections In Protection From Leaded Glasses And Light Weight Leaded Gowns

Lindsay Machan, MD

4:38 - 4:43	Cancer Risk To Patients And Operators From Radiation Exposure From EVAR Peri- And Post-Operatively: Role Of Radiation Sparing Technologies Bijan Modarai, PhD, FRCS
4:44 — 4:49	Small Tips And Modifications In Radiation Safety Can Make A Huge Impact On Staff Exposure: What Are They Maarit Venermo, MD, PhD
4:50 - 4:56	Panel Discussion
	NEW CONCEPTS, ETC.
4:56 — 5:01	The No Intervention Option For Treatment Is More Commonly Elected For Women Than Men With CLTI, AAAs, Ruptured AAAs And Thoracic Aneurysms: It Is Wrong Headed And Unfair: From The WARRIORS Trial
	Janet T. Powell, MD, PhD
5:02 — 5:07	Endovascular Emergency Treatment Of Carotid Blowout From Head And Neck Cancer Or Carotid Patch Infections: Planning, Preparation And Technical Tips Are Essential Michael B. Silva, Jr., MD
5:08 — 5:13	Hybrid Superficial Venous Arterialization For REAL No Option CLTI; Step-By-Step Technical Tips And Patterns Of Failure Which Is Common Miguel F. Montero-Baker, MD John H. Rundback, MD
5:14 — 5:19	What's New In Transvenous Liver Biopsies <i>Jacob Cynamon</i> , <i>MD</i>
5:20 — 5:25	Management Of Pediatric Vascular Trauma: Evolving Endovascular Strategies, Expanded Device Availability, Technical Tips And How To Deal With Spasm Dawn M. Coleman, MD
5:26 — 5:31	The Aortyx Aortic Patch: A More Compliant Way To Seal Aortic Defects: A New Endovascular Approach: How Does It Work, Improved Delivery System And Progress To Date Vicente Riambau, MD, PhD
5:32 — 5:37	Results From The AFX2-LIVE Registry: An Experience With The Outcomes Of 500 AFX EVAR Cases: Benefits, Complications And Conversions Pasqualino Sirignano, MD Francesco Speziale, MD
5:38 — 5:43	With Esophageal Cancer, When Is Prophylactic TEVAR Indicated To Prevent An Aorto-Esophageal Fistula: It Improves Palliation But Does It Improve Survival <i>I-Hui Wu, MD, PhD</i>
5:44 — 5:49	Digital Patient Data: Artificial Intelligence (AI), Machine Learning (ML) And Sensor Technology In The New Era Of Research And Clinical Medicine: What Are They And Why You Better Get Ready Peter A. Schneider, MD
5:50 — 5:58	Panel Discussion
	End of Program G

PROGRAM H (SESSIONS 55-63)

NEW OR IMPROVED DEVICES FOR: STANDARD EVAR, EVAS AND MORE COMPLEX AAAs; REPAIRS OF TAAAs, THE ASCENDING AORTA, THE AORTIC ARCH, AND THE DESCENDING AORTA (TEVAR); NEW DEVICES FOR TREATING LOWER EXTREMITY LESIONS BY ENDO OR OPEN TECHNIQUES; UPDATE ON ENDOANCHORS AND FIXATION DEVICES AND NEW OR IMPROVED DEVICES FOR ENDOVASCULARLY REMOVING CLOT AND OCCLUDING BLOOD VESSELS

Grand Ballroom West, 3rd Floor

SESSION 55 (Grand Ballroom West, 3rd Floor)
NEW OR IMPROVED DEVICES FOR INFRARENAL
AAA REPAIR WITH STANDARD EVAR

Moderators: Thomas L. Forbes, MD Rossi M. Silva, MD Enrico Ascher, MD

- 7:00 7:05 Real World Outcomes With The TREO Endograft (Terumo Aortic): Results From The TIGER Registry Vicente Riambau, MD, PhD
- 7:06 7:11 Update On The Gore Conformable Excluder With Variable Neck Angulation Control For AAAs: Does It Enable EVARs In Patients With Otherwise Unsuitable Necks: Update On Status Of The IDE Trial And FDA Approval Robert Y. Rhee, MD
- 7.12 7.17 European Status Of The Gore Conformable Excluder For EVAR: 3-Year Results From The EXCEL Registry: CE Marked Since 2016
 Colin D. Bicknell, MD
 Marc R.H.M. van Sambeek, MD, PhD
- 7.18 7.23 Altura Endograft With Kissing Proximal Stents For Standard EVAR: Advantages And Limitations: From An Updated Experience With >150 Patients And 5-Year Follow-Up Dainis K. Krievins, MD
- 7.24 7.29 Advantages And Limitations Of The Cook ZENITH
 Alpha (Low Profile) Endograft For EVAR: Based On
 3-Year Results Of The European Multicenter ZEPHYR
 TRIAL
 Philippe W.M. Cuypers, MD, PhD
 Marc R.H.M. van Sambeek, MD, PhD
 Dittmar Böckler, MD
- 7:30 7:35 Panel Discussion
- 7:36 7:41 How And Why Do The Endurant Endograft Results For EVAR In France Differ From The Global Results: What Are The Implications

 Frank R. Arko, MD

 Jean-Pierre Becquemin, MD
- 7:42 7:47

 AAA Repairs With The Endurant Endograft Outside
 The IFU Can Provide Acceptable Results In Some
 Patients: When Is This So And When Not: From The
 EAGLE Registry
 Marc R.H.M. van Sambeek, MD, PhD
- 7.48 7.53 Head To Head Comparison Of Endurant And Excluder Endografts For EVAR In Challenging Asian AAA Anatomy
 Naoki Fujimura, MD, PhD

7.54 – 7.59 AFX 2 Anatomically Fixed Endografts For AAA Repair: The LEOPARD RCT 5-Year Results Show It Has Similar Outcomes To Other Widely Used Proximally Fixed Endografts

Christopher J. Kwolek, MD, MBA

8:00 – 8:05 Why AFX Endografts Work Well In Conical (Flared)
AAA Necks: Favorable 3-Year Results And Are There
Disadvantages
Naoki Fujimura, MD, PhD

8:06 – 8:11 Panel Discussion

SESSION 56 (Grand Ballroom West, 3rd Floor)
NEW OR UPDATED DEVICES FOR STANDARD EVAR,
EVAS (ENDOVASCULAR ANEURYSM SEALING)
AND F/EVAR; ENDOGRAFTS FOR TREATMENT OF
CONNECTIVE TISSUE DISORDERS

Moderators: James H. Black, III, MD Margaret Tracci, MD, JD

- 8:12 8:17

 Alto Endograft (From Endologix) For Standard EVAR:
 This Latest Modification Of The Ovation Endograft Has
 More Proximal Polymer Sealing Rings: Results From
 The ELEVATE Trial And 4+ Year Results From The
 New Zealand Experience Show Advantages: What Is
 The JAGUAR RCT
 Sean P. Lyden, MD
 Andrew Holden, MBChB
- 8:18 8:23 Update On The Alto Ultra Low-Profile Endograft With Adaptive Sealing Technology (From Endologix): From The ALTAIR Registry With Long-Term Results Gianmarco de Donato, MD
- 8:24 8:29 Experience With The Nellix Endograft In 120 Patients With Up To 10 Years Follow-Up: What Is The Device's Future

 Dainis K. Krievins, MD
- 8:30 8:35 Update Of A New Hybrid Device (Thoracoflo From Terumo Aortic) For TAAA Repair: How It Works, Clinical Experience And Advantages

 Sebastian E. Debus, MD, PhD

F/EVAR RELATED TOPICS

- 8.36 8.41 Technical Tips To Perform F/EVAR Through Unilateral Iliac Access: Useful When Contralateral Access Is Impossible

 Barend M.E. Mees, MD, PhD
- 8.42 8.47 Update On Multicenter Real World Results With F/EVAR Using The Fenestrated Anaconda (Terumo Aortic) Endograft: Advantages And Limitations Clark J. Zeebregts, MD, PhD

 Michel M.P. Reijnen, MD, PhD

 Afshin Assadian, MD

ENDOVASCULAR AORTIC REPAIRS FOR CONNECTIVE TISSUE DISORDERS

- 8.48 8.53 Endovascular Repairs In Genetic Connective Tissue Aortopathies: How Genotype-Surgical Phenotype Correlation Impacts Endovascular Repair Outcomes Sherene Shalhub, MD, MPH
- 8:54 8:59 F/B/EVAR In Patients With Connective Tissue Disorders: When And When Not: How Well Do They Work And When Not To Do Them Piergiorgio Cao, MD

9:00 – 9:05

Value Of Endo TAAA Repair In Patients With
Connective Tissue Disorders And Why Is The Gap
Between Fenestration And Aortic Wall Important In F/
EVAR

Gustavo S. Oderich, MD

9.06 – 9.20 Panel Discussion And Break
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 57 (Grand Ballroom West, 3rd Floor) NEW OR IMPROVED DEVICES FOR THE ASCENDING AORTA, THE AORTIC ARCH OR NEAR THE ARCH

Moderators: Tilo Kölbel, MD, PhD Rodney A. White, MD

- 9.20 9.25 Endovascular Repair Of Aortic Arch Lesions With In Situ Fenestration Of A Lifetech Endograft For The Graft Vessels As An Alternative To Branched Endografts Ralf R. Kolvenbach, MD
- 9.26 9.31 Changes In The Aortic Valve And Aortic
 Morphometrics After Ascending Aorta And Arch
 Endograft Placement
 Jean Bismuth, MD
 Ross Milner, MD
- 9.32 9.37 New Developments With Terumo Ascending Aorta Endograft Vicente Riambau, MD, PhD

Afshin Assadian, MD Mo S. Hamady, MD

- 9:38 9:43 Status In The US Of The Relay Branch Investigational Device (Terumo Aortic) For Repair Of Aortic Arch Lesions: How Many Branches Can And Should Be Revascularized: Advantages And Limitations

 Luis A. Sanchez, MD

 Eric E. Roselli, MD
- 9.44 9.49

 Nexus OTS Endograft From Endospan For Treating
 Zone 0 And 1 Lesions Of The Aortic Arch: How Does
 It Work And 4-Year Clinical Results: Status In The US
 Mario L. Lachat, MD
 Ross Milner, MD
 Jean M. Panneton, MD
 Andrew Holden, MBChB
 Daniel G. Clair, MD
 Nicola Mangialardi, MD
- 9.50 9.55 Status Of And When And How To Use The Gore Conformable CTAG Endograft With Variable Angulation Control Optimally: Advantages And Limitations

 Sukgu Han, MD
- 9:56 -10:02 Panel Discussion

SESSION 58 (Grand Ballroom West, 3rd Floor)
NEW OR IMPROVED DEVICES FOR THORACIC
AORTIC LESION REPAIRS (TEVAR) AND FOR
THORACOABDOMINAL ANEURYSM (TAAA)
REPAIRS

Moderators: Giovanni B. Torsello, MD Carlos H. Timaran, MD

	DEVICES FOR TEVAR
10:02-10:07	Low Profile Devices For TEVAR And B/EVAR: Disadvantages And Advantages Based On A 10-Year Experience With Matched Patients Giovanni B. Torsello, MD
10:08-10:13	Long-Term Results With The Cook ZENITH Alpha Thoracic Endograft For TEVAR In More Than 500 Patients In A Real World 10-Year Experience Germano C.G. Melissano, MD Roberto L.V. Chiesa, MD
10:14-10:19	A Modified Candy Plug Technique For False Lumen Treatment After TEVAR For TBAD Ali Azizzadeh, MD
10:20-10:25	Fenestrated Endovascular Aortic Repair Plus Chimney Graft For TAAA Repairs: The FEVARCh Technique Ross Milner, MD
10:26-10:31	Urgent And Emergent Endovascular Repair Of Complex AAAs And TAAAs Are Possible With Off- The-Shelf (OTS) Devices And PMEGs: When Are OTS Devices Preferable Bernardo C. Mendes, MD
10:32-10:37	Panel Discussion
10:37-10:42	The Relay Pro (Terumo Aortic) Endograft For TEVAR And Its Advantages In Treating TBADs: Why Is It Better Than The Older Relay Plus Device Javairiah Fatima, MD Steven D. Abramowitz, MD
10:43-10:48	Patient Specific Custom Designed Relay Pro Endografts (Terumo Aortic): How Do They Work And What Are Their Advantages In Various Circumstances David M. Williams, MD (PowerPoint Presentation With Synched Audio) Mazin Foteh, MD
10:49-10:54	Relay Custom-Made Endografts (Terumo Aortic) For TEVAR: Why Do They Provide Better Wall Apposition For Sealing Fadi Taher, MD Afshin Assadian, MD
	NEW OR IMPROVED ENDO DEVICES FOR TAAA REPAIRS
10:55-11:00	The Novel Artivion (Formerly CryoLife/Jotec) Off- The-Shelf (OTS) Inner Branched Device For TAAAs: Results And Why Is It Better Than Outer Branched OTS Devices: Are There Limitations Lee Bouwman, MD, PhD, MSc
11:01-11:06	Colt 2.0 – The Technology That Evolved From An Outer To Multi Inner Branched Device: How It Works And Mid-Term Outcomes Piotr Szopinski, MD, PhD
11:07-11:12	To Treat Complex TAAAs: Combination Of Relay (Terumo Aortic) TEVAR And Fenestrated And Branched EVAR Is Best: How Has The Treatment Evolved: Technical Tips And Outcomes <i>Mo S. Hamady, MD</i>
11:13-11:18	Panel Discussion
11:19-11:24	Preloaded Fenestrated Endografts With A Modified Biport Handle (From Cook): A Way To Make F/EVAR Easier: Results From An International Multicenter Study Nikolaos Tsilimparis, MD, PhD

11:25-11:30 Comparison Of The Cook t-Branch OTS Endograft Device With The E-nside (Artivion) Multibranched Device For Juxta- And Pararenal AAAs: Advantages And Limitations Of Each Matteo Orrico, MD Nicola Mangialardi, MD 11:31-11:36 Comparison Of 2 OTS Endografts For Urgent TAAA Repairs: E-nside (Artivion) Versus t-Branch (Cook): Advantages And Disadvantages Of Each Luca Bertoglio, MD Roberto L.V. Chiesa, MD Germano C.G. Melissano, MD Valiant Manifold OTS Endograft Device (Medtronic) 11:37-11:42 For Repairing TAAAs: How Does It Work; Update On Clinical Experience And Future Prospects Murray L. Shames, MD 11:43-11:48 Innovative Treatment Of The Thoracoabdominal And Pararenal Aortic Aneurysms Using Fenestrated TREO Endografts (Terumo) And Parallel VBX Stent-Grafts (Gore): Use Of The Shape Memory Impede-FXPlug To Treat Gutter Endoleaks James F. McKinsey, MD 11:49-11:54 Is There A Role For Hyperbaric Oxygen Therapy In Preventing Or Treating Spinal Cord Ischemia After TAAA Repair Thomas F. Lindsay, MDCM 11:55-12:00 Panel Discussion 12:00- 1:00 Lunch Break - Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors) SESSION 59 (Grand Ballroom West, 3rd Floor) NEW OR UPDATED INFORMATION ON RE-ENTRY DEVICES. LOWER EXTREMITY PROSTHETIC GRAFTS (SEE ALSO SESSION 28), PERIGRAFT SEROMA AND . VALUE OF A PROSTHETIC PERIGRAFT SIROLIMUS PATCH Moderators: Samuel R. Money, MD, MBA Patrick J. Lamparello, MD A NEW LOOK AT RE-ENTRY DEVICES 1:00 - 1:05Pros And Cons Of Re-Entry Devices In Treating CTOs: Why, Where And When To Use Them Maria A. Ruffino, MD PROSTHETIC GRAFTS Final 5-Year Results Of The ZILVERPASS RCT 1:06 - 1:11Comparing Prosthetic PTFE Bypasses With Zilver PTX (Cook) Stents To Treat Long Fempop Lesions: Clinical And Financial Results And Their Implications Michel J. Bosiers, MD Marc Bosiers, MD 1:12 - 1:17The BioMimics 3D Spiral Flow Prosthetic Graft From Veryan Medical: Does It Prevent Neointimal Hyperplasia In Leg Bypasses Or A-V Access Hosam F. El Sayed, MD 1:18 - 1:23Heparin Coated (Propaten) PTFE Grafts (Gore) Versus Autologous Vein Grafts For Bypasses To Targets Above And Below The Knee: The Heparin Coated Grafts Are Better And Worth The Cost: Based On A Propensity Matching Analysis David J. Dexter, MD

1:24 – 1:29 Perigraft Seromas After PTFE Lower Extremity And Aortic Arterial Grafts: Frequency, Etiology And What To Do About Them Jae S. Cho, MD

1:30 – 1:35 Update On External Sirolimus Patch Wrap-Arounds For PTFE Graft Anastomoses: Do They Decrease Neointimal Hyperplasia Sriram S. Iyer, MD

1:36 – 1:42 Panel Discussion

SESSION 60 (Grand Ballroom West, 3rd Floor)
NEW OR IMPROVED ENDOVASCULAR DEVICES
FOR LOWER EXTREMITY TREATMENTS:
ATHERECTOMY, STENTS, TACKS, ACCESSORIES,
ETC. (SEE ALSO SESSIONS 23-27)

Moderators: Maciej L. Dryjski, MD, PhD Sateesh Babu, MD Enrico Ascher, MD

ATHERECTOMY RELATED TOPICS

- 1:42 1:47 The Serranator® Balloon Catheter (From Cagent Vascular) For Vessel Prep In BTK Arteries: It Makes Microserrations, Prevents Dissections, Lessens Elastic Recoil With PTA: Current Status Steven Kum, MD Andrew Holden, MBChB
- 1.48 1.53 A Balanced View Of Atherectomy In Ambulatory Surgicenters (ASCs) And OBLs In 2023: Are There Differences And Is The Procedure Overused Krishna Jain, MD
- 1:54 1:59 Atherectomy: When Is It The Best Vessel Prep: What Are Its Complications: How To Prevent And Treat Them: Which Device Is Best Theodosios Bisdas, MD
- 2:00 2:05

Orbital And Laser Atherectomy: Indications, Advantages And Precautions With Above And Below Knee De Novo Lesions And ISR Craig M. Walker, MD

2.06 – 2:11 The Value Of Directional Atherectomy Followed By DCBs For Long Calcified Fempop Lesions As Demonstrated By The Results Of The REALITY Trial Brian G. DeRubertis, MD

ANCILLARY TECHNIQUES

- 2:12 2:17 Value of Wingman Catheter (Reflow Medical) For Crossing Difficult Lesions: How Does It Work And Results

 John R. Laird, MD
- 2:18 2:23 New Dedicated Special Tools And Devices To Facilitate Transradial Access For Lower Extremity Lesion Treatments: How Far Distally Can It Be Effective Ramon L. Varcoe, MBBS, MS, PhD

2:24 - 2:30 Panel Discussion

NEW INFORMATION ON STENTS

2.30 – 2.35 Advantages Of Supera Stent (Vasculomimetic – VMI; From Abbott) For Complex Fempop Occlusive Lesions: Technical Tips: They Work Even In The Subintimal Position

Erwin Blessing, MD

2:36 — 2:41	Updated Value Of The Supera VMI Stent For Common Femoral Artery (CFA) Occlusive Lesions: Better Than Endarterectomy: 3-Year Results And Status Of The SUPERSURG RCT (Versus Open Surgery) Yann Gouëffic, MD, PhD
2:42 — 2:47	Why Are Stents In The Common Femoral Artery (CFA) Bad News: Standard Open Surgery Is Still The Best Option For Treating CFA Lesions Domenico Valenti, DMChir, PhD
2:48 — 2:53	Temporary Stent Assisted DCB Angioplasty In BTK Lesions With The Spur Spiked Stent System (Reflow Medical): Update On The DEEPER OUS Trial Thomas Zeller, MD
2:54 — 2:59	10-Year Experience With Transcatheter Arterialization Of The Deep Veins: My Early Failures; The Lessons I Have Learned; How I Do Them Now With More Success: Can It Be Improved More: Value Of The LimFlow Device Steven Kum, MD
3:00 — 3:06	Panel Discussion
3:06 — 3:18	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
NEW OR FOR LOW	(Grand Ballroom West, 3rd Floor) IMPROVED ENDOVASCULAR DEVICES VER EXTREMITY TREATMENTS: _ASTY BALLOONS
	John R. Laird, MD Thomas Zeller, MD
3:18 — 3:23	Subset Analysis From The TOBA II BTK Trial Of The Tack Device (From Philips) Shows No Loss Of Efficacy With Treatment Of Longer Lesions And A High Percentage Of CTOs Patrick J. Geraghty, MD
3:24 — 3:29	Value Of High-Pressure Non-Compliant Balloons For BTK Arterial Lesion Treatment: Why They Work Better And Other Technical Tips Steven Kum, MD
3:30 — 3:35	How To Obtain Retrograde Access Through The Medial Or Lateral Plantar Arteries Jos C. van den Berg, MD, PhD
3:36 — 3:41	Value Of The Passeo-18Lux DCB For Treating BTK And Popliteal Lesions With Or Without Bare Metal Stents Gunnar Tepe, MD
3:42 - 3:47	Unfavorable Balloon (Candy) Wrap Can Cause Dissections With Angioplasty: What Is The Mechanism: How Can It Be Recognized And Dissection Avoided: When Does Dissection Have To Be Treated And When Not Jos C. van den Berg, MD, PhD
3:48 — 3:53	Evidence-Based Considerations For Repairing Dissections After Angioplasty Of BTK Lesions: The Value Of Tacks Andrew Holden, MBChB
3:54 — 3:59	Chocolate Touch DCBs (From TriReme Medical): How Do They Work, Advantages And Updated Clinical Results From The CHOCALATE TOUCH Trial Thomas Zeller, MD Andrew Holden, MBChB
4:00 - 4:06	Panel Discussion

SESSION 62 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES AND TECHNIQUES TO PREVENT OR TREAT ENDOLEAKS OR DEVICE MIGRATION: ENDOANCHORS, ETC.

Moderators: William D. Jordan, Jr., MD Jean-Paul de Vries, MD, PhD

- 4:06 4:11 Endoanchors Improve Seal Zones And Outcomes With Fenestrated Endografts: When Should They Be Used And Technical Tips
 Shadi J. Abu-Halimah, MD
- 4:12 4:17 New Developments From The ANCHOR Registry
 With Over 5 Years Of Follow-Up Show The Value Of
 Endoanchors (Medtronic) When Used Prophylactically
 For Certain Indications Prevent Endoleaks And
 Migration: Large Diameter Necks Are One Of Those
 Indications
 William D. Jordan, Jr., MD
- 4:18 4:23 New Developments From The ANCHOR Registry With >5 Years Follow-Up Show That Endoanchors Can Be Used To Treat Endoleaks And Migration Effectively In Hostile Neck Anatomy: The Proof Jean-Paul de Vries, MD, PhD
- 4:24 4:29 Update On The VESTECK Catheter Based
 Endosuturing Technology For EVAR And TEVAR
 Fixation: How Does It Work; How Is It Different From
 Endoanchors And Early Successful Clinical Results
 Dainis K. Krievins, MD
 Sean P. Lyden, MD
 David H. Deaton, MD
- 4:30 4:35

 Balloon Optimized Molding For Better Deployment
 And Sealing Of Ovation Alto (From Endologix) Low
 Profile Endografts For EVAR: How To Do It And How
 It Helps Prevent Endoleaks And Migration
 David I. Minion, MD

4:36 – 4:42 Panel Discussion

SESSION 63 (Grand Ballroom West, 3rd Floor)
NEW OR IMPROVED ENDOVASCULAR DEVICES
FOR CLOT REMOVAL OR EMBOLIZATION
(SEE ALSO SESSION 30)

Moderators: James F. Benenati, MD Timothy M. Sullivan, MD

CLOT REMOVING DEVICES

- 4:42 4:47 Newer Pharmaco-Mechanical Endovascular Clot Removal Systems: When And Why Is Each Device Best To Use Guillermo A. Escobar, MD
- 4:48 4:53 Catheter Based Vacuum Assisted Thrombectomy With The Indigo Aspiration System From Penumbra For Acute Limb Ischemia: How Does It Work: Advantages And Limitations: From A Multicenter Study: Key Findings From The INDIAN Trial Gianmarco de Donato, MD Carlo Setacci, MD
- 4.54 4.59 Improved Mechanical Catheter And Computer Based Clot Removal Indigo Systems From Penumbra:
 Modulated Pulsed Aspiration Technology (Lightning Bolt And Thunder Bolt) For The Treatment Of Acute Arterial Clot: How It Works And Why It Improves Clot Removal In Various Vascular Beds

 James F. Benenati, MD

5:00 — 5:05	Different Options For Thrombosuction Devices For Thrombo-Embolectomy For Treating ALI: Which Device In Which Circumstances: When Is Their Use Limited Or Effective Athanasios Katsargyris, MD Eric L.G. Verhoeven, MD, PhD
5:06 — 5:11	Technical Tips For Effective Coil Embolization: Importance Of Dense Packing; Why Non-Fibered Coils Are Better Than Fibered Coils James F. Benenati, MD Constantino Pena, MD
5:12 — 5:17	How To Treat Type 1A Endoleaks And Persistent Enlarging False Lumens After TEVAR For TBAD: Coils, Plugs And New Polymer Based Options: When Will They Work; When Will They Not: Technical Tips <i>Mazin Foteh</i> , <i>MD</i>
5:18 — 5:23	Newer Vascular Occlusion Device: The Azur Device: How Does It Work And Advantages And Limitations Karthikeshwar Kasirajan, MD
5:24 — 5:29	How To Insert Large Vessel Embolization Devices (POD® From Penumbra) Through Low Profile Access Frank R. Arko, MD
5:30 — 5:35	Update On Onyx Liquid Embolic Occlusive Agent (From Medtronic): When And Where Is It Advantageous: Technical Tips For Use Tal M. Hörer, MD, PhD
5:36 — 5:41	Update On A New Liquid Embolic Agent (Lava LES) To Control Bleeding; How Does It Work, Advantages And Pivotal Trial Results Mahmood Razavi, MD
5:42 — 5:52	Panel Discussion
0.42 0.52	End of Program H
SUPERFIC	1 I (SESSIONS 64-73) CIAL VENOUS DISEASE Ilroom, 3rd Floor
Course Lea	ders: Jose I. Almeida, MD Lowell S. Kabnick, MD
	Peter Gloviczki, MD Thomas W. Wakefield, MD Steve Elias, MD
VENOUS HEMOD	Thomas W. Wakefield, MD
VENOUS HEMOD	Thomas W. Wakefield, MD Steve Elias, MD I (Trianon Ballroom, 3rd Floor) CLINICAL EXAMINATION AND YNAMICS Jose I. Almeida, MD Lowell S. Kabnick, MD Thomas W. Wakefield, MD
VENOUS HEMOD' Moderators	Thomas W. Wakefield, MD Steve Elias, MD 4 (Trianon Ballroom, 3rd Floor) 5 CLINICAL EXAMINATION AND YNAMICS 5: Jose I. Almeida, MD Lowell S. Kabnick, MD Thomas W. Wakefield, MD Steve Elias, MD Introduction To Veins At VEITH
VENOUS HEMOD' Moderators 7:00 – 7:04	Thomas W. Wakefield, MD Steve Elias, MD I (Trianon Ballroom, 3rd Floor) CLINICAL EXAMINATION AND YNAMICS Jose I. Almeida, MD Lowell S. Kabnick, MD Thomas W. Wakefield, MD Steve Elias, MD Introduction To Veins At VEITH Jose I. Almeida, MD Anatomy And Physiology Of The Venous And Lymphatic Glycocalyx

7:23 — 7:28	Is It Time To Revise The Definition Of Venous Reflux Fedor Lurie, MD, PhD
7:29 — 7:34	How To Measure DUS Venous Reflux Volume: Is It More Important Than Reflux Time Sergio Gianesini, MD, PhD
7:35 — 7:40	What Can Be Done To Repair Endogenously Or Exogenously The Glycocalyx Joseph D. Raffetto, MD
7:41 — 7:46	Hemodynamics Of Reflux Jose I. Almeida, MD
7:47 — 7:52	Panel Discussion
VENOUS REIMBUR	(Trianon Ballroom, 3rd Floor) GUIDELINES, IMPORTANT PAPERS AND SEMENT Peter Gloviczki, MD
wioderators.	Armando Mansilha, MD, PhD
7:53 — 7:58	European Society for Vascular Surgery Venous Guidelines Armando Mansilha, MD, PhD
7:59 — 8:04	SVS, AVF, AVLS Varicose Vein Guidlines – Part 1 Peter F. Lawrence, MD
8:05 — 8:10	SVS, AVF, AVLS Varicose Vein Guidelines – Part 2 Peter Gloviczki, MD
8:11 — 8:16	So Many Different Guidelines: Does It Make Sense Armando Mansilha, MD, PhD
8:17 — 8:22	Summary Of Important Venous And Lymphatic Articles – Journal of Phlebology – Editor's Choice Alun H. Davies, MD, DM, DSc
8:23 — 8:28	Summary Of Important Venous And Lymphatic Articles – Journal of Vascular Surgery Venous and Lymphatic Disorders – Editor's Choice Peter Gloviczki, MD
8:29 — 8:34	Primary Venous Insufficiency Increases Risk Of Deep Vein Thrombosis Maxim E. Shaydakov, MD
8:35 — 8:40	Forecast Of Venous Reimbursement And What Can Be Done John Blebea, MD, MBA
8:41 — 8:46	Sclerotherapy Of Lower Limb - Consensus Document UIP 2023 Sergio Gianesini, MD, PhD
8:47 — 8:52	Panel Discussion
SUPERFIC	(Trianon Ballroom, 3rd Floor) IAL VEIN TREATMENT STRATEGIES 1 Edward G. Mackay, MD Kursat A. Bozkurt, MD
8:53 — 8:58	The Length Of Treated Great Saphenous Vein As A Marker Of Post-Procedural Improvement In Clinical And Patient Reported Outcomes Faisal Aziz, MD
8:59 — 9:04	Is Cyanoacrylate Safe to Use For Venous Ablation Kursat A. Bozkurt, MD, PhD
9:05 — 9:10	What Do You Treat First In C2s With Reflux Of The GSV, SSV, And Vein Of Giacomini <i>Jean Luc Gerard, MD</i>
9:11 — 9:16	Saphenous Sparing: Why And Instructions For Users

9:17 — 9:22	Thermal Saphenous Vein Recanalization: Risk Factors Edward G. Mackay, MD
9:23 — 9:28	Strategies For Recurrent Varicose Vein Disease Felipe Coelho Neto, MD, MSc, PhD
9:29 — 9:34	US Glue: When I Do Not Use Cyanoacrylate <i>Kathleen D. Gibson, MD</i>
9:35 — 9:40	Synchronous Trial 6 Months Follow-Up Data (Simultaneous AASV Treatment For Patients Undergoing GSV Ablation) Tobias Hirsch, MD, PhD
9:41 — 9:46	Effects Of Truncal Ablation On Pregnancy Kursat A. Bozkurt, MD
9:47 — 9:52	Saphenous Ablation On Direct Oral Anticoagulants: Is It Safe, Effective And Durable <i>Glenn Jacobowitz, MD</i>
9:53 — 9:58	Panel Discussion
SUPERFIC	(Trianon Ballroom, 3rd Floor) CIAL VEIN TREATMENT STRATEGIES II : Alun H. Davies, MA, DM, DSc Kathleen J. Ozsvath, MD
9:59 -10:04	Decision Making In Saphenous Ablation: What To Use When Steve Elias, MD
10:05-10:10	Endovenous Foam Therapy Complications – What Now (French Government) Matthieu M.J. Josnin, MD, PhD
10:11-10:16	Systematic Review: Cyanoacrylate Truncal Ablation And Its Complications Omar L. Esponda, MD
10:17-10:22	Treatment For The Incompetent Sciatic Vein Julianne Stoughton, MD
10:23-10:28	SVT Treatment During Pregnancy: Treatment Choices Kathleen J. Ozsvath, MD
10:29-10:34	Would Treatment Of The Whole Length Of The GSV Reduce Recurrence/Reinterventions Alun H. Davies, MA, DM, DSc
10:35-10:40	Thermal Ablation: Still The Gold Standard Lowell S. Kabnick, MD
10:41-10:46	American Venous Forum: Venous Patient Outreach Study Faisal Aziz, MD
10:47-10:52	Panel Discussion
SUPERFIC	(Trianon Ballroom, 3rd Floor) CIAL VEIN TREATMENT STRATEGIES III Mohamed A. Nagib, MD, PhD Manjit S. Gohel, MD, PhD
10:53-10:58	When To Use Simultaneous Foam Sclerotherapy And Thermal Treatment In Varicose Vein Treatment Tobias Hirsch, MD
10:59-11:04	Complications Of Endovenous Thermal Ablation Of The GSV Lowell S. Kabnick, MD
11:05-11:10	When Is It OK To Ablate The Truncal Leg Veins With
	Chronic Iliofemoral Outflow Obstruction Houman Jalaie, MD, PhD
11:11-11:16	SVT Management: Anything New In 2023 Manjit S. Gohel, MD, PhD

11:17-11:22	How To Treat Vulvar Varicose Veins: Phlebectomy And/Or Sclerotherapy Aleksandra Jaworucka-Kaczorowska, MD, PhD
11:23-11:28	Chronic Venous Disease Is Indicative Of A Shorter Life Alun H. Davies, MA, DM, DSc
11:29-11:32	What You Should Know About Klippel-Trenaunay Syndrome Byung-Boong Lee, MD
11:33-11:38	Treatment And Pitfalls: Lateral Marginal Vein Peter Gloviczki, MD
11:39-11:44	Overview Of Multicenter Venclose Study And Early Results Erin H. Murphy, MD
11:45-11:50	Great Saphenous Vein "Crossectomy" For Recurrence Prevention Of Varicose Vein Mohamed A. Nagib, MD
11:51-11:56	Panel Discussion
11:57-12:24	Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors)
SUPERFIC	(Trianon Ballroom, 3rd Floor) EIAL VEIN TREAMENT STRATEGIES IV Mikel Sadek, MD Lowell S. Kabnick, MD Thomas W. Wakefield, MD
12:25-12:30	Does Deep Venous Reflux Matter With Superficial Ablation Mikel Sadek, MD
12:31-12:36	JURY Trial Antonios P. Gasparis, MD
12:37-12:42	The Thresholds Of Caprini Score Associated With Increased Risk Of Venous Thromboembolism Across Different Specialties: A Systematic Review Tomasz Urbanek, MD, PhD
12:43-12:48	Proposed EFIT Classification Lowell S. Kabnick, MD
12:49-12:54	Adjunctive Techniques To Minimize Thrombotic Complications Following Microfoam Ablation Of Symptomatic Truncal And Tributary Vein Juan C. Jimenez, MD, MBA
12:55- 1:00	Treatment And Contemporary Outcomes Associated With Adjunct Tourniquet Use During Phlebectomy Of Complex, Voluminous Truncular Varicosities Thomas W. Wakefield, MD
1:01 - 1:06	Foam Therapies (PCF Versus Pem): When To Use And Does It Make A Difference Edward G. Mackay, MD
1:07 — 1:12	Risks And Contraindications Of Medical Compression Treatment – A Critical Reappraisal – An International Consensus Statement Mark H. Meissner, MD
1:13 — 1:18	Sclerotherapy Of Pudendal And Vulvar Varicose Veins Claudine M. Hamel-Desnos, MD
1:19 — 1:24	Panel Discussion
	(Trianon Ballroom, 3rd Floor) IAL VEIN TREAMENT STRATEGIES V

Moderators: Jose I. Almeida, MD Natalie A. Marks, MD, RPVI, RVT Enrico Ascher, MD

1:25 — 1:30	
	Randomized Controlled Study Of EVLA And Foam In The SSV-FOVELASS Study: 3-Year Results Claudine M. Hamel-Desnos, MD
1:31 — 1:36	US Based Ultrasound Guided Sclerotherapy 3,565 Consecutive Cases: Efficacy And Complication Rates Natalie A. Marks, MD, RPVI, RVT Enrico Ascher, MD
1:37 — 1:42	Which Saphenous Vein Recanalization Should Be Treated And By What Method – Evidence Based Jose I. Almeida, MD
1:43 — 1:48	Patterns Of Anterior Saphenous Vein Reflux (A.K.A AAGSV) And Implications Of Treatment Nicos Labropoulos, BSc (Med), PhD, DIC
1:49 — 1:54	Is There Any Evidence For Compression Trial Prior To Insurance Approval <i>Omar L. Esponda, MD</i>
1:55 — 2:00	HIFU: What Do We Know And Report – Global Report Steve Elias, MD
2:01 — 2:06	New Device (Compression, Oxygen, And Humidification) – Does It Improve Wound Healing Joann M. Lohr, MD
2:07 — 2:12	New Devices And Not Yet Approved Lowell S. Kabnick, MD
2:13 — 2:18	Panel Discussion
AESTHET	(Trianon Ballroom, 3rd Floor) IC PHLEBOLOGY AND SCLEROTHERAPY
STRATEG	
Moderators:	Victor Canata, MD, PhD Steve Elias, MD
2:19 — 2:24	Venous Lesions Of The Face Kasuo Miyake, MD, PhD (PowerPoint Presentation With Synched Audio)
2:25 — 2:30	DEBATE: Foam Sclerotherapy Is The Best Treatment For C1: Pro <i>Matthieu M.J. Josnin, MD</i>
2:25 — 2:30 2:31 — 2:36	For C1: Pro
	For C1: Pro Matthieu M.J. Josnin, MD DEBATE: Foam Sclerotherapy Is The Best Treatment For C1: Against
2:31 — 2:36	For C1: Pro Matthieu M.J. Josnin, MD DEBATE: Foam Sclerotherapy Is The Best Treatment For C1: Against Edward G. Mackay, MD Ultrasound Guided Foam Sclerotherapy For Reticular Venous Plexus: Systematization Of The Technique
2:31 - 2:36 2:37 - 2:42	For C1: Pro Matthieu M.J. Josnin, MD DEBATE: Foam Sclerotherapy Is The Best Treatment For C1: Against Edward G. Mackay, MD Ultrasound Guided Foam Sclerotherapy For Reticular Venous Plexus: Systematization Of The Technique Alvaro Orrego, MD Ultrasound Imaging For Cosmetic Venous Issues
2:31 - 2:36 2:37 - 2:42 2:43 - 2:48	For C1: Pro Matthieu M.J. Josnin, MD DEBATE: Foam Sclerotherapy Is The Best Treatment For C1: Against Edward G. Mackay, MD Ultrasound Guided Foam Sclerotherapy For Reticular Venous Plexus: Systematization Of The Technique Alvaro Orrego, MD Ultrasound Imaging For Cosmetic Venous Issues Nicos Labropoulos, BSc (Med), PhD, DIC CLaCS Guided By Augmented Reality: Patient Selection, Method And Expected Results
2:31 - 2:36 2:37 - 2:42 2:43 - 2:48 2:49 - 2:54	For C1: Pro Matthieu M.J. Josnin, MD DEBATE: Foam Sclerotherapy Is The Best Treatment For C1: Against Edward G. Mackay, MD Ultrasound Guided Foam Sclerotherapy For Reticular Venous Plexus: Systematization Of The Technique Alvaro Orrego, MD Ultrasound Imaging For Cosmetic Venous Issues Nicos Labropoulos, BSc (Med), PhD, DIC CLaCS Guided By Augmented Reality: Patient Selection, Method And Expected Results Kasuo Miyake, MD, PhD (PowerPoint Presentation With Synched Audio) Tips And Tricks Of Sclerotherapy – What Makes It Easier And Successful
2:31 - 2:36 2:37 - 2:42 2:43 - 2:48 2:49 - 2:54 2:55 - 3:00	For C1: Pro Matthieu M.J. Josnin, MD DEBATE: Foam Sclerotherapy Is The Best Treatment For C1: Against Edward G. Mackay, MD Ultrasound Guided Foam Sclerotherapy For Reticular Venous Plexus: Systematization Of The Technique Alvaro Orrego, MD Ultrasound Imaging For Cosmetic Venous Issues Nicos Labropoulos, BSc (Med), PhD, DIC CLaCS Guided By Augmented Reality: Patient Selection, Method And Expected Results Kasuo Miyake, MD, PhD (PowerPoint Presentation With Synched Audio) Tips And Tricks Of Sclerotherapy – What Makes It Easier And Successful Victor Canata, MD, PhD How To Avoid Complications From Sclerotherapy Harold J. Welch, MD Cosmetic Treatment Of Hand And Foot Veins
2:31 - 2:36 2:37 - 2:42 2:43 - 2:48 2:49 - 2:54 2:55 - 3:00 3:01 - 3:06	For C1: Pro Matthieu M.J. Josnin, MD DEBATE: Foam Sclerotherapy Is The Best Treatment For C1: Against Edward G. Mackay, MD Ultrasound Guided Foam Sclerotherapy For Reticular Venous Plexus: Systematization Of The Technique Alvaro Orrego, MD Ultrasound Imaging For Cosmetic Venous Issues Nicos Labropoulos, BSc (Med), PhD, DIC CLaCS Guided By Augmented Reality: Patient Selection, Method And Expected Results Kasuo Miyake, MD, PhD (PowerPoint Presentation With Synched Audio) Tips And Tricks Of Sclerotherapy – What Makes It Easier And Successful Victor Canata, MD, PhD How To Avoid Complications From Sclerotherapy Harold J. Welch, MD

3:19 — 3:24	Quick Case 2: Ask The Panel Or Audience What Would You Do (Cosmetic) Edward G. Mackay, MD
3:25 — 3:30	Panel Discussion
SUPERFIC	(Trianon Ballroom, 3rd Floor) IAL VEIN TREATMENT STRATEGIES VI Raghu Kolluri, MD Gloria Salazar, MD
3:31 — 3:36	Global Epidemiology Of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis Alun H. Davies, MD, DM, DSc Sarah Onida, MD, PhD
3:37 — 3:42	When Evaluating Superficial Disease, When Do You Look For Deep Venous Obstruction Gloria Salazar, MD
3:43 — 3:48	Not All C2 Disease Should Be Treated: An Algorithm To Predict Severity $Mikel Sadek, MD$
3:49 — 3:54	Results Of Truncal Vein Ablation Utilizing Polidocanol Endovenous Microfoam Delivered In A Retrograde Fashion Steven T. Deak, MD
3:55 — 4:00	Varithena® VLU Registry: The Effects Of Polidocanol Endovenous Microfoam On Wound Healing And Recurrence Raghu Kolluri, MD
4:01 — 4:06	Phlebectomy And Foam Sclerotherapy For Varicose Veins: Which Is Better And When Felipe Coelho Neto, MD, MSc, PhD
4:07 — 4:12	Ambulatory Phlebectomy – Utilization And Clinical Outcomes John Blebea, MD, MBA
4:13 — 4:18	Outcome Of A Single Center Trial Comparing A Large Patient Cohort With Retrograde Administration Of Ultrasound-Guided Polidocanol Endovenous Microfoam Versus Endovenous Laser Steven T. Deak, MD
4:19 — 4:24	Radiofrequency Ablation Versus Polidocanol Endovenous Microfoam Ablation Of Large Diameter Saphenous And Tributary Veins Juan Jimenez, MD
4:25 — 4:30	How To Survive An Insurance Audit Harold J. Welch, MD
4:31 — 4:36	Venaseal Spectrum RCT: Update Manjit S. Gohel, MD
4:37 — 4:42	VERITAS Study: Polidocanol Endovenous Microfoam Versus Thermal Steve Elias, MD
4:43 — 4:48	How To Avoid Complications Of The Small Saphenous Vein <i>Jean Luc Gerard, MD</i>
4:49 — 5:04	Panel Discussion
	(Trianon Ballroom, 3rd Floor) A, LYMPHEDEMA, PHLEBOLYMPHEDEMA,

AND ULCERS

Moderators: Thomas F. O'Donnell, Jr., MD Mark D. Iafrati, MD

5:05 — 5:10	Lower Extremity Edema Workup Antonios P. Gasparis, MD
5:11 — 5:16	What is Lipedema And The Current Management Steven M. Dean, DO
5:17 — 5:22	Overview Of Lymphatic Anatomy And Physiology Thomas F. O'Donnell, Jr., MD
5:23 — 5:28	The American Venous Forum, American Vein & Lymphatic Society, And The Society for Vascular Medicine Expert Opinion Consensus On Lymphedema Diagnosis And Treatment Mark D. Iafrati, MD
5:29 - 5:34	The Critical Role Of Phlebolymphedema And Cellulitis (85,000 Patients) Thomas F. O'Donnell, Jr., MD
5:35 — 5:40	Venolymphatic Edema And Its Treatment Options Raghu Kolluri, MD
5:41 — 5:46	The Need For Lymphatic-Specific Treatment In Phlebolymphedema And Its Results Thomas F. O'Donnell, Jr., MD
5:47 — 5:52	Role Of Hydrotherapy In Lymphedema Treatment Mohamed A. Nagib, MD
5:53 — 5:58	Are Lymphedema, Lipedema, And Edema Related Steven M. Dean, DO
5:59 — 6:04	Pharmacological Treatment For Lymphedema Monika L. Gloviczki, MD, PhD
6:05 — 6:10	Risks And Contraindications Of Medical Compression Treatment – A Critical Reappraisal: An International Consensus Statement Tomasz Urbanek, MD, PhD
6:11 — 6:16	Venous Ulcers: The Contributions Of Deep, Perforator, And Superficial Procedures On Wound Healing Peter F. Lawrence, MD
6:17 — 6:22	What Type Of Skin Graft And When To Use Mark D. Iafrati, MD
6:23 — 6:28	Adjuvant Pharmacologic Therapy For Venous Leg Ulcer Monika L. Gloviczki, MD, PhD
6:29 - 6:34	Review Of Current Evidence For Topical Treatment For Venous Leg Ulcers Maxim E. Shaydakov, MD
6:35 — 6:40	Panel Discussion End of Program I

PROGRAM J (SESSIONS 74-78)

MULTIDISCIPLINARY ACUTE STROKE

MANAGEMENT

Murray Hill Suites, 2nd Floor

Course Leader: Allan L. Brook, MD

SESSION 74 (Murray Hill Suites, 2nd Floor)

EMERGING TRENDS IN ISCHEMIC STROKE

TREATMENT

Moderators: Allan L. Brook, MD Joshua A. Hirsch, MD

8:00 – 8:10 Introduction
Allan L. Brook, MD

8:11 — 8:18	Latest Trials Update: Understanding The Evidence – ASPECTS 3-5 David S. Liebeskind, MD (PowerPoint Presentation With Synched Audio)
8:19 — 8:26	Latest Trials Update: ASPECTS 3-5 Nuances And Practicality Rafael A. Ortiz, MD
8:27 — 8:34	Imaging Predictors Of Outcomes – Association Between New Water Uptake And Functional Outcome In Patients With Low ASPECTS Richard L. Zampolin, MD
ACCESS Moderators:	(Murray Hill Suites, 2nd Floor) SSUES (PROXIMAL AND DISTAL): PEARLS Allan L. Brook, MD Joshua A. Hirsch, MD
8:35 — 8:42	Can You Be Too Distal For Thrombectomy David Fiorella, MD, PhD
8:43 — 8:50	Tandem Occlusions: Should We Stent James Milburn, MD
8:51 — 8:58	Direct Carotid Access: Has The Time Emerged Ajay K. Wakhloo, MD, PhD (PowerPoint Presentation With Synched Audio)
8:59 — 9:06	Mevo And Devo: Definition And Review Literature, When And How I Do It Sudhakar R. Satti, MD
9:07 — 9:14	Intrasaccular Treatments Are Now The Standard Of Care And Why David J. Altschul, MD
	(Murray Hill Suites, 2nd Floor) TROKE THROMBECTOMY MASTERS
	David Gordon, MD Neil Haranhalli, MD
9:15 — 9:22	DAPT: Acute Platelet Loading Protocols, Cangrelor, And Optimizing Blood Pressure Post-Thrombectomy When Acute Stenting David Fiorella, MD, PhD
9:23 — 9:30	Radial Access And Complication Management Eytan Raz, MD
9:31 — 9:38	Step-By-Step How I Choose My Thrombectomy Equipment Chirag D. Gandhi, MD
9:39 — 9:46	What Are The Limits To Acute Stroke Thrombectomy In Our Population Ansaar T. Rai, MD
9:47 — 9:54	Acute Ischemic Stroke – Who We Should NOT Treat <i>Johanna Seiden, MD, MPH</i>
	(Murray Hill Suites, 2nd Floor) AND CEREBRAL ANEURYSMS LATEST
Moderators:	Peter K. Nelson, MD Allan L. Brook, MD
9:55 —10:10	Keynote Presentation: An Endovascular Experience From The War Zone In Ukraine <i>Peter K. Nelson, MD</i>
10:11-10:18	Carotid Blowout: Role Of Endovascular Care And Timing Of Treatment Guilherme Dabus, MD

10:19-10:26	The Posterior Circulation Is Different And Why It Matters Maksim Shapiro, MD
10:27-10:34	A Neiman Fellow Analyzes Trends In Stroke <i>Joshua A. Hirsch, MD</i>
10:35-10:42	Stroke Imaging Triage: Pearls And Nuances Of Daily Practice Reade A. De Leacy, MBBS
10:43-10:50	Pediatric Stroke Issues Mario Muto, MD
10:51-10:58	CTA For Stroke And Aneurysm Detection And Optimization Lawrence N. Tanenbaum, MD
10:59-11:06	When My Partners Have Stroke Complications, How I Manage Peter K. Nelson, MD
11:07-11:14	Dural Sinus Stenosis: Is There A Standard Of Care Seon-Kyu Lee, MD, PhD
11:15-11:22	Artificial Intelligence And Telemedicine: How It Is Changing And Influencing Our Daily Practice Allan L. Brook, MD
11:23-11:30	MMA Embolization: SDH – When And When Not To Do J Mocco, MD, MS
CAROTIC LATEST T	(Murray Hill Suites, 2nd Floor) ARTERY THERAPY STARS AND RENDS Thomas G. Brott, MD Don Heck, MD Frank J. Veith, MD
11:31-11:38	Carotid Artery Disease: New Trials And Best Literature 2023
11:39-11:46	Thomas G. Brott, MD TCAR Is Better Than True Percutaneous Carotid Stenting: Myth Or Reality Peter A. Schneider, MD
11:47-11:54	CAS Versus CEA: Optimum Cases For Each (Kumbaya) Don Heck, MD
11:55-12:02	CEA Done Through A Micro-Incision Versus TCAR: Reality Drama At Its Best Enrico Ascher, MD
12:03-12:10	Long-Term Value Of The C-Guard MicroNet Mesh Covered Stent For CAS In High Risk Carotid Lesions Versus Surgery: TCAR Pearls And Wisdom Of Data D. Christopher Metzger, MD Piotr Musialek, MD
12:10-12:30	Panel Discussion
	End of Program J

FRIDAY, NOVEMBER 17, 2023

6:00 A.M. General Registration - Rhinelander Gallery, 2nd Floor 6:00 A.M. Faculty Registration - Gramercy Suite West, 2nd Floor

6:15 A.M. Continental Breakfast - Rhinelander Gallery, 2nd Floor

CONCURRENT FRIDAY PROGRAMS

PROGRAM K (SESSIONS 79-86)

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACS), String Sign, Carotid Clot, Significance Of MRI Lesions, Carotid Controversies And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care 6:40 A.M. – 5:56 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM L (SESSIONS 87-94)

New Developments In The Treatment Of Popliteal Disease: Aneurysms, Entrapment And Occlusive Lesions; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Augmented Reality And Artificial Intelligence; Recorded Live Complex Endovascular Cases From Münster, Germany; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular

6:52 A.M. – 5:40 P.M. Grand Ballroom West, 3rd Floor

PROGRAM M (SESSIONS 95-104) **Deep Venous Disease**

7:00 A.M. – 5:57 P.M. Trianon Ballroom, 3rd Floor

PROGRAM K (SESSIONS 79-86)

PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) WITH TAAAs AND COMPLEX AORTIC ANEURYSM REPAIRS; NEW DEVELOPMENTS IN CAROTID ARTERY DISEASE AND ITS TREATMENT: MESH COVERED STENTS AND TCAR, COGNITIVE CHANGES, TIMING OF TREATMENT, MEDICAL TREATMENT, UPDATE ON CAROTID TRIALS, TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS), STRING SIGN, CAROTID CLOT, SIGNIFICANCE OF MRI LESIONS. CAROTID CONTROVERSIES AND MORE CAROTID TOPICS; OTHER NEW ENDOVASCULAR TREATMENT CONCEPTS, TECHNIOUES: UPDATE ON PERCUTANEOUS ACCESS CLOSURE DEVICES AND WOUND CARE Grand Ballroom East, 3rd Floor

SESSION 79 (Grand Ballroom East, 3rd Floor)
PROGRESS IN THE PREVENTION AND TREATMENT
OF SPINAL CORD ISCHEMIA (SCI) ASSOCIATED
WITH THE TREATMENT OF THORACIC,
THORACOABDOMINAL AND COMPLEX
ABDOMINAL ANEURYSMS

Moderators: Germano C.G. Melissano, MD Christian D. Etz, MD Salvatore T. Scali, MD

- 6:40 6:45 Key New Concepts Presented At A Recent International Summit Conference On Spinal Cord Ischemia (SCI)

 Hamdy Awad, MD
- 6:46 6:51 With Complex AAAs And Type IV TAAAs,
 The Incidence Of SCI Is 3 Times Greater With
 Endovascular Repairs Than Open Repairs: Why Is This
 A Controversial Finding
 George Geroulakos, MD, PhD
- 6.52 6.57 With Endovascular Repair Of TAAAs, Analysis Of Aortic Anatomy And Extent Of Endograft Coverage Allows Prediction Of SCI And Its Neurological Consequences: What Can Be Done To Reduce This Risk Bijan Modarai, PhD
- 6:58 7:03 Shifts In Prevention Protocols For SCI During Open And Endovascular TAAA Repairs: What Is Agreed On And What Remains Controversial Germano C.G. Melissano, MD Roberto L.V. Chiesa. MD
- 7:04 7:09 Update On The Value Of Motor Evoked Potentials (MEPs) To Decrease SCI With TAAA Repairs: What Is The Difference Between Peripheral And Central SCI Geert Willem H. Schurink, MD, PhD Barend M.E. Mees, MD, PhD Michael J. Jacobs, MD
- 7.10 7.15 DEBATE: Why Cerebrospinal Fluid (CSF) Drainage To Decrease SCI With TAAA Repair Is Not A Benign Procedure: When To Use It And When Not Gustavo S. Oderich, MD
- 7:16 7:21 DEBATE: CSF Drainage Need Not Be Associated With High Rates Of Complications: How To Prevent Them And The Case For Wide Prophylactic Placement Salvatore T. Scali, MD
- 7:22 7:27

 Prevention Of Spinal Cord Ischemia In Endovascular TAAA Repairs: Lessons Learned From The US Aortic Research Consortium (USARC): Why An RCT Is Still Needed And Being Initiated

 Adam Beck, MD

 Mark A. Farber, MD

 Andres Schanzer, MD
- 7.28 7.33 Near Infrared Spectrometry (NIRS) Monitoring Is Helpful In Decreasing SCI And Avoiding Spinal Drainage With TAAA Repairs: When And How Should It Be Used Carlos H. Timaran, MD
- 7:34 7:39 Current Strategies To Minimize SCI With TAAA
 Repairs (Endo And Open) By Improving The
 Intraspinal Collateral Arterial Network: Status Of
 Intercostal Embolization As Preconditioning To
 Prevent Ischemia (MIS2ACE): Progress Of The PAPAARTIS RCT
 Christian D. Etz, MD, PhD

7:40 - 7:45Updated Single Center Clinical Experience With Intercostal Coil Embolization (MIS2ACE) To Prevent SCI With Endovascular TAAA Repair Daniela Branzan, MD Andrej Schmidt, MD Christian D. Etz, MD, PhD

7:46 - 7:53**Panel Discussion**

SESSION 80 (Grand Ballroom East, 3rd Floor) NEW DEVELOPMENTS IN THE TREATMENT OF CAROTID STENOSIS WITH MESH COVERED STENTS AND TCAR (TRANSCERVICAL CAROTID ARTERY REVASCULARIZATION)

Moderators: Klaus D. Mathias, MD Sumaira Macdonald, MD, PhD

MESH COVERED STENTS

7:53 - 7:58Long-Term Results Of Micromesh Stents Show Their Value In Carotid Artery Stenting (CAS): Are There Limitations: Do The Differences In The 3 Micromesh Stents Matter D. Christopher Metzger, MD

Max Amor, MD

7:59 - 8:04Update On The MicroNet-Covered Stents (C-Guard From InspireMD) For CAS: Value Overall, With High-Risk Lesions And With TCAR: Are There Any Downsides Piotr Musialek, MD, DPhil Stefan Müller-Hülsbeck, MD

8:05 - 8:10New Multicenter Data Showing The Long-Term Value Of The C-Guard MicroNet Mesh Covered Stent For CAS In High Risk Carotid Lesions (Thrombotic, Calcified And Symptomatic) From The FLOW-GUARD

> And Other Trials D. Christopher Metzger, MD Piotr Musialek, MD, DPhil

8:11 - 8:16 Results From A Multicenter Italian Study Of The C-Guard Micromesh Stent For CAS: Advantages And Complications Pasqualino Sirignano, MD

Francesco Speziale, MD Gianmarco de Donato, MD Wassim Mansour, MD Carlo Setacci, MD

8:17 - 8:22Real-World Results Of ~2,000 Patients Treated With The Roadsaver (Terumo) Dual-Layer Micro Mesh Carotid Stent: Advantages And Limitations Stefan Müller-Hülsbeck, MD

8:23 - 8:28Panel Discussion

TCAR RELATED TOPICS

8:29 - 8:34**DEBATE:** TCAR Versus CEA (Carotid Endarterectomy): 3-Year Results From A Large Propensity Matched VQI-Medicare Database Show Similar Stroke, And Death Rates At 3 Years For Symptomatic And Asymptomatic Patients: At 3-Years: TCAR Can Replace CEA More Widely Mahmoud B. Malas, MD, MHS Marc L. Schermerhorn, MD Vikram S. Kashyap, MD

8:35 — 8:40	DEBATE: Not So Fast: TCAR Is Not Yet Ready To Replace CEA Widely: We Still Need Further Proof And More Studies Possibly Including An RCT <i>Bruce A. Perler, MD, MBA</i>
8:41 — 8:46	How Adjunctive Techniques (EEG And IVUS) Help With TCAR And Decrease Stroke Rates Todd R. Vogel, MD, MPH
8:47 — 8:52	DEBATE: TCAR Is Better Than TFCAS And Brachial/ Radial Access For CAS Marc L. Schermerhorn, MD Mahmoud B. Malas, MD, MHS
8:53 — 8:58	DEBATE: Not So: TCAR Is No Better And Is More Costly Than TFCAS And Brachial/Radial Access CAS If One Has Appropriate Skills D. Christopher Metzger, MD William A. Gray, MD
8:59 — 9:04	Should TCAR Replace Most CEAs Or Is CEA Still The Gold Standard For Most Cases Requiring Invasive Treatment Based On A Cost Analysis Michel Makaroun, MD
9:05 — 9:10	TCAR Is Safe In Recently Symptomatic Patients And Those With Contralateral Carotid Occlusions: Why It Should Be The Procedure Of Choice In Those Conditions Peter A. Schneider, MD
9:11 — 9:16	Pre-Dilatation And Post Dilatation Strategies For TCAR: Do They Differ From TFCAS: Does Patient Sex Affect TCAR Outcomes <i>Vikram S. Kashyap, MD</i>
9:17 — 9:24	Panel Discussion
9:17 — 9:24 9:24 — 9:34	Panel Discussion Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
9:24 – 9:34 SESSION 81 MORE CA MINI-INC DEFECTS	Break - Visit Exhibits And Pavilions (2nd and 3rd Floors) (Grand Ballroom East, 3rd Floor) AROTID HOT TOPICS RELATED TO TCAR, CISION CEA, SIGNIFICANCE OF DW MRI AND COGNITIVE FUNCTION Thomas G. Brott, MD Ross Naylor, MD
9:24 – 9:34 SESSION 81 MORE CA MINI-INC DEFECTS	Break - Visit Exhibits And Pavilions (2nd and 3rd Floors) (Grand Ballroom East, 3rd Floor) AROTID HOT TOPICS RELATED TO TCAR, CISION CEA, SIGNIFICANCE OF DW MRI AND COGNITIVE FUNCTION Thomas G. Brott, MD Ross Naylor, MD Michael B. Silva, Jr., MD Image Analysis Using AI With Siemens I-Flow Can Improve Prediction Of Stroke Risk In Carotid Disease: How Does It Work And How Reliable Is It Ravi K. Veeraswamy, MD
9:24 – 9:34 SESSION 81 MORE CA MINI-INC DEFECTS Moderators: 9:35 – 9:40	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) (Grand Ballroom East, 3rd Floor) AROTID HOT TOPICS RELATED TO TCAR, CISION CEA, SIGNIFICANCE OF DW MRI AND COGNITIVE FUNCTION Thomas G. Brott, MD Ross Naylor, MD Michael B. Silva, Jr., MD Image Analysis Using AI With Siemens I-Flow Can Improve Prediction Of Stroke Risk In Carotid Disease: How Does It Work And How Reliable Is It Ravi K. Veeraswamy, MD CAROTID STENOSIS AND COGNITIVE FUNCTION
9:24 – 9:34 SESSION 81 MORE CA MINI-INC DEFECTS Moderators:	Break - Visit Exhibits And Pavilions (2nd and 3rd Floors) (Grand Ballroom East, 3rd Floor) AROTID HOT TOPICS RELATED TO TCAR, CISION CEA, SIGNIFICANCE OF DW MRI AND COGNITIVE FUNCTION Thomas G. Brott, MD Ross Naylor, MD Michael B. Silva, Jr., MD Image Analysis Using AI With Siemens I-Flow Can Improve Prediction Of Stroke Risk In Carotid Disease: How Does It Work And How Reliable Is It Ravi K. Veeraswamy, MD

9.53 – 9.58 DEBATE: Not So Fast: There Is Still Great Doubt
That Eliminating ACS Improves Cognitive Function:
It Should Not Be A Reason For Treating More ACS
Patients

Kosmas I. Paraskevas, MD

SIGNIFICANCE OF SMALL DW MRI DEFECTS AFTER CEA/CAS

- 9.59 -10:04 DEBATE: Silent DWI MRI Brain Lesions (Small Infarcts) After CEA/CAS Don't Matter
 Thomas G. Brott, MD
 James F. Meschia, MD
- 10.05-10:10 DEBATE: Not So: Silent Brain Infarcts (DW MRI Defects) After CEA/CAS Really Matter And Affect Cognitive Changes: The Size And Number Of DW MRI Defects Are Critical

 Wei Zhou, MD
- 10:11-10:16 Highlights Of The 2022 SVS US Guidelines For The Management Of Carotid Disease: How Important Is Medical Treatment And Has It Changed Ali F. AbuRahma, MD
- 10:17-10:22 Highlights Of The 2023 European Guidelines For The Management Of Carotid Disease And How They Differ From The US Guidelines

 Ross Naylor, MD*

10:23-10:30 Panel Discussion

SESSION 82 (Grand Ballroom East, 3rd Floor)

MORE CAROTID RELATED NEW DEVELOPMENT TOPICS RELATED TO TCAR, NEW DEVICES, MESH COVERED STENTS, MINI-INCISION CEA, TIMING OF TREATMENT, MEDICAL TREATMENT AND DEALING WITH DISTAL (HIGH) CAROTID LESIONS

Moderators: Richard J. Powell, MD Wei Zhou, MD Frank J. Veith, MD

- 10:30-10:35 Comparative Cost Effectiveness Of TCAR, CEA, TFCAS: CEA Is More Cost Effective Than TCAR And TCAR Is More Cost Effective Than TFCAS Mohammad H. Eslami, MD, MPH
- 10:36-10:41 DEBATE: Since TCAR Already Has It, Reimbursement For Transfemoral And Transbrachial Carotid Stenting Should Be Expanded To Include Asymptomatic Patients *Thomas G. Brott, MD*
- 10.42-10.47 DEBATE: There Should Be No Reimbursement For Carotid Stenting (CAS Or TCAR) For Asymptomatic Or Symptomatic Patients

 Anne L. Abbott, MD, PhD
- 10.48-10.53 Value Of Lithotripsy (Shockwave) For CAS In Heavily Calcified Lesions: How To Do It Safely And Technical Tips: Limitations And Precautions: A Quick Word About The Value Of Lithotripsy In All Vascular Beds Frank R. Arko, MD Max Amor, MD
- 10:54-10:59 OCT Optical Coherence Tomography (OCT) Proves CAS Is Rendered Safer Because Emboli Are Decreased By Mesh Covered Stents: The Imaging Evidence And What It Shows About The Interaction Between Stent And Plaque

Carlo Setacci, MD Francesco Setacci, MD 11:00-11:05 Minimal Incision CEA (MICE) Versus TCAR: Technical Tips For MICE, Cost Effectiveness, Advantages And Limitations Of Both Enrico Ascher, MD

11:06-11:12 Panel Discussion

TIMING OF CAROTID INTERVENTIONS AFTER SYMPTOM ONSET

11:12-11:17 Optimal Timing Of Carotid Revascularization (CEA, TFCAS, TCAR) After Symptom Onset: Within 48 Hours Stroke Risk Is Increased For All Procedures; After 48 Hours Risk Is Less With CEA And TCAR Than With TFCAS: Based On A Large National Database Study: Can Artificial Intelligence (AI) Help To Predict Stroke Risk

Mahmoud B. Malas, MD, MHS

11:18-11:23 **DEBATE:** It's Reasonable To Perform CEA Within 48 Hours After A Stroke's Symptoms Start: Under What Conditions And What Precautions Should Be Taken *R. Clement Darling III, MD*

11:24-11:29 **DEBATE:** Not So Fast: If The Presenting Stroke Is Severe By NIH Severity Score, The Outcome Of Urgent Interventions (CEA, CAS, TCAR, Etc.) Is Poor: Should They Always Be Avoided Hernan A. Bazan, MD

11:30-11:35 With Crescendo TIAs And Thrombus Overlying A
Plaque What Is The Best Invasive Treatment And When
Should It Be Performed
Domenico Valenti, DMChir, PhD

11:36-11:41 When Is Urgent (Within 48 Hours) CEA Or CAS
Fairly Indicated After A Stroke: How Does Use Of tPA
Influence Indications And Neurologic Outcomes In
This Setting
Hernan A. Bazan, MD

11.42-11.47 What Is The Best Medical Treatment For Patients With Carotid Stenosis (Asymptomatic And Symptomatic):
Can High Risk Plaques Be Made Low Risk And Smaller: All Stroke Patients Should Be On Statins Because They Decrease Recurrent Stroke And Mortality Rates Markedly
J. David Spence, MD

11:48-11:53 Technical Tips And Maneuvers To Make Treatment Of High Carotid Lesions Safe And Relatively Simple Richard J. Powell, MD

11:54-12:00 Panel Discussion

12:00-12:54 Lunch Break - Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 83 (Grand Ballroom East, 3rd Floor)
MORE HOT CAROTID TOPICS: UPDATES ON
KEY CAROTID RCTs; NEW INFORMATION
ON TREATMENT OF TANDEM LESIONS,
CAROTID ANEURYSMS AND STROKES DURING
INTERVENTION

Moderators: Christopher J. Kwolek, MD, MBA Anne L. Abbott, MD, PhD

12:54-12:59 Current Best Treatment For Strokes Apparent During Or Right After CEA, CAS Or TCAR: Best Diagnostic Modalities And Treatments: Who Should Be Involved And What Skills Are Needed Gert J. de Borst, MD, PhD

UPDATE ON CAROTID RCTs

- 1:00 1:05

 5-Year Results From SPACE 2: CEA Versus Best Medical Treatment (BMT) And CAS Versus BMT For ACS: These Results Support A More Conservative Approach To ACS: What More Is Needed Hans-Henning Eckstein, MD, PhD (PowerPoint Presentation With Christoph Knappich, MD)

 Synched Audio)
- 1:06 1:11 DEBATE: Update On ACST 2: This RCT Found That CEA And CAS For ACS Had Comparable Adverse Event Rates And Implied That Both Invasive Treatments Were Superior To BMT: Does CEA Prevent Dementia Richard Bulbulia, MA, MD Alison Halliday, MS
- 1:12 1:17 DEBATE: Not So Fast! ACST 2 Like CREST Has Flaws That Invalidate Their Conclusions: Invasive Therapies May NOT Be Better Than BMT *J. David Spence, MD*
- 1:18 1:23

 Update On CREST 2: CEA Versus BMT And CAS
 Versus BMT For ACS: Recruitment And Findings To
 Date: Why Not Present The 30-Day And 1 Year Results:
 If BMT Showed No Difference In Stroke And Death
 Rates With Those Of CAS Or CEA, Wouldn't It Remove
 Justification For Invasive Treatment Of ACS
 Brajesh K. Lal, MD
 Thomas G. Brott, MD
- 1:24 1:29 Consecutive Monocenter Results With CAS For Asymptomatic Carotid Stenosis (ACS): We Should Not Need A RCT: Why Do We Still Need One Klaus D. Mathias, MD Ann Zeller, MD
- 1:30 1:35 CEA Versus CAS For High-Grade ACS: RCTs (ACT 1 And CREST) Analyzed By Age And Sex: Are There Important Differences

 Jon S. Matsumura, MD

TANDEM CAROTID LESIONS

- 1:36 1:41 DEBATE: Tandem Lesions At The Carotid Bifurcation Plus The Common Carotid Or Innominate Arteries: Stroke And Mortality Risks Are Higher Than For Simple Bifurcation Lesions: How Best To Treat: Endo, Open, Staged, Hybrid W. Darrin Clouse, MD, RPVI Mark Conrad, MD, MMSc
- 1:42 1:47 **DEBATE:** Tandem Carotid Lesions: Treatment Risks Need NOT Be Increased: Based On A Meta-Analysis: How Best To Treat To Minimize Risk Ross Naylor, MD
- 1:48 1:53

 Silent Coronary Ischemia As Detected By FFR_{CT} Is
 Common In Carotid Stenosis Patients: Coronary
 Revascularization In Such Patients Decreases Mortality:
 When Should It Be Done Before Or After Carotid
 Treatment
 Christopher K. Zarins, MD
 Dainis K. Krievins, MD
- 1:54 2:02 Panel Discussion

MORE HO IN 2023 C SIGN, CA MANAGE CENTRAL PLATELET BENIGNA ANESTHE WAY TO	(Grand Ballroom East, 3rd Floor) OT CAROTID TOPICS: TREATMENT OF PATCH INFECTIONS, STRING ROTID DISSECTIONS AND WEBS; EMENT OF ARTERIAL INJURIES DURING VENOUS CATHETERIZATION; OPTIMAL F AND PROTAMINE STRATEGIES; ANCY OF ACS; VALUE OF LOCAL ESIA; STROKE RISK WITH ACS PLAQUES - A PREDICT HIGH RISK PLAQUES Wesley S. Moore, MD Glenn M. LaMuraglia, MD Peter L. Faries, MD
2:02 — 2:07	Optimal Management Of Carotid Patch Infections: Which Is The Best Material For Carotid Patching: How About None Clark J. Zeebregts, MD, PhD
2:08 — 2:13	How Best To Diagnose And Treat Near Occlusion Of The Internal Carotid Artery (ICA) In 2023: Based On A Meta-Analysis: Is This The ICA String Sign Of Past Descriptions Gert J. de Borst, MD, PhD
2:14 — 2:19	Update On Isolated Carotid Webs As A Cause Of Cryptogenic Stroke: How Best To Diagnose And Treat: How Should Asymptomatic Webs Be Treated W. Charles Sternbergh, III, MD Clayton J. Brinster, MD
2:20 — 2:25	Value Of Protamine Use During CEA, CAS And TCAR. When And How Should It Be Used And With What Precautions David H. Stone, MD
2:26 - 2:31	The Number Of Carotid Interventions For Symptomatic Carotid Disease Has Declined In The UK Over The Last Decade: Why Is This So Ross Naylor, MD
2:32 — 2:38	Panel Discussion
2:38 - 2:43	Restenosis After CEA And CAS Is Benign And Should Rarely Be Treated: When Can It Cause Strokes Justifying Prophylactic Treatment Ross Naylor, MD
2:44 — 2:49	DEBATE: Local Anesthesia And Intraoperative Control With Duplex Or Angiography Is Key To Safe CEA: How To Do Them Hans-Henning Eckstein, MD, PhD (PowerPoint Presentation With

- 2:50 2:55

 DEBATE: Not So: CEA Can Be Performed Safely And Optimally Under General Anesthesia And Without Completion Duplex Or Angio Control: What Is Required To Do So And Are There Downsides To Duplex Or Angio Controls

 Ali F. AbuRahma, MD

 2:56 3:01

 Are Symptomatic And Asymptomatic Carotid Stenosis
- 2:56 3:01 Are Symptomatic And Asymptomatic Carotid Stenosis Really 2 Different Diseases With Different Pathology As Some Suggest Thomas G. Brott, MD James F. Meschia, MD
- 3:02 3:07 What Vascular Surgeons And Vascular Specialists Need To Know About What Can Be Learned From MRI And MRA Studies Of The Head And Neck Emmanuel M. Houdart, MD

3:08 - 3:13	When An Asymptomatic Carotid Stenosis (ACS)
	Patient Has An Unheralded Stroke, How Does
	Its Magnitude And Outcome Differ From Other
	Strokes: Does It Make The Case For More Or Fewer
	Prophylactic CEAs And CASs
	Gianluca Faggioli, MD

3:14 – 3:20 Panel Discussion

3:20 – 3:30 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 85 (Grand Ballroom East, 3rd Floor)
NEW OR UPDATED CONCEPTS FOR
ENDOVASCULAR TREATMENTS AND MORE HOT
AND CONTROVERSIAL CAROTID TOPICS

Moderators: Ali F. AbuRahma, MD Anne L. Abbott, MD, PhD Michael H. Wholey, MD, MBA

NEW OR UPDATED CONCEPTS FOR ENDO TREATMENTS

- 3.30 3.35 Bronchial Artery Embolization For Massive Hemoptysis: A Life Saving Procedure: How To Do It Jacob Cynamon, MD
- 3.36 3.41 Endovascular Suturing Devices At The Tip Of An 8-9
 French Catheter To Close Large Bore Sheath Access
 From Inside: The Novelrad Device: How Does It Work
 And Present Status
 Elchanan Bruckheimer, MBBS (PowerPoint Presentation With
 Synched Audio)
- 3:42 3:47 Clinical Judgment Is Required In The Application Of Evidence Based Medicine: RCTs Can Have Flaws Leading To Misleading Conclusions J. David Spence, MD
- 3.48 3.53

 A Recent Multicenter Propensity Matched Comparison Of Endo Versus Open Infrainguinal Treatment For CLTI Shows That Open Treatment Is Superior And Supports The Findings Of BEST-CLI

 Jean-Baptiste Ricco, MD, PhD
- 3:54 3:59 How Vascular Surgeons Can Cure Erectile Dysfunction:
 Diagnosis And Treatment Of Cavernous Leak And
 Other Pathology
 Eric Allaire, MD, PhD
- 4:00 4:05 Embolic Treatment Of Hemorrhoids: How To Do It And How Well Does It Work Gloria Salazar, MD
- 4:06 4:11 Panel Discussion

HOT CAROTID TOPICS

- 4:12 4:17 Risks And Causes Of Non-Ipsilateral Stroke Complicating CEA Mark Conrad, MD, MMSc W. Darrin Clouse, MD
- 4:18 4:23 Surveillance Imaging Following CEA: Are We Looking For Recurrence, Progression Of Contralateral Disease Or Is It Really Unnecessary

 Reese A. Wain, MD
- 4:24 4:29 Performing CEA In Recently Symptomatic Patients
 With Dual Platelet Therapy On Board: The Benefits
 Outweigh The Risks: What Precautions Should Be
 Taken
 Ross Naylor, MD

4:30 — 4:35	DEBATE: CAS Is The Best Treatment For Young Healthy Patients With A High-Grade Asymptomatic Carotid Stenosis (ACS) D. Christopher Metzger, MD
4:36 - 4:41	DEBATE: Not So: Even Young Patients With A High-Grade ACS Should Not Be Treated By CAS Or CEA
4:42 — 4:47	Anne L. Abbott, MD, PhD Why We Need A RCT Comparison Of TCAR With TFCAS, Transradial CAS And Best Medical Treatment For ACS And Symptomatic Carotid Stenosis Michael H. Wholey, MD, MBA
4:48 - 4:53	Panel Discussion
NEW CO PERCUTA WOUND	(Grand Ballroom East, 3rd Floor) NCEPTS AND NEW DEVELOPMENTS IN NEOUS ACCESS CLOSURE AND CARE Kenneth Ouriel, MD, MBA Mark A. Adelman, MD
4:54 — 4:59	Update On Large Bore Percutaneous Access Closure: Current Status, New Devices, How To Avoid Complications And Where Do We Go From Here Zvonimir Krajcer, MD (PowerPoint Presentation With Synched Audio)
5:00 — 5:05	The Femoral Fascial Suture Technique For Percutaneous Access Closure: Technique, Value And Contraindications Tal M. Hörer, MD, PhD Thomas Larzon, MD, PhD
5:06 — 5:11	RCT Comparing Collagen (Femoseal) Versus Suture Based (Proglide) Vascular Closure Devices After Lower Extremity Endo Arterial Revascularizations Yann Gouëffic, MD, PhD
	PROGRESS IN WOUND CARE
5:12 — 5:17	Management Of Lymphatic Fistulas After Vascular Surgery: What Are The Treatment Options Martin Storck, MD, PhD
5:18 - 5:23	The TIVITA System To Predict Wound And Amputation Healing: Hyperspectral Imaging Can Non-Invasively Determine Oxygenation And Perfusion: How Does It Work And Results <i>Jan-Willem Elshof, MD</i>
5:24 — 5:29	New Developments in Percutaneous Arterial Closure Maciej L. Dryjski, MD, PhD
5:30 — 5:35	A Single Device (From AOTI) With Triple Therapy (Local Oxygen, Compression And Humidification) Enhances Healing Of Non-Healing Lower Extremity Incisions David J. Dexter, MD
5:36 — 5:41	Optimal Treatment For Groin Infection After Prosthetic Bypasses From The Common Femoral Artery: How To Save The Graft And The Leg <i>Hosam F. El Sayed, MD</i>
5:42 - 5:47	Optimizing Wound Healing Using A Fully Synthetic Resorbable Electros Spun Material: A New Approach Wayne J. Caputo, DPM
5:48 — 5:56	Panel Discussion End of Program K

PROGRAM L (SESSIONS 87-94)
NEW DEVELOPMENTS IN THE TREATMENT OF
POPLITEAL DISEASE; ADVANCES IN TREATING
ARTERIAL AND GRAFT INFECTIONS; ADVANCES
IN VASCULAR IMAGING AND GUIDANCE;
AUGMENTED REALITY AND ARTIFICIAL
INTELLIGENCE; RECORDED LIVE COMPLEX
ENDOVASCULAR CASES FROM MÜNSTER,
GERMANY; NEW DEVELOPMENTS IN THORACIC
OUTLET SYNDROME MANAGEMENT; ADVANCES
IN MEDICAL, DRUG, ANTICOAGULANT AND RARE
VASCULAR DISEASE TREATMENT; AND ADVANCES
IN THE TREATMENT OF VASCULAR TRAUMA

SESSION 87 (Grand Ballroom West, 3rd Floor)
POPLITEAL DISEASE TOPICS RELATED TO
ANEURYSM TREATMENT (PRIMARY AND REDO),
ENTRAPMENTS, ADVENTITIAL CYSTIC DISEASE
LOWER EXTREMITY OCCLUSIVE LESION
TREATMENT WITH DCBs AND ATHERECTOMY

Moderators: Enrico Ascher, MD Martin Björck, MD, PhD

Grand Ballroom West, 3rd Floor

POPLITEAL ANEURYSMS AND THEIR BEST CURRENT TREATMENTS

- 6:52 6:57 A Hybrid Approach To Repairing Large Popliteal Aneurysm: Technique, Results, And Advantages *Enrico Ascher, MD*
- 6.58 7.03 Treatment Of Popliteal Aneurysms: When Conservative, When Open, When Endovascular: What Are The Hard Data

 Martin Björck, MD, PhD
- 7:04 7:09 Endovascular Versus Open Repair: Why After 20 Years
 Of Selective Endografting, Now Favor Open Repair In
 Most Patients
 Martin R. Back. MD
- 7:10 7:15 Update On Optimal Treatment For Popliteal Aneurysms: Should They Be Treated Differently In Women And Why: When Should They Best Be Observed

Fred A. Weaver, MD, MMM

7:16 – 7:21 Rescue Procedures For Failed Endovascular Repairs Of Popliteal Aneurysms: Observation May Be Enough: If Not, Hybrid Versus Open Repair: Technical Tips

Jose Fernandes e Fernandes, MD, PhD (PowerPoint Presentation With Synched Audio)**

ENCOURAGING RESULTS FOR SELUTION SIROLIMUS DCBs

- 7.22 7.27 Japanese Multicenter 12-Month Data For Selution Sirolimus DCB Treatment Of Femoropopliteal Lesions Show Unmatched Primary Patency And Freedom From Clinically Driven TLR Patrick J. Geraghty, MD
- 7:28 7:35 Panel Discussion

POPLITEAL ENTRAPMENTS AND ADVENTITIAL CYSTIC DISEASE

- 7:36 7:41 Update On Popliteal Entrapment Syndromes: Benefits Of Dynamic Imaging With Duplex Or Angiography In Diagnosis And Treatment
 Niten Singh, MD
- 7.42 7.47 Management Of Functional Popliteal Artery
 Entrapment Syndrome In Athletes: What Is The
 Pathological Anatomy And What Symptoms Does It
 Cause: Technique Of Surgical Repair
 Jason T. Lee, MD
- 7.48 7.53 Adventitial Cystic Disease Of The Popliteal Artery: Pathogenesis, Symptoms, And Optimal Treatment Irwin V. Mohan, MBBS, MD

POPLITEAL ARTERY INJURY

7:54 – 7:59 Surgical Approach And Graft Usage For Popliteal Artery Injury From Posterior Knee Dislocation Charles J. Fox, MD

POPLITEAL ARTERY ATHERECTOMY

- 8:00 8:05 Value Of Orbital Atherectomy For Popliteal Artery Occlusive Lesions: New Developments And Expanded Versatility Of The Device Brian G. DeRubertis, MD
- 8:06 8:12 Panel Discussion

SESSION 88 (Grand Ballroom West, 3rd Floor)
NEW DEVELOPMENTS IN TREATING ARTERIAL
(INCLUDING AORTIC) GRAFT INFECTIONS

Moderators: Keith D. Calligaro, MD Peter F. Lawrence, MD

8:12 – 8:17 Update On The NAIS Procedure (Deep Vein Reconstruction For Infected Aortic Grafts): How To Make The Operation Easier And Better *John F. Eidt, MD*

TREATMENT OF MYCOTIC ANEURYSMS

- 8:18 8:23 Radical Or Less Radical Treatment Of Mycotic
 Aneurysms: What Are They: When And How Should
 They Be Performed: Can EVAR Ever Be The Definitive
 Treatment: Importance Of Drainage
 Martin Malina, MD, PhD
- 8:24 8:29 Rifampin Soaked Endografts To Treat Mycotic AAAs: How To Prepare Them And When To Use Them: Are They Stand-Alone Treatment Or Do They Need Adjunctive Techniques Guillermo A. Escobar, MD
- 8:30 8:35 Why Open Repair Is The Best Treatment For Mycotic AAAs: Is EVAR Ever Of Value Yamume Tshomba, MD
- 8:36 8:41 TEVAR For The Treatment Of Aorto-Esophageal And Aorto-Bronchial Fistulas: Is It Only A Bridging Procedure Or Is It Ever A Definitive Treatment Markus K. Furrer, MD
- 8:42 8:48 Panel Discussion

TREATMENT OF AORTIC AND ARTERIAL GRAFT AND ENDOGRAFT INFECTIONS

- 8.48 8.53 Infected Endografts After EVAR: Etiological Factors, Diagnosis, Treatment, Outcomes: Does The Endograft Always Have To Be Removed

 Mohammad H. Eslami, MD, MPH
- 8.54 8.59 Optimal Techniques For Treating Aorto-Iliac Graft And Endograft Infections In 2023

 Anders Wanhainen, MD, PhD (PowerPoint Presentation With Synched Audio)
- 9.00 9.05

 Update Of Surgical Treatment For Infected Aortic Grafts And Aortic-Enteric And Aortic-Bronchial Fistulas: Current Results In A Committed Center: Value Of An Antimicrobial Silver/Triclosan Graft Germano C.G. Melissano, MD
 Roberto L.V. Chiesa, MD
 Luca Bertoglio, MD
 Andrea Kahlberg, MD
- 9.06 9.11 Update On Progress In The Optimal Treatment Of Aortic And Arterial Graft Infections: What's New In 2023: When Is Percutaneous Drainage Acceptable And Helpful Jean-Paul de Vries, MD, PhD
- 9.12 9.17 Semi-Conservative Therapy Saving All Or Part Of An Infected Aortic Graft: When Is It The Best Treatment And How To Make It Work: From The MAGIC Registry And VASGRA Study Zoran Rancic, MD, PhD
- 9.18 9.23 EVAR Endograft Infections Can Be Treated By Local Catheter Techniques: How, When And When Not Tal M. Hörer, MD, PhD
- 9.24 9.29 When And What Is The Best Treatment For An Infected Aortic Endograft: Conservative, Antibiotics, Drainage And Excision Of Infected Tissue Or Graft Removal; Replacement: In Situ Or Extra-Anatomic Clark J. Zeebregts, MD, PhD
- 9.30 9.35 Management Of Mid-Visceral Aortic Infections (Mycotic Suprarenal And TAAAs Before And After Repair): Can Infected Grafts Sometimes Be Preserved Salvatore T. Scali, MD
- 9:36 9:52 Panel Discussion And Break
 (Visit Exhibits And Pavilions 2nd and 3rd Floors)

SESSION 89 (Grand Ballroom West, 3rd Floor)
PROGRESS IN VASCULAR IMAGING AND
GUIDANCE FOR ENDOVASCULAR TREATMENTS
WITH LESS RADIATION EXPOSURE OR CONTRAST
TOXICITY

Moderators: Barry T. Katzen, MD Cynthia K. Shortell, MD Isabelle Van Herzeele, MD, PhD

VASCULAR HOLOGRAPHY

9:52 – 9:57 The ARCUS System Of Augmented Reality (Derived From A Contrast CT) And Its Value In Vascular Surgery: How Will The Microsoft HoloLens 2 Project Vascular Anatomy And Its Lesions On Patients' Bodies: How This Can Facilitate Surgical And Endovascular Procedures

Jan M.M. Heyligers, MD, PhD

9.58 -10:03 Update On Real View Holographic Imaging: How Will It Help In Endovascular Treatments: Is It Available In The US

Elchanan Bruckheimer, MBBS (PowerPoint Presentation With Synched Audio)

10:04-10:09 Holographic Guidance Of Endovascular Procedures Guidance (With Augmented Reality Goggles And No Screen): How Does It Work: What Is Possible And What Is Not

Claude Mialhe, MD

DUPLEX AND INTRAVASCULAR ULTRASOUND

10:10-10:15 Duplex Ultrasound Guidance: How, Where And When Can It Replace Fluoroscopy For Endovascular Procedures: Advantages, Limitations, And Why Its Use Is Increasing

Enrico Ascher, MD

Natalie A. Marks, MD, RPVI, RVT

10:16-10:21 Intravascular Ultrasound (IVUS) Assistance In EVAR And TEVAR: Advantages And Limitations - Based On A Multicenter Study Jean-Baptiste Ricco, MD, PhD

10:22-10:28 Panel Discussion

IMPROVED IMAGING

10:28-10:33 Contrast Induced Nephropathy Is Over-Exaggerated: When Patients Need A Contrast Study, They Should Get It: How To Minimize Consequences

Lindsay Machan, MD

10.34-10.39 Totally Radiation Free Deployment Of A Complex AAA Endograft Using An Intraoperative Positioning System (IOPS From Centerline) And Positional Markers On Graft Components As Well As Catheters And Wires To Enable Accurate 3D Guidance: It Is Analogous To Precise GPS Targeting Gustavo S. Oderich, MD

10.40-10.45 Update On Cydar Medical System's Evolution To Facilitate Fusion With All Digital Fluoroscopes: How The System Uses AI To Improve EVAR Planning, Guidance And Deployment: Are There Disadvantages Jan M.M. Heyligers, MD, PhD

10:46-10:51 Cydar Maps Joining In EVAR Planning, Intraprocedural Guidance And Outcome Assessment: How Does AI Help At Each Step And Compensate For Artery Movement Caused By Wires, Devices, Etc.

Cynthia K. Shortell, MD

10.52-10.57 New Imaging And Navigation Technologies To Facilitate And Improve Complex AAA Repair: Comparison Of Cydar, FORS (Philips) And Centerline Biomedical IOPS Systems: Are They Ready For Widespread Use

Venkatesh G. Ramaiah, MD

10:58-11:05 Panel Discussion

SESSION 90 (Grand Ballroom West, 3rd Floor)
AUGMENTED REALITY (AR), MIXED REALITY AND
ARTIFICIAL INTELLIGENCE (AI): HOW WILL THEY
IMPROVE OUTCOMES, IMAGING AND DEVICE
GUIDANCE DURING VASCULAR PROCEDURES

Moderators: Gustavo S. Oderich, MD Alan B. Lumsden, MD

11:05-11:10	Generative AI For Vascular Imaging – The Promise And Perils Elsie Ross, MD, MSc
11:11-11:16	Personalized Treatment Of AAAs With AI: The Vasculaid Project Kak Khee Yeung, MD, PhD
11:17-11:22	Understanding Branch Stent-Graft Occlusions With Assessment Of Computational Fluid Dynamics Kenneth Tran, MD
11:23-11:28	Learning Curve Of Endovascular Naïve Operators With Plain Fluoroscopy, Flat Plane And Augmented Reality Intraoperative Position System Sophia Khan, MD
11:29-11:34	Intraoperative Position System To Minimize Radiation Exposure On Lateral Views During Catheterization Of Mesenteric Vessels Muhammad Ali A. Rana, MD
11:35-11:46	Edited Case: Workflow For Endovascular FB-EVAR Of Thoracoabdominal Aortic Aneurysms Aleem K. Mirza, MD
11:47-12:00	Panel Discussion
12:00 - 1:00	Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors)
TWO PRI	(Grand Ballroom West, 3rd Floor) ESENTATIONS AND CHALLENGING
	ED LIVE CASES FROM MÜNSTER,
GERMAN	
Moderators:	Giovanni B. Torsello, MD Marco V. Usai, MD
1:00 — 1:05	Münster Strategy To Avoid SCI And Results Martin J. Austermann, MD (PowerPoint Presentation With Synched Audio)
1:06 — 1:11	In Situ Fenestration In The Arch During Complex EVAR: Early Experiences Marco V. Usai, MD
1:12 — 1:44	Live Recorded Cases By Drs. Austermann And Usai Martin J. Austermann, MD (PowerPoint Presentation With Marco V. Usai, MD Synched Audio)
NEW DEV	(Grand Ballroom West, 3rd Floor) VELOPMENTS IN THE TREATMENT OF IC OUTLET SYNDROMES (TOSs)
	Mark A. Adelman, MD Robert W. Thompson, MD Bauer E. Sumpio, MD, PhD
1:44 — 1:49	Neurogenic Thoracic Outlet Syndrome (NTOS) Can Be Effectively Treated By Injecting Botulinum Toxin (Botox) Into Scalene And Pectoral Muscles: Technique And Results Pierre-Olivier Thiney, MD
1:50 — 1:55	Supraclavicular Approach To Arterial And Neurogenic TOSs (Video Presentation) Ramesh K. Tripathi, MD (PowerPoint Presentation With Synced Audio) Mark A. Adelman, MD (Presenter)
1:56 — 2:01	Minimally Invasive Transaxillary First Rib Resection Under Local And Regional Anesthesia: Advantages And Limitations Francesco Spinelli, MD

2:02 - 2:07

	Surgery Fails: Strategy And Outcomes Michael J. Singh, MD
	VENOUS TOSs
2:08 — 2:13	Evolving Approaches For Venous Thoracic Outlet Syndrome Keith D. Calligaro, MD
2:14 — 2:19	Assessment And Treatment Of Persistent Or Recurrent Symptoms After Surgical Treatment For Venous Thoracic Outlet Syndrome Robert W. Thompson, MD
2:20 - 2:26	Panel Discussion
2:26 — 2:36	Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
NEW DENTREATME	(Grand Ballroom West, 3rd Floor) VELOPMENTS IN MEDICAL AND DRUG ENTS: BEST ANTIPLATELET REGIMENS; ON RARE VASCULAR DISEASES Caron B. Rockman, MD James H. Black, III, MD
	ANTIPLATELET REGIMENS
2:36 — 2:41	Optimal Antiplatelet Management With CEAs, Lower Extremity Bypasses And Open AAA Repairs David H. Stone, MD
2:42 — 2:47	Current Optimal Anticoagulation And Antiplatelet Treatment For High Risk Lower Extremity Bypasses – Vein And PTFE: How Are DOACs Useful Peter Henke, MD
2:48 — 2:53	What Is The Best Medical Treatment After Carotid, Aortic And Lower Extremity Endovascular Treatments Maciej L. Dryjski, MD, PhD
2:54 — 2:59	Why Clopidogrel Is Effective In <50% Of Patients At Standard Doses: How To Identify And Fix This Problem
	Karthikeshwar Kasirajan, MD
	NEW DEVELOPMENTS IN LIPID MANAGEMENT – STATINS
3:00 — 3:05	Safety And Benefit Of Statins And Medical Treatment In Vascular Patients: Why These Treatments Are Underutilized – Especially In Women: Statin Intolerance Has Been Over Emphasized: LDL-C Should Be Monitored And Treated To An Optimal Level Christian A. Behrendt, MD
3:06 — 3:11	The Importance Of Lipoprotein Little a [Lp(a)] Levels In Determining Atherosclerotic Risk: When Should It Be Measured And If High, How Treated: Do PCSK-9 Inhibitors Help: Will An Oral PCSK-9 Inhibitor Be Available Caron B. Rockman, MD
3:12 - 3:17	Jeffrey S. Berger, MD, MS Lowering LDL-C And Controlling Elevated Blood Pressure Can Lower Cardiovascular Risk 80%: What To Do If Patients Can't Tolerate A Statin Dose: Ezetimide,

(Zetia), A PCSK9 Inhibitor, Inclisiran, Bempedoic Acid

Management Of Recurrent NTOS After Primary

(Nexletol)

Richard Bulbulia, MA, MD

Value And Limitations Of Statins And Non-Statin Lipid Lowering Agents In Patients With Carotid Artery

	Stenosis
3:24 — 3:32	Kosmas I. Paraskevas, MD Panel Discussion
3:24 — 3:32	OTHER DISEASE RELATED TOPICS
3:32 — 3:37	Diagnosis And Treatment Of Buerger's Disease In 2023: Does It Exist Or Is It Just A Variant Of Atherosclerosis Kamphol Laohapensang, MD
3:38 — 3:43	How To Make Operations For Complications Of Vascular Ehlers Danlos Syndrome Go Well James H. Black, III, MD
3:44 — 3:49	Medical Treatment Of Patients With Vascular Ehlers Danlos Syndrome: How Does Celiprolol Treatment Work And How Does It Help Martin Björck, MD, PhD
3:50 - 4:00	Panel Discussion (All Session 93 Topics)
ADVANC OF VASC	(Grand Ballroom West, 3rd Floor) EES IN THE ENDO AND OPEN TREATMENT ULAR TRAUMA Tal M. Hörer, MD, PhD Todd E. Rasmussen, MD
4:00 - 4:05	Advances In Endovascular Control Of Hemorrhage: Techniques: When Should They Be Used And When Not Ravi R. Rajani, MD
	UPDATE ON REBOA
4:06 — 4:11	Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA): When Is It A Valuable Procedure And When Is It Not: Limitations And Precautions <i>Gilbert R. Upchurch, MD</i>
4:12 — 4:17	Value Of REBOA For Pending And Actual Cardiac Arrest: What Is Partial And Intermittent REBOA And How Is It Helpful Tal M. Hörer, MD, PhD
4:18 — 4:23	Value Of Simulator Based Training For REBOA: How Does It Work: Can It Improve Results And Decrease Mishaps Lars B. Lonn, MD, PhD
4:24 - 4:29	Transradial Access (R2P) For Endovascular Trauma Management Is Safe And Sometimes Better: Technical Tips And Devices Charles J. Fox, MD
4:30 — 4:35	Contrary To Current Teaching, With Complex Extremity Injuries Involving Fractures And Large Blood Vessels, Why And How Revascularization Should PRECEDE External Bone Fixation: How To Get The Vascular Repair Length Right Erica L. Mitchell, MD, MEd
4:36 — 4:41	Long-Term Results Of Arterial And Venous Reconstructions (Bypasses And Interposition Grafts) For Vascular Trauma: How Do They Compare To The Results For Similar Procedures For PAD Samy S. Nitecki, MD
4:42 — 4:47	Update On Best Current Management Of Pediatric Vascular Injuries: When Conservative; When Open; When Endo And Precautions

Michael C. Dalsing, MD

3:18 - 3:23

4:48 - 4:54	Panel Discussion
	BLUNT THORACIC AORTIC INJURY (BTAI)
4:54 4:59	Classification Of BTAIs: Are We Overtreating Lesser Injuries Joseph Dubose, MD Pedro Teixeira, MD
5:00 — 5:05	What Is The New Role Of Endovascular Repairs Of Thoracic Aortic Injuries: Concepts, Techniques, And Management Waclaw B. Kuczmik, MD, PhD
5:06 — 5:11	BTAI In Pediatric Patients: When Should They Undergo Invasive Treatment: When Endo, When Open: Technical Tips And Precautions Elina Quiroga, MD, MPH
5:12 — 5:17	How To Manage Heparin In TEVAR For BTAI When Head Or Other Injuries Are Also Present: Some, None Or Just Sheath Flushing Charles J. Fox, MD
5:18 — 5:23	Why Rapid And Complete Aortic Healing After TEVAR For BTAI Allows Minimization Of The Seal Zone And Endograft Length Used Shang Loh, MD
5:24 — 5:29	New Findings From The Aortic Trauma Foundation Global Registry On Outcomes Of TEVAR For Repair Of Traumatic Aortic Injuries: Do Lesser Degrees Of BTAI Require TEVAR Ali Azizzadeh, MD
5:30 — 5:40	Panel Discussion End of Program L
DEEP VEI	1 M (SESSIONS 95-104) NOUS DISEASE Ilroom, 3rd Floor
Course Lea	ders: Jose I. Almeida, MD Lowell S. Kabnick, MD Peter Gloviczki, MD Thomas W. Wakefield, MD Steve Elias, MD
DEEP VEI CHARAC	(Trianon Ballroom, 3rd Floor) NOUS WORK-UP, VENOUS STENT STERISTICS : Jose I. Almeida, MD Lowell S. Kabnick, MD Peter Gloviczki, MD Thomas W. Wakefield, MD Steve Elias, MD
7:00 — 7:04	Introduction: Deep System Lowell S. Kabnick, MD
7:05 — 7:10	Iliocaval Duplex Ultrasound With Image Optimization <i>Jan M. Sloves, RVT</i>
7:11 — 7:16	Noninvasive Measurement Of Ambulatory Venous Pressures Seshadri Raju, MD
7:17 — 7:22	Physiologic Assessment Of The Severity Of Iliac Vein Obstruction Fedor Lurie, MD, PhD
7:23 — 7:28	Validation Of A Chronic Venous Obstruction Classification System Houman Jalaie, MD, PhD

7:29 — 7:34	Outcomes And Predictors Of Failure Of Iliac Vein Stenting Rabih A. Chaer, MD
7:35 — 7:40	Iliac Vein Post-Thrombotic Disease Stent Considerations Jose I. Almeida, MD
7:41 — 7:46	What Is Aspect Ratio And What Does The Clinical Data Reveal Lowell S. Kabnick, MD
7:47 — 7:52	Invasive Diagnostics To Indicate Stenting For MTS To Improve Outcome Cees H.A. Wittens, MD, PhD
7:53 — 7:58	Impact Of Stent Structure On Venous Flow (In Vitro Investigations With A Designed Fluid Dynamic Model) Houman Jalaie, MD , PhD
7:59 — 8:04	What Should The 3rd Generation Stents Look Like Cees H.A. Wittens, MD, PhD
8:05 — 8:10	Calf Pump Dysfunction: What Is It Brajesh K. Lal, MD
8:11 — 8:16	Iliac Vein Obstruction And Associated Infrainguinal Reflux: Is There A Best Approach To Treatment Elna M. Masuda, MD
8:17 — 8:22	Panel Discussion
	(Trianon Ballroom, 3rd Floor) STENT TRIALS
	Paul J. Gagne, MD Michael K.W. Lichtenberg, MD
8:23 — 8:28	Reporting Standards For Acute Deep Vein Thrombosis Trials: Results Of The Delphi Consensus Raghu Kolluri, MD
8:29 — 8:34	Reporting Standards For Stenting Chronic Iliofemoral Venous Obstructions: Results Of The Delphi Consensus Peter Gloviczki, MD
8:35 — 8:40	The BEYOND Venous Stent Registry Michael K.W. Lichtenberg, MD
8:41 — 8:46	FIH Trial: RevCore Chronic Deep Venous Stent Occlusion For In Stent Restenosis Steven D. Abramowitz, MD
8:47 — 8:52	The First Randomized Controlled Trial Comparing Venous Stenting With Conservative Treatment In Patients With Deep Venous Obstruction Houman Jalaie, MD, PhD
8:53 — 8:58	Current Deep Vein Interventions: What Are They And When Are They Reasonable Iris Baumgartner, MD
8:59 — 9:04	Living In The Post-SOX World: Update On Compression Trials Andrea T. Obi, MD
9:05 — 9:10	Vernacular Trial: 3-Year Update Michael K.W. Lichtenberg, MD
9:11 — 9:16	Zilver Vena Stent Trial: 3-Year Outcomes Anthony J. Comerota, MD
9:17 — 9:22	ABRE Trial Results Erin H. Murphy, MD
9:23 — 9:28	Will The BEST Trial Answer The Question On Iliac Stenting Alun H. Davies, MA, DM, DSc

9:29 — 9:34	Panel Discussion
FEMORO OCCLUSI AND OTH	(Trianon Ballroom, 3rd Floor) -ILIOCAVAL CHRONIC TOTAL ONS, RECANALIZATION TECHNIQUES HER CONSIDERATIONS Jose I. Almeida, MD Steve Elias, MD
9:35 — 9:40	Options To Improve Inflow When Stenting – ACCESS PTS/SSTA With Chameleon/Angioplasty Alone Steve Elias, MD
9:41 — 9:46	Utilizing The Radiofrequency Power Wire To Vaporize A Channel Through Chronic Iliocaval Venous Obstructions (CICVO) Patrick E. Muck, MD
9:47- 9:52	Azygous Vein Stenting: Alternate Route For Caval Agenesis Jose I. Almeida, MD
9:53 — 9:58	My Techniques For Recanalizing Thrombosed IVC Filters And Iliocaval Occlusions Jose I. Almeida, MD
9:59 -10:04	Endovascular Techniques And Indications For Retroperitoneal/Extravascular Iliocaval Reconstruction Steven D. Abramowitz, MD
10:05-10:10	Sniper Technique To Treat Difficult And Chronic Central Venous Occlusions Marcelo Guimaraes, MD
10:11-10:16	Hybrid Open And Endovascular Techniques For Complex Iliofemoral Disease Erin H. Murphy, MD
10:17-10:22	Why Iliofemoral Deep Venous Stents Fail, And How To Manage It $Kush\ R.\ Desai,\ MD$
10:23-10:28	Panel Discussion
VENOUS STRATEG Moderators:	(Trianon Ballroom, 3rd Floor) THROMBOSIS SCIENCE AND TREATMENT IES Thomas W. Wakefield, MD Peter Henke, MD
10:29-10:34	Venous Thromboembolism In The Context Of Chronic Venous Disease Thomas W. Wakefield, MD
10:35-10:40	Should All Patients With Acute VTE Be Treated With A Statin: When And Dose Anthony J. Comerota, MD
10:41-10:46	Our Experience With DVT/PE During The COVID Era Young Erben MD
10:47-10:52	Inflammation, Selectins And Venous Thrombosis Thomas W. Wakefield, MD
10:53-10:58	Update On Experimental DVT Pathogenesis And Resolution Peter Henke, MD
10:59-11:04	Comprehensive Thrombus Removal Strategies Versus Selective Stenting In Acute Symptomatic Iliofemoral Venous Thrombosis Arjun Jayaraj, MD
11:05-11:10	Panel Discussion

THROMB AND OTH	(Trianon Ballroom, 3rd Floor) BUS REMOVAL THROMBECTOMY DEVICES HER ISSUES TO CONSIDER Patrick E. Muck, MD Brian G. DeRubertis, MD
11:11-11:16	P-Max Study: Mechanical Thrombectomy For Iliofemoral DVT With Aspirex Michael K.W. Lichtenberg, MD
11:17-11:22	Thrombolysis For Acute DVT: Guidance From Current Clinical Trials Brian G. DeRubertis, MD
11:23-11:28	New Percutaneous Thrombectomy Reperfusion System $\it Patrick~E.~Muck,~MD$
11:29-11:34	CLOUT Registry For The Inari CloTriever David J. Dexter, MD
11:35-11:40	Mechanical Thrombectomy Of Acute DVT: What Are The Ideal Device Features That We Are Missing Marcelo Guimaraes, MD
11:41-11:46	The Dexterity Study: Anti-Inflammatory Potential In Treating Venous Disease Mahmood Razavi, MD
11:47-11:52	Management Of IVC Thrombus Using Large Bore Mechanical Thrombectomy Constantino Pena, MD
11:53-11:58	Panel Discussion
VENOUS) (Trianon Ballroom, 3rd Floor) REFLUX ISSUES Mikel Sadek, MD Marzia Lugli, MD
11:59-12:04	Deep Venous Reflux In Patients Undergoing Venous Treatments Mikel Sadek, MD
12:05-12:09	Deep Reflux: What Happens After Concomitant Obstruction Correction Marzia Lugli, MD
12:10-12:15	When Deep Venous Reflux Repair Is Not Effective: What Next Marzia Lugli, MD
12:16-12:21	Does Vein Stenting Reduce Great And Small Saphenous Venous Reflux Natalie A. Marks, MD, RPVI, RVT
12:22-12:27	Long-Term Fate Of Limb Reflux After Iliac Vein Stenting Seshadri Raju, MD
12:28- 12:33	Panel Discussion
12:34- 12:57	Lunch Break – Rhinelander Gallery, 2nd Floor Visit Exhibits And Pavilions (2nd and 3rd Floors)
SESSION 101	(Trianon Ballroom, 3rd Floor)
	EIN DISORDERS
	Peter Gloviczki, MD Mark H. Meissner, MD
12:58- 1:03	FDA Compliant Patient-Reported Outcome Measure For Use In Clinical Trials For Venous Origin Chronic Pelvic Pain In Women Neil M. Khilnani. MD

1:04 — 1:09	RCT Of Pelvic Venous Embolization Versus Sham Procedure For Venous Origin Chronic Pelvic Pain In Women Neil M. Khilnani, MD
1:10 — 1:15	Venographic Techniques To Identify Pelvic Anatomy And Escape Points Mark H. Meissner, MD
1:16 — 1:21	Male Pelvic Congestion And Varicose Veins: How Much Of A Problem Mark S. Whiteley, MS
1:22 — 1:27	Ovarian Vein Embolization: Which Patient Benefits And Reimbursement Kathleen D. Gibson, MD
1:28 — 1:33	We Need Dedicated Venous Stents For Nutcracker Syndrome And We Need Them Now Peter Gloviczki, MD
1:34 — 1:39	Outcomes Of Left Renal Vein Stenting In Patients With Nutcracker Syndrome Rabih Chaer, MD
1:40 — 1:45	Open Surgery For Nutcracker: Techniques And Results Cynthia K. Shortell, MD
1:46 — 1:51	Management Of Symptomatic Vulvar Varices With And Without Pelvic Symptoms $Steve\ Elias,\ MD$
1:52 — 1:57	Panel Discussion
MORE VE	(Trianon Ballroom, 3rd Floor) ENOUS THROMBOSIS, IVC Thomas S. Maldonado, MD Timothy K. Liem, MD, MBA
1:58 — 2:03	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD
1:58 - 2:03 2:04 - 2:09	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia
	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD
2:04 — 2:09	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia Timothy K. Liem, MD, MBA Advanced IVC Filter Retrieval: When And How
2:04 - 2:09 2:10 - 2:15	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia Timothy K. Liem, MD, MBA Advanced IVC Filter Retrieval: When And How Kush R. Desai, MD Which DOAC For What Disease: Review Of Ongoing Trials Andrea T. Obi, MD Who Needs Lifelong Anticoagulation
2:04 - 2:09 2:10 - 2:15 2:16 - 2:21	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia Timothy K. Liem, MD, MBA Advanced IVC Filter Retrieval: When And How Kush R. Desai, MD Which DOAC For What Disease: Review Of Ongoing Trials Andrea T. Obi, MD
2:04 - 2:09 2:10 - 2:15 2:16 - 2:21 2:22 - 2:27	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia Timothy K. Liem, MD, MBA Advanced IVC Filter Retrieval: When And How Kush R. Desai, MD Which DOAC For What Disease: Review Of Ongoing Trials Andrea T. Obi, MD Who Needs Lifelong Anticoagulation Rachel Rosovsky, MD, MPH SVT Treatment Options: DOAC, LMWH, Nothing Steve Elias, MD Update On Reversal Agents For The DOACs
2:04 - 2:09 2:10 - 2:15 2:16 - 2:21 2:22 - 2:27 2:28 - 2:33	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia Timothy K. Liem, MD, MBA Advanced IVC Filter Retrieval: When And How Kush R. Desai, MD Which DOAC For What Disease: Review Of Ongoing Trials Andrea T. Obi, MD Who Needs Lifelong Anticoagulation Rachel Rosovsky, MD, MPH SVT Treatment Options: DOAC, LMWH, Nothing Steve Elias, MD
2:04 - 2:09 2:10 - 2:15 2:16 - 2:21 2:22 - 2:27 2:28 - 2:33 2:34 - 2:39	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia Timothy K. Liem, MD, MBA Advanced IVC Filter Retrieval: When And How Kush R. Desai, MD Which DOAC For What Disease: Review Of Ongoing Trials Andrea T. Obi, MD Who Needs Lifelong Anticoagulation Rachel Rosovsky, MD, MPH SVT Treatment Options: DOAC, LMWH, Nothing Steve Elias, MD Update On Reversal Agents For The DOACs Timothy K. Liem, MD, MBA IVC Management In Pregnant Patients
2:04 - 2:09 2:10 - 2:15 2:16 - 2:21 2:22 - 2:27 2:28 - 2:33 2:34 - 2:39 2:40 - 2:45	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia Timothy K. Liem, MD, MBA Advanced IVC Filter Retrieval: When And How Kush R. Desai, MD Which DOAC For What Disease: Review Of Ongoing Trials Andrea T. Obi, MD Who Needs Lifelong Anticoagulation Rachel Rosovsky, MD, MPH SVT Treatment Options: DOAC, LMWH, Nothing Steve Elias, MD Update On Reversal Agents For The DOACs Timothy K. Liem, MD, MBA IVC Management In Pregnant Patients Joann Lohr, MD Pediatric DVT: An Evidence Summary
2:04 - 2:09 2:10 - 2:15 2:16 - 2:21 2:22 - 2:27 2:28 - 2:33 2:34 - 2:39 2:40 - 2:45 2:46 - 2:51	What To Do With Fractured Filters And Embolic Filter Fragments Constantino Pena, MD Update On Heparin-Induced Thrombocytopenia Timothy K. Liem, MD, MBA Advanced IVC Filter Retrieval: When And How Kush R. Desai, MD Which DOAC For What Disease: Review Of Ongoing Trials Andrea T. Obi, MD Who Needs Lifelong Anticoagulation Rachel Rosovsky, MD, MPH SVT Treatment Options: DOAC, LMWH, Nothing Steve Elias, MD Update On Reversal Agents For The DOACs Timothy K. Liem, MD, MBA IVC Management In Pregnant Patients Joann Lohr, MD Pediatric DVT: An Evidence Summary Dawn M. Coleman, MD The Future Of Lymphedema Care: Non-Pneumatic Compression Results In Improved Outcomes And Greater Patient Compliance

3:10 - 3:15	Why Temporary Filters Are Not Removed: Clinical Predictors In 1,000 Consecutive Cases Heron E. Rodriguez, MD
3:16 — 3:21	Open Removal Of Chronically Occluded IVC And Iliofemoral Stents Steven D. Abramowitz, MD
3:22 — 3:27	Breakthrough DVT – Aren't They All
0.22 0.27	Peter Henke, MD
3:28 - 3:33	Panel Discussion
DEEP VEIN STRATEG VENOUS	(Trianon Ballroom, 3rd Floor) N VALVE TECHNOLOGIES, MORE IES FOR CORRECTING SEVERE DEEP REFLUX AND/OR OBSTRUCTION Jose I. Almeida, MD William A. Marston, MD
3:34 — 3:39	Tips And Tricks For Optimal Management Of Primary And Secondary IVC Tumors Jill J. Colglazier, MD
3:40 — 3:45	Deep Vein Valve Devices: What Outcome Measures Should Be Used Fedor Lurie, MD, PhD
3:46 — 3:51	US Experience Of The BlueLeaf® Endovenous Valve Formation: Update William A. Marston, MD
3:52 — 3:57	Novel Transcatheter Endovascular Device For Treatment Of Deep Venous Reflux Jorge H. Ulloa, MD
3:58 — 4:03	Three-Year Outcomes Of An Implantable Bioprosthetic Valve For The Treatment Of Deep Venous Reflux Jorge H. Ulloa, MD
4:04 — 4:09	An Update On The Cook Venous Valve Project Paul J. Gagne, MD
4:10 — 4:15	Outcome Of Venous Stents In Adolescents, Teenagers, And Pregnancy Mahmood Razavi, MD
4:16 — 4:21	Acute Iliofemoral DVT In Adolescents And Young Adults And Whether They Should Undergo Stenting For May Thurner At The Time Of DVT Intervention William A. Marston, MD
4:22 — 4:27	Shortcomings Of Stents: Positioning, Migration, Patency And Anticoagulation Cees H.A. Wittens, MD, PhD
4:28 — 4:33	Ruptured IVC And Iliac Vein: Now What <i>Jose I. Almeida, MD</i>
4:34 — 4:39	IVC Reconstruction Options Erin H. Murphy, MD
4:40 - 4:45	Panel Discussion
SESSION 104	(Trianon Ballroom, 3rd Floor)
VENOUS	ANEURYSMS, MORE IMPORTANT DEEP
	CONCEPTS
Moderators:	Peter F. Lawrence, MD Thomas W. Wakefield, MD
4:46 — 4:51	Venous Aneurysms: Should They Be Treated Peter F. Lawrence, MD
4:52 — 4:57	Closed Plication Is A Safe And Effective Method For Treating Popliteal Venous Aneurysm Thomas W. Wakefield, MD

4:58 — 5:03	Do Venous Stent Fractures Matter David J. Dexter, MD
5:04 — 5:09	Most Common Venous Stenting Complications And How To Avoid Them Erin H. Murphy, MD
5:10 — 5:15	Suprainguinal Lymphatic Disease In Patients Undergoing Stenting For Chronic Iliofemoral Venous Obstruction Arjun Jayaraj, MD
5:16 - 5:21	Outcomes Of Acute Superior Mesenteric Venous Thrombosis Rabih A. Chaer, MD
5:22 - 5:27	Open Surgical And Endovascular Treatment Of Superior Vena Cava Syndrome Manju Kalra, MBBS
5:28 - 5:33	Endophlebectomy Of Common Femoral Vein: When And How Houman Jalaie, MD, PhD
5:34 — 5:39	Contralateral Limb Improvement After Unilateral Iliac Vein Stenting: Argument Against Simultaneous Bilateral Stenting Seshadri Raju, MD
5:40 - 5:45	Stenting Across The IVC Filter Is A Safe And Effective Alternative To Complex Removal Efthymios (Makis) Avgerinos, MD
5:46 — 5:51	Venous Stent For The Iliofemoral Vein Investigational Clinical Trial Using The Duo Venous Stent System: The VIVID Trial Mahmood Razavi, MD
5:52 — 5:57	Panel Discussion End of Program M

SATURDAY, NOVEMBER 18, 2023

6:15 A.M. General Registration — Gramercy Suite East, 2nd Floor

6:00 A.M. Faculty Registration - Gramercy Suite West, 2nd Floor

6:30 A.M. Continental Breakfast — 3rd Floor Promenade/Foyer

CONCURRENT SATURDAY PROGRAMS

PROGRAM N (SESSIONS 105-108)

Topics Too Important To Miss In The Treatment Of Lower **Extremity, Aortic Or Carotid Disease**

7:00 A.M. - 12:40 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM O (SESSIONS 109-113)

Improving Outcomes In Hemodialysis Access

8:00 A.M. - 4:00 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM P (SESSIONS 114-123)

Advances In Vascular Imaging And Diagnosis

7:00 A.M. - 5:30 P.M.

Murray Hill Suites, 2nd Floor

PROGRAM N (SESSIONS 105-108)

TOPICS TOO IMPORTANT TO MISS IN THE TREATMENT OF LOWER EXTREMITY. AORTIC OR

CAROTID DISEASE

Grand Ballroom East, 3rd Floor

SESSION 105 (Grand Ballroom East, 3rd Floor)

LOWER EXTREMITY TOPICS TOO IMPORTANT TO

MISS (4 3/4-MINUTE TALKS)

Moderators: Keith D. Calligaro, MD

Timothy M. Sullivan, MD Venita Chandra, MD

7:00 - 7:05Despite Recent Improved Endo Techniques, Acute Limb Ischemia (ALI) Still Has High Amputation And Mortality Rates: Why, Is It Because The Disease Has Evolved And Become More Complex: What Is Needed To Improve Results

Loay S. Kabbani, MD, MHSA

7:05 - 7:10When Should Endovascular Treatments Be The First Choice For Common Femoral Artery (CFA) Occlusive Lesions: When Are They Contraindicated Brian G. DeRubertis, MD

The Open Treatment First For CLTI In The Era Of 7:10 - 7:15BEST-CLI Yana Etkin, MD

With Arterialization Of Pedal Veins (DVA) Improved 7.15 - 7.20Foot Perfusion Persists After The DVA Occludes: The "Pramook Phenomenon": What Is The Mechanism Steven Kum, MD

7:20 - 7:25 **DEBATE**: An Endo First Approach Is Best For Treating CLTI In Almost All Patients: The Role For Open Bypasses Is Very Limited: Has BEST-CLI And BASIL 2 Changed My Practice

Christopher J. Abularrage, MD

7:25 - 7:30**DEBATE**: Open Bypass Should Be The First Treatment For Many CLTI Patients: When Is This So And In What Percentage Of CLTI Patients Karan Garg, MD

7:30 -	- 7:35	Panel Discussion
7:35 -	- 7:40	Four Pillars To Optimize The Salvage Of Threatened Limbs: Metabolic Management, Revascularization, Good Wound Care, And Spinal Stimulation For Diabetic Neuropathy: How Does The Latter Help Krishna Jain, MD
7:40 -	- 7:45	Pedal Medial Arterial Calcification (pMAC); Is It A Predictor Of Poor Outcomes: Does It Make Limb Salvage Hopeless Michael S. Conte, MD
7:45 -	- 7:50	DEBATE: Multivessel Tibial Revascularization Does Not Improve Limb Salvage In CLTI Patients: From A VQI Study Venita Chandra, MD
7:50 -	- 7:55	DEBATE: Not So: In Some Circumstances Multivessel Tibial Revascularization Does Improve Outcomes In CLTI Patients: Which Circumstances <i>Brian G. DeRubertis, MD</i>
7:55 -	- 8:00	Panel Discussion
8:00 -	- 8:05	Indication And Technical Tips For Performing Retrograde Popliteal Artery Access Jeffrey J. Siracuse, MD
8:05 -	- 8:10	Prograde SFA Access Can Be Safe And Effective For Lower Extremity Endo Procedures; When And How To Do It Safely Todd Berland, MD Karan Garg, MD
8:10 -	- 8:15	Isolated Pedal Interventions For CLTI: When Are They Worthwhile And Who Should Do Them Mark G. Davies, MD
8:15 -	- 8:20	What Defines The No-Option CLTI Foot As A Candidate For Venous Arterialization: What Is The Medial Arterial Calcium (MAC) Score And How Does It Help Miguel F. Montero-Baker, MD
8:20 -	- 8:25	Panel Discussion
MC IMP	RE LC	5 (Grand Ballroom East, 3rd Floor) DWER EXTREMITY TOPICS TOO NNT TO MISS (4 3/4-MINUTE TALKS) David J. Minion, MD R. Clement Darling III, MD
8:25 -	- 8:30	Below The Ankle Recanalizations Of Occlusive Lesions: Why Are They Important; Is The Restored Patency Durable; Technical Tips To Do Them Lorenzo Patrone, MD
8:30 -	- 8:35	Value Of Shockwave Lithotripsy For The Treatment Of Calcified Lesions Above And Below The Knee In Patients With CLTI And Those On Hemodialysis Venita Chandra, MD
8:35 -	- 8:40	Impact Of A Dedicated Limb Preservation/Limb Salvage Service On Amputation Rates: Must It Include An Open Bypass Surgery Component Niten Singh, MD
8:40 -	- 8:45	Atherectomy In Patients With CLTI, ISR And Diabetes: When Is It Helpful; How Durable Is It: Which Devices Are The Best <i>Ignacio Escotto, MD</i>

8:45 — 8:50	Long-Term Outcomes Of Atherectomy – Stand Alone Or With DCBs – For Fempop Lesions: Indications, Limitations: Which Device Is Best: Update On The FLEX Vessel Prep System Eric A. Secensky, MD, MSc (PowerPoint Presentation With Synched Audio)
8:50 — 8:55	Panel Discussion
8:55 — 9:00	Duplex Flow Waveform And Flow Volume (In Addition To Flow Velocity) Can Determine Failing Vein Grafts So Patency Can Be Preserved Kimihiro Komori, MD, PhD
9:00 — 9:05	Impact Of The Severity Of Chronic Kidney Disease On The Outcomes Of Lower Extremity Bypasses For CLTI: Is There A Difference Between Vein And Prosthetic Bypasses Hepeel Chang, MD
9:05 — 9:10	Updated Experience With Open Leg Bypasses After Multiple Endo Treatment Failures For CLTI: They Can Produce Long-Term (>10 Years) Limb Salvage <i>Julien G. Sfeir, MD</i>
9:10 — 9:15	Patient Survival In 2023 After Below-Knee Amputation (BKA), Above-Knee Amputation (AKA), Bilateral Amputations For Trauma; For Vascular Disease: Saving Limbs Especially In Vascular Patients Enhances Survival Philip P. Goodney, MD, MS
9:15 — 9:25	Panel Discussion
9:25 — 9:30	Value Of Duplex Gray Scale In Predicting Successful SFA CTO Crossing, Re-Entry And The Need For Distal Access Natalie A. Marks, MD, RPVI, RVT
9:30 - 9:35	Effect Of Short-Term Complications Of Lower Extremity Revascularizations On Long-Term Outcomes And Patient Survival Panos Kougias, MD, MSc Sherene E. Sharath, PhD, MPH Joseph L. Mills, MD
9:35 — 9:40	Role Of Atherectomy For Lower Extremity Lesions In The Post BEST-CLI Era James F. McKinsey, MD
9:40 — 9:45	How To Use Microcatheters To Facilitate Complex Peripheral Interventions Jos C. van den Berg, MD, PhD
9:45 — 9:50	Panel Discussion
9:50 -10:00	Break - Visit Exhibits And Pavilions (3rd Floor)
AORTIC (4 3/4-MIN (6-MINU)	7 (Grand Ballroom East, 3rd Floor) TOPICS TOO IMPORTANT TO MISS JUTE TALKS) AND SPINE EXPOSURE TE TALKS) Timur P. Sarac, MD Mark A. Adelman, MD
10:00-10:05	Fenestrated EVAR Versus Chimney EVAR For Juxtarenal AAAs: When Is One Better Than The Other And What Are The Critical Considerations Piergiorgio Cao, MD
10:05-10:10	Improved System For Evaluating Aortic Neck Anatomy And Suitability For EVAR And Need For F/EVAR David J. Minion, MD

10:10-10:15

SPINE EXPOSURE SURGERY 10:15-10 21 Technical Tips And Tools For The Vascular Surgeon To Provide Anterior Exposure For Spine Procedures (6-Minute Presentation) Jeffrey Jim, MD, MPHS 10:22-10:28 Vascular Complications Of Anterior Spine Exposures; How To Avoid Them And How To Treat Them If They Occur (6-Minute Presentation) William P. Robinson, MD 10:28-10:33 Outcomes Of EVAR In Over 18,000 High-Risk Patients Ineligible For Open Repair: When Is EVAR Justified Over No Intervention In Such Patients: Why Is EVAR 2 No Longer Relevant George A. Antoniou, MD, PhD, MSc 10:34-10:39 Should The Celiac Artery Be Stented Or Not During Complex Aortic Aneurysm Repair In Patients With Median Arcuate Ligament Syndrome (MALS) Or In Any Patients With MALS Jesse M. Manunga, MD 10:40-10:45 Open Versus Endovascular Treatment For Chronic Mesenteric Ischemia: Operative Outcomes And Patient Survival Michael C. Stoner, MD 10:45-10:50 Panel Discussion DEBATE: Evolution Of Stent-Graft Design And 10:50-10:55 Changes In Appropriate Neck Lengths Make F/EVAR Superior To Ch/EVAR Athanasios Katsargyris, MD Eric L.G. Verhoeven, MD, PhD 10:55-11:00 **DEBATE:** Not So: Properly Performed Ch/EVAR Can Have Comparable Outcomes To F/EVAR: Technical Tips For Optimal Ch/EVAR Performance Manish Mehta, MD, MPH 11:00-11:05 The Vascular Surgeon's Role In TAVR Procedures Via The Common Carotid Artery: Pitfalls And Technical Tips Gregg S. Landis, MD 11:05-11:10 With Juxtarenal Aorto-Iliac Occlusive Disease, Infrarenal Aortic Transection And Endarterectomy Combined With Thrombectomy Avoids Supraceliac Clamping: How To Do It Without Renovisceral Embolization: 10-Year Experience And Technical Tips Wayne W. Zhang, MD 11:10-11:15 Transcaval Access For TEVAR: When And How To Do It Without Aortic Or Retroperitoneal Bleeding Ross Milner, MD 11:15-11:20 **Panel Discussion**

SESSION 108 (Grand Ballroom East, 3rd Floor)

Patrick J. Lamparello, MD Frank J. Veith, MD

TO MISS (4 ¾-MINUTE TALKS) Moderators: Manish Mehta, MD, MPH

AORTIC AND CAROTID TOPICS TOO IMPORTANT

Hybrid Preservation Of Hypogastric Artery Flow Using A Viabahn Stent-Graft Followed By Open Repair For

Large Hypogastric Aneurysms Benjamin J. Pearce, MD

TOPICS RELATED TO THE AORTA AND ITS BRANCHES

- 11:20-11:25 DEBATE: The Vast Majority Of Failed EVARs Can Be Treated Endovascularly Ross Milner, MD
- 11:25-11:30 DEBATE: Not So: Many Failed EVARs Are Best Repaired By Open Conversion Michel Makaroun, MD
- 11:30-11:35 Techniques For Improving Proximal Landing Zones For TEVARs And Aortic Dissections Involving The Aortic Arch; Parallel Grafts And Extra-Anatomic Bypasses R. Clement Darling III, MD
- 11:35-11:40 Comparison Of Results Of Primary F/EVAR With Those Of F/EVAR After Failed EVAR: Technical Tips For The Latter

 Mark L. Schermerhorn, MD
- 11:40-11:45 When And How To Treat Isolated Visceral Artery Aneurysms: The Value Of Embolization Coils Paulo E. Ocke-Reis, MD, PhD
- 11:45-11:50 Primary Use Of Endoanchors For Hostile Proximal Neck Anatomy With EVAR: Mid-Term Results Show Their Value

 Apostolos K. Tassiopoulos, MD
- 11:50–11:55 Reinterventions After F/EVAR: What Are They And What Is Their Individual Impact On Survival Iason T. Lee, MD
- 11:55-12:05 Panel Discussion

CAROTID TOPICS

- 12:05-12:10 Avoidable Errors During TCAR And How To Avoid Them: How To Detect And Manage Intolerance To Flow Reversal

 Thomas S. Maldonado, MD
- 12:10-12:15 Tips And Tricks For Successful TCAR And When Is CEA And Best Medical Treatment Better Than TCAR Jeffrey Jim, MS, MPHS
- 12:15-12:20 How To Use The Silk Road TCAR Device In The Treatment Of Tandem Carotid Lesions: Technical Tips And Results

 Michael C. Stoner, MD
- 12:20-12:25 Radiation To The Neck Creates Significant Risk For Carotid Artery Complications Without And With Surgery (CEA): Can Anything Be Done About Them Cynthia K. Shortell, MD
- 12:25-12:30 Techniques For Dealing With Challenging Carotid Lesions: How Does TCAR Facilitate Treatment When Nothing Else Could Work

 Joseph J. Ricotta II, MD, MS
- 12:30-12:35 Mini-Incision CEA With Standard Or Eversion Techniques: How To Do It Safely: It's Better Than Transfemoral CAS Or TCAR

 Alan M. Dietzek, MD
- 12:35-12:40 Panel Discussion End of Program N

VEITHsymposium continues with the A-V Access Program in the Grand Ballroom West, 3rd floor, and the Advances in Vascular Imaging and Diagnosis Program in the Murray Hill Suites, 2nd floor.

IMPROVI	o (sessions 109-113) NG OUTCOMES IN HEMODIALYSIS
ACCESS	
	oom West, 3rd Floor
Course Lead	ders: Larry A. Scher, MD Anton N. Sidawy, MD, MPH Haimanot (Monnie) Wasse, MD, MPH
8:00 — 8:05	Introduction
	Larry A. Scher, MD Anton N. Sidawy, MD, MPH
IMPORTA	9 (Grand Ballroom West, 3rd Floor) ANT ISSUES IN HEMODIALYSIS ACCESS
1	TE TALKS) Larry A. Scher, MD
	Anton N. Sidawy, MD, MPH
8:06 — 8:13	Vascular Access Cosmesis: Does It Really Matter <i>Charmaine Lok, MD</i>
8:14 — 8:21	Put The Books Aside! Novel Tools For Teaching Vascular Access To The Millennials Samira Farouk, MD
8:22 — 8:29	40-Year Lack Of Progress In Hemodialysis Access Cannulation Deborah Brouwer-Maier, RN, CNN
8:30 — 8:37	Buttonhole Dialysis Access Cannulation: A 2023
	Update Dori R. Schatell, MS
8:38 — 8:45	Home Dialysis And Self-Cannulation: What Are The Challenges From A Patient's Perspectives Lissette Ramos-Multani
8:46 — 8:53	Ultrasound Guided Cannulation Of HD Access: Pearls And Pitfalls Vandana D. Niyyar, MD
8:54 — 9:04	Panel Discussion
9:05 — 9:12	Improving Kidney Care For The Geriatric Population Charmaine Lok, MD
9:13 — 9:20	Surgeon Factors Have A Greater Effect On Vascular Access Type And Outcomes Than Patient Factors Peter F. Lawrence, MD Karen Woo, MD, PhD
9:21 — 9:28	Are Long-Term Tunneled Catheters Ever The Best Option For Hemodialysis Jeffrey J. Siracuse, MD, MBA
9:29 — 9:36	Cannulation Of Deep AV Fistulas – What Are My Options John R. Ross, Sr., MD
9:37 — 9:44	Creating Successful Hemodialysis Access In Children Vincent I. Rowe, MD
9:45 — 9:52	Clinical Trial Management: Pitfalls And Lessons Learned
	Karl A. Illig, MD
9:53 -10:03	Panel Discussion
10:04-10:25	Break - Visit Exhibits And Pavilions (3rd Floor)
	(Grand Ballroom West, 3rd Floor) MPORTANT ISSUES IN HEMODIALYSIS

ACCESS (7-MINUTE TALKS)

Moderators: Haimanot (Monnie) Wasse, MD, MPH Evan C. Lipsitz, MD, MBA

10:26-10:33	Tracking Dialysis Access Outcomes: Frustrations Of A Practicing Dialysis Access Surgeon <i>John F. Lucas III, MD</i>
10:34-10:41	Can The SVS Vascular Quality Initiative Provide Practical Quality Measures For Hemodialysis Access Evan C. Lipsitz, MD, MBA
10:42-10:49	Does Preoperative Vascular Mapping Matter Before Access Creation Charmaine Lok, MD
10:50-10:57	Intraoperative Vascular Mapping During Hemodialysis Access Surgery Should Be Incorporated Into Routine Practice Yana Etkin, MD
10:58-11:05	Volume Flow Measurement In Dialysis Access: Why Is It Important Deborah Brouwer-Maier, RN, CNN
11:06-11:13	Flow Reduction Techniques And Their Importance In Access Durability William Jennings, MD
11:14-11:24	Panel Discussion
	MANAGEMENT OF HEMODIALYSIS ACCESS ANEURYSMS
11:25-11:32	Use Of Deep Learning To Classify Arteriovenous Access Aneurysms Peter Kotanko, MD
11:33-11:40	Risk Stratification For Hemodialysis Access Aneurysms $\it Christian\ Ochoa,\ MD$
11:41-11:48	Surgical Options For Managing AV Access Aneurysms $\it Vicki J. Teodorescu, MD$
11:49-11:59	Panel Discussion
12:00- 1:00	Lunch Break – Mercury Rotunda & Ballroom, 3rd Floor
POLITICA HEMODIA	(Grand Ballroom West, 3rd Floor) AL, ECONOMIC AND LEGAL ISSUES IN ALYSIS ACCESS (7-MINUTE TALKS) Larry A. Scher, MD Anton N. Sidawy, MD, MPH
1:00 — 1:07	Current Landscape Of Legal Enforcement In The Vascular Access World Terry Litchfield, MPA
1:08 — 1:15	Training Surgeons And Interventionalists In Vascular Access: What Are The Options Karl A. Illig, MD
1:16 — 1:23	How Old Is Too Old: How Can I Stay Relevant In My Specialty John R. Ross, Sr., MD
1:24 — 1:31	Development Of MIPS (Merit Based Incentive Payment System) Value Pathways For Dialysis Access Evan C. Lipsitz, MD, MBA
1:32 — 1:39	Coding Integrity: Compliance 101 For Vascular Access Providers Terry Litchfield, MPA
1:40 — 1:50	Panel Discussion

	(Grand Ballroom West, 3rd Floor) "ECHNOLOGIES IN HEMODIALYSIS
	7-MINUTE TALKS)
	Haimanot (Monnie) Wasse, MD, MPH Clifford M. Sales, MD, MBA
1:51 — 1:58	Initial Clinical Experience With A Novel Ultrasound System: Feasibility Trial Update Alex Yevzlin, MD
1:59 — 2:06	Potential Use Of Infrared Hyperspectral Imaging To Predict Hemodialysis Fistula Maturation And Complications John E. Aruny, MD
2:07 — 2:14	Natural Vascular Scaffolding: What Is It And How Can It Be Used In Hemodialysis Access <i>Venita Chandra, MD</i>
2:15 — 2:22	Is There A Role For Intravascular Lithotripsy In Hemodialysis Access Surgery Surendra Shenoy, MD, PhD
2:23 — 2:30	The Future Of AV Graft Technology: What Is In The Pipeline Buddy D. Ratner, PhD
2:31 — 2:38	Novel Endovascular Venous Anastomotic Device For AV Graft Implantation: Results Of A Prospective Multicenter Trial Alex Yevzlin, MD
2:39 — 2:49	Panel Discussion
UPDATE HEMODI	(Grand Ballroom West, 3rd Floor) ON CLINICAL CHALLENGES IN ALYSIS ACCESS (7-MINUTE TALKS) Larry A. Scher, MD Surendra Shenoy, MD, PhD
	DEBATE: THORACIC OUTLET DECOMPRESSION AFTER HEMODIALYSIS ACCESS CREATION
2:50 — 2:57	DEBATE: Transaxillary First Rib Resection For Thoracic Outlet Decompression For Subclavian Venous Stenosis After Ipsilateral Hemodialysis Access Creation <i>Sungho Lim, MD</i>
2:58 — 3:05	DEBATE: Selective Use Of First Rib Resection Versus Medical Claviculectomy For Thoracic Outlet Decompression After Hemodialysis Access Creation Surendra Shenoy, MD, PhD
3:06 — 3:13	Optimizing AV Fistula Maturation With The VasQ Device: Update On Clinical Trials Ellen D. Dillavou, MD
3:14 - 3:21	Creating AV Access In Patients With Ipsilateral Central Venous Stenosis William Jennings, MD
3:22 - 3:29	New Paradigms To Treat Cephalic Arch Stenosis: Go With The Flow Mark G. Davies, MD
3:30 — 3:37	Optimizing Dialysis Access Strategies In The Geriatric And Bariatric Population Jason K. Wagner, MD
3:38 - 3:45	Hemodialysis Access: Which Patients Fare Well, Which Patients Fare Poorly Laura E. Niklason, MD, PhD
3:46 — 3:56	Panel Discussion

3:57 — 4:00	Closing Remarks Larry A. Scher, MD
	End of Program O
PROGRAM	P (SESSIONS 114-123)
ADVANC DIAGNO	ES IN VASCULAR IMAGING AND SIS
•	Suites, 2nd Floor
Course Lead	ders: George L. Berdejo, BA, RVT Natalie A. Marks, MD, RPVI, RVT Ann Marie Kupinski, PhD Laurence Needleman, MD
7:00 — 7:10	Welcome And Opening Remarks: Navigating The Meeting And Optimizing Your Experience George L. Berdejo, BA , RVT
VASCULA CHRONIC	(Murray Hill Suites, 2nd Floor) AR SONOGRAPHY IN ACUTE AND C LIMB ISCHEMIA George L. Berdejo, BA, RVT
7:10 — 7:20	Still Important Role Of Physiologic Testing Anahita Dua, MD, MS, MBA
7:20 — 7:30	Infrapopliteal And Pedal Artery Imaging Jill S. Sommerset, BS, RVT
7:30 — 7:40	Clinical Decision Making Based On The Results Of Noninvasive Testing David L. Dawson, MD
7:40 — 7:50	Duplex Guided Interventions Natalie A. Marks, MD, RPVI, RVT
7:50 — 8:00	Post-Operative Surveillance: When, How Often R. Eugene Zierler, MD
8:00 - 8:20	Panel Discussion
WAVEFO WITH UN FURTHER	(Murray Hill Suites, 2nd Floor) RMS — LESSONS LEARNED FROM CASES NQUE WAVEFORMS WHICH LEAD TO TESTING OR UNUSUAL PATHOLOGY George L. Berdejo, BA, RVT
	Global Cardiac Effects On The Peripheral Vascular
	Evaluation David M. Williams, MS, RDCS, RVT
	CASE STUDY PRESENTATIONS
8:30 — 8:38	Vein Imaging Nicos Labropoulos, BSc (Med), PhD, DIC, RVT
8:38 — 8:46	Cerebrovascular Maya Hutchinson, MHS
8:46 — 8:54	Abdominal Traci B. Fox, EdD, RDMS, RVT
8:54 — 9:02	Hemodialysis Access Ann Marie Kupinski, PhD, RVT
9:02 — 9:20	Panel Discussion
9:20 — 9:45	Break - Visit Exhibits (3rd Floor)
LESSONS THROUG	(Murray Hill Suites, 2nd Floor) LEARNED IN THE VASCULAR LAB H THE QA ACCREDITATION PROCESS Ann Marie Kupinski, PhD, RVT

9.45 – 9.53 Instantaneous Vascular Lab QA Reporting From The EVS Suite And OR

David M. Williams, MS, RDCS, RVT

9.53 -10:01 Reports: Improving The Interpretation David L. Dawson, MD

Quality Improvement Metrics – What We Need To

Look For

Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS

10:09-10:17 Potpourri

10:01-10:09

Laurence Needleman, MD

10:17-10:35 Panel Discussion

SESSION 117 (Murray Hill Suites, 2nd Floor)
BEYOND THE CORE CONCEPTS IN VASCULAR
TESTING: ARE YOU MEETING THE STANDARD

(This session will venture into advanced vascular evaluation related to vascular testing as it relates to pre-operative diagnosis and post-intervention follow-up and patient evaluation and will describe appropriate use, standard and non-standard image acquisition and other components that define the "complete" vascular examination.)

Moderator: Natalie A. Marks, MD, RPVI, RVT

10:35-10:45 Lower Extremity Imaging After Endovenous

Procedures: When, What To Expect And How To

Report Your Findings Neil M. Khilnani, MD

10:45-10:55 "Limited" Imaging Protocols In A Covid-19 World:

How Safe Is This; Are They Still Necessary

Anahita Dua, MD

10:55-11:05 Carotid Artery Imaging Pre And Post Stenting And/Or

Endarterectomy: It's More Than The Usual Protocol

Mava Hutchinson, MHS

11:05-11:15 Evaluation Of Fibromuscular Dysplasia

Nicos Labropoulos, BSc (Med), PhD, DIC, RVT

11:15-11:35 Panel Discussion

11:35-11:50 Lunch Break - South Corridor, 2nd Floor

SESSION 118 (Nassau Suites East & West, 2nd Floor) TECHNICAL SKILLS LAB

(This session will be an informal setting which will allow you to visit with recognized experts in the field and will provide an opportunity for "hands-on" time and conversation to glean technical tips in the various areas of vascular ultrasound and physiologic testing.)

Moderators: Fernando Amador, RVT

Richard Dubin, AAS-DMS, RVT, RDMS

11:50-12:50 Station 1: Pedal Artery Imaging

Jill S. Sommerset, BS, RVT Station 2: Carotid Artery Imaging

William N. Del Valle, RVT

Station 3: Transcranial Duplex

Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS

Station 4: Pelvic Venous Reflux Testing

Jan M. Sloves, RVT

Station 5: Renal Artery Imaging

Robert De Jong, RDMS, RVT

Station 6: Physiologic Testing

Kayla Wieseckel,MHSc, RVT, RVS, RPhS

Station 7: Hemodialysis Access Ann Marie Kupinski, PhD, RVT

SESSION 119 (Murray Hill Suites, 2nd Floor)

INTERPRETING WITH THE MASTERS

Moderator: Ann Marie Kupinski, PhD, RVT

Panel Discussion: Interpreting With The Masters

David L. Dawson, MD Panelists: Anahita Dua, MD, MS, MBA Ann Marie Kupinski, PhD, RVT R. Eugene Zierler, MD, RPVI SESSION 120 (Murray Hill Suites, 2nd Floor) VENOUS IMAGING: TESTING FOR LEG REFLUX AND PELVIC VEIN DISORDERS Moderator: Nicos Labropoulos, BSc (Med), PhD, DIC, RVT 1:50 - 1:58 The Clinical Examination Matters And Guides The Ultrasound Examination Anahita Dua, MD, MS, MBA 5 Top Tips For Lower Extremity Vein Mapping 1:58 - 2:06Richard Dubin, AAS-DMS, RVT, RDMS 2:06 - 2:145 Top Tips For Pelvic Vein Imaging Jan M. Sloves, RVT The Role Of IVUS In Vein Procedures 2:14 - 2:22Steven Elias, MD 2:22 - 2:30Common And Uncommon Reflux Pathways Nicos Labropoulos, BSc (Med), PhD, DIC, RVT **Panel Discussion** 2:30 - 2:38SESSION 121 (Murray Hill Suites, 2nd Floor) ERGONOMICS - AUDIT YOUR VASCULAR LAB: ARE YOU ERGONOMICALLY "SOUND"; ERGONOMICS "SOS" (SOUND OCCUPATIONAL STRATEGIES) (This important session will discuss strategies designed to help you to Ergonomically Enhance the Experience for the Vascular Sonographer by 1) increasing awareness around health and safety in the workplace; 2) recognizing factors that influence the Vascular ultrasound professionals' likelihood of developing work-related musculoskeletal disorders; and 3) reducing ergonomic injury and prevent long-term permanent bodily damage.) Moderators: George L. Berdejo, BA, RVT Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS 2:38 - 2:46Managing Turbulent High Volumes And High Impact Examinations - Save Your Staff, Enhance Sonographer Satisfaction And Maximize Productivity And Maximize Careers: Advocating On Behalf Of Yourself And Your Staff - How And Why It's Important Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS Increase Your "Ergonomic Index" - Basic And 2:46 - 2:54Innovative Ways To Make Exams More Ergonomic -"Accessorizing" The Vascular Lab Suite Kayla Wieseckel, MHSc, RVT, RVS, RPhS 2:54 - 3:02How To Be Ergonomically Sound With Obese And **Uncooperative Patients** Robert De Jong, RDMS, RVT 3:02 - 3:15Break SESSION 122 (Murray Hill Suites, 2nd Floor) PRACTICE ENHANCEMENTS AND PHILOSOPHICAL **ISSUFS** Moderator: George L. Berdejo, BA, RVT 3:15 - 3:25Critical Vascular Lab Findings: Which Are They And

How Do You Manage This R. Eugene Zierler, MD

12:50- 1:50

3:25 — 3:33	IAC Consensus Criteria 0 - How Widespread Is Its Us In IAC Accredited Labs And How To Incorporate It Into Your Practice Aubrey Rybyinski, BS, RDMS, RVT			
3:33 — 3:41	CEA – When Duplex Is And Is Not Enough Or Redundant Testing/Imaging Prior To CEA: Is There Too Much Happening; When Is Duplex Enough And When Is More Imaging Necessary, If At All David L. Dawson, MD			
3:41 - 3:49	Patterns Of Infrapopliteal Arterial Occlusive Disease: Lessons Learned From A Survey Of A Small Community Hospital William N. Del Valle, RVT			
3:49 — 3:57	IAC Updates Aubrey Rybyinski, BS, RDMS, RVT			
3:57 — 4:05	Reimbursement Updates Joseph P. Hughes, MBA, RVT, RVS, RPhS, NVS			
4:05 — 4:20	Panel Discussion (Combined Sessions 121 And 122)			
ABDOME	(Murray Hill Suites, 2nd Floor) EN; CURVEBALLS AND CONTROVERSIES Richard C. Pennell, MD, RPVI			
4:10 — 4:20	Renal Artery Evaluation: 5 Top Tips Robert De Jong, RDMS, RVT			
4:20 — 4:30	The Endograft Examination From A to Z Kayla Wieseckel, MHSc, RVT, RVS, RPhS			
4:30 — 4:40	Common And Not So Common Aortic Pathologies <i>Richard C. Pennell, MD, RPVI</i>			
4:40 — 4:50	Critical Vascular Lab Findings: Which Are They And How Do You Manage This R. Eugene Zierler, MD			
4:50 — 5:00	Hemodialysis Access "Surveillance": Flow Volume, Flow Velocity And How Often Is Appropriate Anahita Dua, MD, MS, MBA			
5:00 — 5:10	Pre-Operative Dialysis Access Mapping Including Endo-AVF Creation: Tips And Tricks Richard Dubin, AAs-DMS, RVT, RDMS			
5:10 — 5:30	Panel Discussion End of Program			

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING



Anne L. Abbott, MD, PhD *Melbourne, Australia*

Dorothy B. Abel, BSBME New York, New York

Cherrie Z. Abraham, MD Portland, Oregon

Steven D. Abramowitz, MD *Washington, District of Columbia*

Shadi J. Abu-Halimah, MDCharleston West Virginia

Christopher J. Abularrage, MD *Baltimore, Maryland*

Ali F. AbuRahma, MD Charleston, West Virginia

Zach AbuRahma, DOCharleston, West Virginia

George L. Adams, MD Raleigh, North Carolina

Joshua D. Adams, MD Roanoke, Virginia

Mark A. Adelman, MD New York, New York

Sam S. Ahn, MD, FACS, MBA Fort Worth, Texas

Olamide Alabi, MD Atlanta, Georgia

Eric Allaire, MD, PhD Paris, France

Jose I. Almeida, MD, FACS, RPVI, RVT Miami, Florida

Jean-Marc Alsac, MD, PhD *Paris, France*

David J. Altschul, MD *Bronx, New York*

Fernando Amador, RVT New York, New York

Ali Amin, MD, RVT Reading, Pennsylvania

Gary M. Ansel, MD *Columbus, Ohio*

George A. Antoniou, MD, PhD, MSc *Manchester, United Kingdom*

Frank R. Arko, MD Charlotte, North Carolina

Zachary M. Arthurs, MD *Charleston, South Carolina*

Charleston, South Carolina
John E. Aruny, MD

Orangeburg, South Carolina
Enrico Ascher, MD
New York, New York

Afshin Assadian, MD Vienna, Austria

Martin J. Austermann, MD Münster, Germany

Efthymios (Makis) Avgerinos, MD
Athens. Greece

Hamdy Awad, MD Arlington, Ohio

Faisal Aziz, MD Hershey, Pennsylvania

Ali Azizzadeh, MD Los Angeles, California **Nobuyoshi Azuma, MD** Asahikawa, Hokkaido, Japan



Sateesh C. Babu, MD Valhalla, New York

Martin R. Back, MD Gainesville, Florida

Michael E. Barfield, MD Chattanooga, Tennessee

Iris Baumgartner, MD *Bern, Switzerland*

Hernan A. Bazan, MD New Orleans, Louisiana

Robert E. Beasley, MD Miami Beach, Florida

Carlos F. Bechara, MD Chicago, Illinois

Adam Beck, MD Birmingham, Alabama

Christian A. Behrendt, MD *Hamburg, Germany*

James F. Benenati, MD Miami, Florida

George L. Berdejo, BA, RVTWhite Plains, New York

Jeffrey S. Berger, MD, MS New York, New York

Ramon Berguer, MD, PhD Ann Arbor, Michigan

Todd Berland, MD New York, New York

Luca Bertoglio, MD *Brescia, Italy*

Colin D. Bicknell, MD *London, United Kingdom*

Theodosios Bisdas, MD Maroussi, Greece

Jean Bismuth, MD Houston, Texas

Martin Björck, MD, PhD *Uppsala, Sweden*

James H. Black, III, MD *Baltimore, Maryland*

Jan D. Blankensteijn, MD *Amsterdam, The Netherlands*

John Blebea, MD, MBA *Saginaw, Michigan*

Erwin Blessing, MD Hamburg, Germany

Dittmar Böckler, MD Heidelberg, Germany

Michel J. Bosiers, MD Bern, Switzerland

Lee Bouwman, MD, PhD, MSc *The Netherlands*

Jonathan R. Boyle, MD, MA(Cantab) *Cambridge, United Kingdom*

Kursat A. Bozkurt, MD Istanbul, Turkey

Andrew W. Bradbury, MD, FRCSEd *Birmingham, United Kingdom*

Daniela Branzan, MD Leipzig, Germany

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Clayton J. Brinster, MD

Chicago, Illinois

Marianne Brodmann, MD

Graz, Austria

Allan L. Brook, MD

Bronx, New York

Thomas G. Brott, MD

Jacksonville, Florida

Deborah Brouwer-Maier, RN, CNN

Lansdale, Pennsylvania

Kellie R. Brown, MD

Milwaukee, Wisconsin

O. William Brown, MD, JD Royal Oak, Michigan

Elchanan Bruckheimer, MBBS

Petah-Tikva, Israel

Richard Bulbulia, MA, MD Oxford, United Kingdom

Jacques Busquet, MD

Paris, France



Keith D. Calligaro, MD

Philadelphia, Pennsylvania

Victor M. Canata, MD, PhD

Asuncion, Paraguay

Ludovic Canaud, MD, PhD

Montpellier, France

Piergiorgio Cao, MD

Rome, Italy

Laura Capoccia, MD, PhD

Avezzano, Italy

Francis Caputo, MD

Cleveland, Ohio

Wayne J. Caputo, DPM Belleville, New Jersey and

New York, New York

Neal S. Cayne, MD New York, New York

Rabih A. Chaer, MD

Pittsburgh, Pennsylvania

Venita Chandra, MD

Stanford, California

Heepeel Chang, MD Valhalla, New York

Robert W. Chang, MD

San Francisco, California

Zhong Chen, MD Beijing, China

Laurent Chiche, MD

Paris, France

Jae S. Cho, MD

Cleveland, Ohio

Timothy A.M. Chuter, MD

San Francisco, California

Daniel G. Clair, MD

Nashville, Tennessee

Rachel E. Clough, PhD, FRCS

London, United Kingdom

W. Darrin Clouse, MD

Charlottesville, Virginia

Felipe Coelho Neto, MD, MSc, PhD

Londrina, Brazil

Dawn M. Coleman, MD Durham, Carolina

Jill J. Colglazier, MD

Rochester, Minnesota Anthony J. Comerota, MD

Alexandria, Virginia

Mark Conrad, MD, MMSc Brighton, Massachusetts

Michael S. Conte, MD

San Francisco, California

Joseph S. Coselli, MD

Houston, Texas Frank J. Criado, MD

Baltimore, Maryland

Jack L. Cronenwett, MD

Lebanon, New Hampshire Philippe W.M. Cuypers, MD, PhD

Eindhoven, The Netherlands

Jacob Cynamon, MD New York, New York

Martin Czerny, MD Freiburg, Germany



Guilherme Dabus, MD

Miami, Florida

Michael D. Dake, MD

Tucson, Arizona

Ronald L. Dalman, MD

Stanford, California

Michael C. Dalsing, MD Indianapolis, Indiana

R. Clement Darling III, MD

Albany, New York

Alun H. Davies, MA, DM, DSC London, United Kingdom

Mark G. Davies, MD Houston, Texas

David L. Dawson, MD

Temple, Texas

Gert J. de Borst, MD, PhD

Utrecht, The Netherlands

Gianmarco de Donato, MD Siena, Italy

Robert De Jong, RDMS, RVT Baltimore, Maryland

Reade A. De Leacy, MBBS

New York, New York

Jean-Paul de Vries, MD, PhD Groningen, The Netherlands

Steven T. Deak, MD, PhD

Somerset, New Jersey

Steven M. Dean, DO

Columbus, Ohio

David H. Deaton, MD

Crownsville, Maryland

Sebastian E. Debus, MD, PhD

Hamburg, Germany

William N. Del Valle, RVT

Bronx, New York

Brian G. DeRubertis, MD

New York, New York

Kush R. Desai, MD

Chicago, Illinois

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Nimesh Desai, MD, PhD

Philadelphia, Pennsylvania

David J. Dexter, MD

Norfolk, Virginia

Nuno V. Dias, MD, PhD

Malmö, Sweden

Alan M. Dietzek, MD, RPVI

Danbury, Connecticut

Ellen D. Dillavou, MD

Raleigh, North Carolina Hasan H. Dosluoglu, MD

Buffalo, New York

Maciej L. Dryjski, MD, PhD

Buffalo, New York

Anahita Dua, MD, MS, MBA

Boston, Massachusetts

Richard Dubin, AAS-DMS, RVT, ŔDMŚ

Bronx, New York

Joseph J. DuBose, MD

Austin, Texas

David M. Dudzinski, MD

Boston, Massachusetts

Yazan Duwayri, MD MBA

Atlanta, Georgia



Matthew J. Eagleton, MD

Boston, Massachusetts

Hans-Henning Eckstein, MD, PhD

Munich, Germany

John F. Eidt, MD Dallas, Texas

Hosam F. El Sayed, MD Norfolk, Virginia

Jens Eldrup-Jorgensen, MD

Portland, Maine

Steve Elias, MD

Englewood, New Jersey

Jan-Willem Elshof, MD

Venlo, The Netherlands

Luis H. Eraso, MD

Philadelphia, Pennsylvania

Young Erben, MD

Ponte Vedra Beach, Florida

Guillermo A. Escobar, MD

Atlanta, Georgia

Ignacio Escotto, MD

Mexico City, Mexico Mark K. Eskandari, MD

Chicago, Illinois

Mohammad H. Eslami, MD, MPH

Pittsburgh, Pennsylvania

Omar L. Esponda, MD

Fort Myers, Florida

Anthony L. Estrera, MD

Houston, Texas

Yana Etkin, MD

Lake Success, New York

Christian D. Etz, MD, PhD

Rostock, Germany



Dominique Fabre, MD, PhD

Le Plessis-Robinson, France

Gianluca Faggioli, MD Bologna, Italy

Alexander Fairman, MD

XXX

Fabrizio Fanelli, MD

Florence, Italy

Alik Farber, MD, MBA

Boston, Massachusetts

Mark A. Farber, MD

Chapel Hill, North Carolina

Peter L. Faries, MD *New York, New York*

Samira S. Farouk, MD, MS

New York, New York

John M. Felder, MD Royal Oak, Missouri

Jose Fernandes e Fernandes, MD

Lisbon, Portugal

Roberto Ferraresi, MD

Milano, Italy

Marcelo Ferreira, MD

Rio de Janeiro, Brazil

Ciro Ferrer, MD, PhD

Rome, Italy

David Fiorella, MD, PhD

Stony Brook, New York

Thomas L. Forbes, MD

Toronto, Ontario, Canada

Mazin Foteh, MD

Dallas, Texas

Charles J. Fox, MD Baltimore, Maryland

Traci B. Fox, EdD, RDMS, RVT Philadelphia, Pennsylvania

Weiguo Fu, MD

Shanghai, China

Naoki Fujimura, MD, PhD Tokyo, Japan

Markus K. Furrer, MD

Chur, Switzerland



Paul J. Gagne, MD

Darien, Connecticut

Katherine A. Gallagher, MD

Ann Arbor, Michigan

Chirag D. Gandhi, MD Valhalla, New York

Ripal T. Gandhi, MD

Miami, Florida

Lawrence A. Garcia, MD

Boston, Massachusetts

Karan Garg, MD New York, New York

Antonios P. Gasparis, MD

Stony Brook, New York

Patrick J. Geraghty, MD

Saint Louis, Missouri

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Jean Luc Gerard, MD

Creteil, France

George Geroulakos, MD, PhD

Athens, Greece

Brian B. Ghoshhajra, MD, MBA

Boston, Massachusetts

Sergio Gianesini, MD, PhD

Ferrara, Italy

Richard G.J. Gibbs, FRCS

London, United Kingdom

Kathleen D. Gibson, MD

Bellevue, Washington

Jay Giri, MD, MPH Philadelphia, Pennsylvania

Rocco Giudice, MD

Rome, Italy

Monika L. Gloviczki, MD, PhD

Rochester, Minnesota

Peter Gloviczki, MD

Scottsdale, Arizona

Manj S. Gohel, MD

Cambridge, United Kingdom

Jerry Goldstone, MD

Stanford, California

Philip P. Goodney, MD, MS

Lebanon, New Hampshire

David Gordon, MD

Mt. Kisco, New York

Yann Gouëffic, MD, PhD

Paris, France

Peter C.J. Goverde, MD

Antwerp, Belgium

Juan F. Granada, MD

New York, New York William A. Gray, MD

Philadelphia, Pennsylvania

Franco Grego, MD

Padua, Italy

Marcelo Guimaraes, MD, MBA Charleston, South Carolina

Wei Guo, MD

Beijing, China



Mo S. Hamady, MD

London, United Kingdom

Claudine M. Hamel-Desnos, MD

Paris, France

Sukgu Han, MD

Los Angeles,California

Neil Haranhalli, MD

Bronx, New York

Linda M. Harris, MD

Buffalo, New York

Stephan Haulon, MD

Paris, France

Don Heck, MD

Winston-Salem, North Carolina

Peter Henke, MD

Ann Arbor, Michigan

Jan M.M. Heyligers, MD, PhD

Tilburg, The Netherlands

Caitlin W. Hicks, MD, MS

Baltimore, Maryland

Anil P. Hingorani, MD Brooklyn, New York

Jade S. Hiramoto, MD San Francisco, California

Joshua A. Hirsch, MD

Boston, Massachusetts

Tobias Hirsch, MD

Halle, Germany

Kim J. Hodgson, MD

Springfield, Illinois

Andrew Holden, MBChB

Auckland, New Zealand

Tal M. Hörer, MD, PhD Örebro, Sweden

Emmanuel M. Houdart, MD

Paris, France

Jeffrey H. Hsu, MD

Alta Loma, California

Joseph P. Hughes, MBA, RVT, RVS

Taunton, Massachusetts

Maya Hutchinson, MHS, ACS, RVT, RDMS, PS, RDCS (AE/PE)

• • • • • • • • • • • • • • • • •

St. Louis, Missouri



Mark D. Iafrati, MD

Nashville, Tennessee

Osamu Iida, MD, PhD

Osaka, Japan

Karl A. Illig, MD Houston, Texas

Sriram S. Iyer, MD

New York, New York



Glenn Jacobowitz, MD

New York, New York

Michael J. Jacobs, MD Maastricht, The Netherlands

Michael R. Jaff, DO

Boston, Massachusetts

Krishna Jain, MD

Kalamazoo, Michigan

Houman Jalaie, MD, PhD

Aachen, Germany

Aleksandra Jaworucka-Kaczorowska, MD, PhD

Gorzów Wlkp., Poland

Arjun Jayaraj, MD

Jackson, Mississippi

Michael P. Jenkins, MBBS, BSC, MS

London, United Kingdom

William Jennings, MD

Tulsa, Oklahoma

Jeffrey Jim, MD, MPHS

Minneapolis, Minnesota

Juan Carlos Jimenez, MD, MBA

Los Angeles, California

William D. Jordan Jr., MD

Atlanta, Georgia

Matthieu M.J. Josnin, MD

La Roche sur Yon, France

FACILITY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING



Loay S. Kabbani, MD, MHSA Detroit, Michigan

• • • • • • • • • • • • • • •

Lowell S. Kabnick, MD Lake Worth, Florida

Andrea Kahlberg, MD Milano, Italy

Stavros K. Kakkos, MD, PhD

Manju Kalra, MBBS

Patras, Greece

Rochester, Minnesota

Vikram S. Kashyap, MD Grand Rapids, Michigan

Karthik Kasirajan, MD Pleasanton, California

Piotr M. Kasprzak, MD Regensburg, Germany

Konstantinos Katsanos, MSc, MD, PhD

Patras, Greece

Athanasios Katsargyris, MD Nuremberg, Germany &

Athens, Greece Barry T. Katzen, MD

Miami, Florida

John A. Kaufman, MD, MS Portland, Oregon

William B. Keeling, MD Atlanta, Georgia

Patrick W. Kelly, MD Sioux Falls, South Dakota

Sophia Khan, MD

Houston, Texas

Neil M. Khilnani, MD New York, New York

Ali B. Khoynezhad, MD, PhD

Los Angeles, California

Nicholas Kipshidze, MD, PhD, DSc New York, New York

Tilo Kölbel, MD, PhD Hamburg, Germany

Raghu Kolluri, MD Columbus, Ohio

Ralf R. Kolvenbach, MD Duesseldorf, Germany

Kimihiro Komori, MD, PhD

Nagoya, Japan Peter Kotanko, MD

New York, New York Panos Kougias, MD, MSc

Brooklyn, New York

Zvonimir Krajcer, MD Houston, Texas

Dainis K. Krievins, MD Riga, Latvia

Boonprasit Kritpracha, MD Hat Yai, Songkhla, Thailand

Waclaw B. Kuczmik, MD, PhD Katowice, Poland

Steven Kum, MD Singapore

Ann Marie Kupinski, PhD, RVT Albany, New York

Toru Kuratani, MD, PhD

Osaka, Japan

Christopher J. Kwolek, MD, MBA

Boston, Massachusetts



• • • • • • • • • • • Nicos Labropoulos, BSc (MED), PhD, DIC, RVT

Stony Brook, New York

Mario L. Lachat, MD Zurich, Switzerland

John R. Laird, MD

St. Helena, California

Brajesh K. Lal, MD Baltimore, Maryland

Patrick J. Lamparello, MD New York, New York

Glenn M. LaMuraglia, MD Boston, Massachusetts

Gregg S. Landis, MD New Hyde Park, New York

Werner Lang, MD

Erlangen, Germany

Kamphol Laohapensang, MD Chiang Mai, Thailand

Igor A. Laskowski, MD, PhD Valhalla, New York

Peter F. Lawrence, MD Los Angeles, California

Jeffrey H. Lawson, MD, PhD Durham, North Carolina

Byung-Boong Lee, MD Washington, District of Columbia

Jason T. Lee, MD Stanford, California

Seon-Kyu Lee, MD, PhD New York, New York

W. Anthony Lee, MD Boca Raton, Florida

Luis R. Leon, MD, RVT Tucson, Arizona

Christos D. Liapis, MD

Athens, Greece Michael K.W. Lichtenberg, MD

Arnsberg, Germany

David S. Liebeskind, MD Los Angeles, California

Timothy K. Liem, MD, MBA Portland, Oregon

Francesco Liistro, MD Arezzo, Italy

Sungho Lim, MD Chicago, Illinois

Hans Lindgren, MD, PhD Helsingborg, Sweden

Jes S. Lindholt, MD Odense, Denmark

Thomas F. Lindsay, MDCM, FRCS Toronto, Ontario, Canada

Evan C. Lipsitz, MD, MBA New York, New York

Terry Litchfield, MPA Blanchardville, Wisconsin

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Armando C. Lobato, MD, PhD

São Paulo, Brazil

Ian Loftus, MD

London, United Kingdom

Shang Loh, MD

Philadelphia, Pennsylvania

Joann M. Lohr, MD

Columbia, South Carolina

Charmaine Lok, MD

Toronto, Ontario, Canada

Joseph V. Lombardi, MD, MBA Camden, New Jersey

Lars B. Lonn, MD, PhD

Copenhagen, Denmark

Robert A. Lookstein, MD, MHCDL

New York, New York

Qingsheng Lu, MD

Shanghai, China

John F. Lucas III, MD

Greenwood, Mississippi

Marzia Lugli, MD

Modena, Italy

Alan B. Lumsden, MD

Houston, Texas

Fedor Lurie, MD, PhD

Toledo, Ohio & Ann Arbor, Michigan

Sean P. Lyden, MD

Cleveland, Ohio



Sumaira Macdonald, MD, PhD

Sunnyvale, California

Lindsay Machan, MD

Vancouver, British Columbia, Canada

Edward G. Mackay, MD

St. Petersburg, Florida

Michel Makaroun, MD

Pittsburgh, Pennsylvania

Mahmoud B. Malas, MD, MHS

San Diego, California

Thomas S. Maldonado, MD

New York, New York

Martin Malina, MD, PhD

London, United Kingdom

Nicola Mangialardi, MD

Rome, Italy

Armando Mansilha, MD, PhD

Porto, Portugal

Ashraf Mansour, MD

Grand Rapids, Michigan

Jesse M. Manunga, MD

Minneapolis, Minnesota

Marco G. Manzi, MD

Abano Terme, Italy

Michael L. Marin, MD

New York, New York

Natalie A. Marks, MD, RPVI, RVT

Brooklyn, New York

William A. Marston, MD

Chapel Hill, North Carolina

Elna M. Masuda, MD

Honolulu, Hawaii

Klaus D. Mathias, MD

Hamburg, Germany

Jon S. Matsumura, MD Aurora, Colorado

Mark A. Mattos, MD Flint, Michigan

David T. McGreevy, MD

Örebro, Sweden

James F. McKinsey, MD

New York, New York

Robert B. McLafferty, MD, MBA

Portland, Oregon

Barend M.E. Mees, MD, PhD

Maastricht, The Netherlands

Roxana Mehran, MD

New York, New York

Manish Mehta, MD, MPH Latham, New York

Mark H. Meissner, MD

Seattle, Washington

Germano C.G. Melissano, MD

Milano, Italy

Matthew W. Mell, MD, MS

Sacramento, California

Matthew T. Menard, MD

Boston, Massachusetts

Bernardo C. Mendes, MD

Rochester, Minnesota

Valerie M. Merkle, PhD

Silver Spring, Maryland

D. Christopher Metzger, MD Kingsport, Tennessee

Mark W. Mewissen, MD, RVT

Milwaukee, Wisconsin

Claude Mialhe, MD

Le Tholonet, France

James Milburn, MD New Orleans, Louisiana

Charles C. Miller, PhD

Houston, Texas

Joseph L. Mills, MD

Houston, Texas

Ross Milner, MD

Chicago, Illinois

David J. Minion, MD

Lexington, Kentucky

Aleem K. Mirza, MD Houston, Texas

Erica L. Mitchell, MD, MEd Memphis, Tennessee

Kasuo Miyake, MD, PhD

São Paulo, Brazil

J Mocco, MD, MS

New York, New York Bijan Modarai, PhD, FRCS

London, United Kingdom

Irwin V. Mohan, MBBS, MD

Sydney, Australia

Frans L. Moll, MD, PhD

Utrecht, The Netherlands

Samuel R. Money, MD, MBA New Orleans, Louisiana

Miguel F. Montero-Baker, MD Houston, Texas

Robert A. Montgomery, MD, DPhil New York, New York

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Randy D. Moore, MD

Chestermere, Alberta, Canada

Wesley S. Moore, MD

Los Angeles, California

Robert A. Morgan, MD

London, United Kingdom

Patrick E. Muck, MD

Cincinnati, Ohio

Stefan Müller-Hülsbeck, MD

Flensburg, Germany

Dipankar Mukherjee, MD Falls Church, Virginia

Erin H. Murphy, MD

Charlotte, North Carolina

Piotr Musialek, MD, DPhil Krakow, Poland

Pramook Mutirangura, FRCS (EDINBURGH)

Bangkok, Thailand

Mario Muto, MD

Naples, Italy

Piotr Myrcha, MD, PhD

Warsaw, Poland



Mohamed A. Nagib, MD

Alexandria, Egypt

Yuliia Nahaliuk, MD

Kiev, Ukraine

Ross Naylor, MD

Leicester, United Kingdom

Laurence Needleman, MD

Philadelphia, Pennsylvania

Peter K. Nelson, MD New York, New York

Richard F. Neville, MD

Fairfax, Virginia

Christoph A. Nienaber, MD, PhD London, United Kingdom

Laura E. Niklason, MD, PhD Durham, North Carolina

Sigrid Nikol, MD

Hamburg, Germany

Samy S. Nitecki, MD

Haifa, Israel

Vandana D. Niyyar, MD

Atlanta, Georgia

Katariina M. Noronen, MD, PhD

Helsinki, Finland

Furuzan Numan, MD

Istanbul, Turkey

Andriy O. Nykonenko, MD

Zaporizhzhia, Ukraine



David O'Connor, MD

Hackensack, New Jersey

Thomas F. O'Donnell, Jr., MD Boston, Massachusetts

Andrea T. Obi, MD

Ann Arbor, Michigan

Christian Ochoa, MD

Los Angeles, California

Paulo E. Ocke Reis, MD, PhD

Niterói, Rio de Janeiro, Brazil

Gustavo S. Oderich, MD

Houston, Texas

Alvaro Orrego, MD

Vina Del Mar, Chile

Matteo Orrico, MD Rome, Italy

Rafael A. Ortiz, MD

New York, New York

Kenneth Ouriel, MD, MBA

New York, New York

Kathleen J. Ozsvath, MD Troy, New York



•••••• Jean M. Panneton, MD

Norfolk, Virginia

Rajiv Parakh, MBBS, MS

Gurgaon, India

Kosmas I. Paraskevas, MD

Athens, Greece

Sahil A. Parikh, MD

New York, New York

Lorenzo Patrone, MD

London, United Kingdom

Benjamin J. Pearce, MD Birmingham, Alabama

Felice Pecoraro, MD

Palermo, Italy

Constantino Pena, MD

Miami, Florida

Richard C. Pennell, MD, RPVI

St. Louis, Missouri

Bruce A. Perler, MD, MBA

Baltimore, Maryland

Jennifer L. Perri, MD, MBA

Durham, North Carolina Ivo Petrov, MD, PhD

Sofia, Bulgaria

Janet T. Powell, MD, PhD

London, United Kingdom

Richard J. Powell, MD

Lebanon, New Hampshire

Carlo Pratesi, MD

Florence, Italy

Giovanni Pratesi, MD

Genoa, Italy

Ourania Preventza, MD

Charlottesville, Virginia

Robert M. Proczka, MD, PhD

Warsaw, Poland



Elina Quiroga, MD, MPH

Seattle, Washington



Joseph D. Raffetto, MD

West Roxbury, Massachusetts

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Ansaar T. Rai, MD

Morgantown, West Virginia

Ravi R. Rajani, MD

Atlanta, Georgia

Seshadri Raju, MD

Jackson, Mississippi

Venkatesh G. Ramaiah, MD

Scottsdale, Arizona

Lissette Ramos-Multani

Bronx, New York

Muhammad Ali A. Rana, MD

Albuquerque, New Mexico

Zoran Rancic, MD, PhD

Lachen, Switzerland

Hisham Rashid, FRCS, FRCS(GEN)

London, United Kingdom

Todd E. Rasmussen, MD Rochester, Minnesota

Animesh Rathore, MD

Norfolk, Virginia

Buddy D. Ratner, PhD

Seattle, Washington

Eytan Raz, MD

New York, New York

Mahmood Razavi, MD

Orange, California

Michel M.P. Reijnen, MD, PhD

Arnhem, The Netherlands

Timothy A. Resch, MD, PhD

Copenhagen, Denmark

Robert Y. Rhee, MD

Brooklyn, New York

Vicente Riambau, MD, PhD

Barcelona, Spain

Jean-Baptiste Ricco, MD, PhD Poitiers, France

Götz M. Richter, MD, PhD

Stuttgart, Germany

Joseph J. Ricotta II, MD, MS Boca Raton, Florida

Celia Riga, MD

London, United Kingdom

William P. Robinson, MD

Springfield, Illinois

Caron B. Rockman, MD New York, New York

Sean P. Roddy, MD Albany, New York

Heron E. Rodriguez, MD Chicago, Illinois

Sonia Ronchey, MD, PhD Rome, Italy

Eric E. Roselli, MD Cleveland, Ohio

Kenneth Rosenfield, MD

Boston, Massachusetts

Rachel Rosovsky, MD, MPH Boston, Massachusetts

Elsie Ross, MD, MSc

San Diego, California

John R. Ross, Sr., MD Orangeburg, South Carolina

Vincent L. Rowe, MD

Los Angeles, California

Maria A. Ruffino, MD

Lugano, Switzerland

Aubrey J. Rybyinski, BS, RDMS, RVT

Turnersville, New Jersey



Mikel Sadek, MD

New York, New York

Hazim J. Safi, MD

Houston, Texas

Natzi Sakalihasan, MD, PhD

Sart Tilman, Liege, Belgium

Gloria Salazar, MD

Chapel Hill, North Carolina

Clifford M. Sales, MD, MBA

Livingston, New Jersey

Russell H. Samson, MD, RVT Sarasota, Florida

Luis A. Sanchez, MD

St. Louis, Missouri

Wilhelm Sandmann, MD

Duesseldorf, Germany

Timur P. Sarac, MD

Columbus, Ohio

Pierre G. Sarradon, MD

Toulon, France

Sudhakar R. Satti, MD

Newark, Delaware

Salvatore T. Scali, MD

Gainesville, Florida Andres Schanzer, MD

Worcester, Massachusetts

Dori R. Schatell, MS

Catonsville, Maryland

Dierk Scheinert, MD Leipzig, Germany

Larry A. Scher, MD Bronx, New York

Marc L. Schermerhorn, MD

Boston, Massachusetts

Andrej Schmidt, MD

Leipzig, Germany Darren B. Schneider, MD

Philadelphia, Pennsylvania

Peter A. Schneider, MD

San Francisco, California

Geert Willem H. Schurink, MD,

Maastricht, The Netherlands

Eric A. Secemsky, MD, MSc Boston, Massachusetts

Johanna Seiden, MD, MPH

Bronx, New York

Carlo Setacci, MD

Siena, Italy

Francesco Setacci, MD

Milan, Italy

Jonathan J. Sexton, MD

Bethesda, Maryland

Julien G. Sfeir, MD

Beirut, Lebanon

Sherene Shalhub, MD, MPH

Portland, Oregon

FACILITY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Murray L. Shames, MD

Tampa, Florida

Maksim Shapiro, MD

New York, New York

Palma M. Shaw, MD, RPVI

Syracuse, New York

Maxim Shaydakov, MD, PhD

Pittsburgh, Pennsylvania

Malachi Sheahan, MD

New Orleans, Louisiana

Surendra Shenoy, MD, PhD

St. Louis, Missouri

Chun Che Shih, MD, PhD

Taipei, Taiwan

Cynthia K. Shortell, MD

Durham, North Carolina

Chang Shu, MD

Beijing, China & ChangSha, Hunan Province, China

Anton N. Sidawy, MD, MPH

Washington, District of Columbia

Adnan H. Siddiqui, MD, PhD

Buffalo, New York

Kolja Sievert, MD

Frankfurt, Germany

Michael B. Silva, Jr., MD

Galveston, Texas

Rossi M. Silva, MD

Rio de Janeiro, Brazil

Jessica P. Simons, MD, MPH

Worcester, Massachusetts

Michael J. Singh, MD

Pittsburgh, Pennsylvania

Niten Singh, MD

Seattle, Washington

Jeffrey J. Siracuse, MD

Boston, Massachusetts

Pasqualino Sirignano, MD

Rome, Italy Jan M. Sloves, RVT

New York, New York

Christopher J. Smolock, MD

New York, New York

Jill S. Sommerset, BS, RVT

Houston, Texas

J. David Spence, MD

London, Ontario, Canada

Francesco Spinelli, MD

Rome, Italy

James C. Stanley, MD

Ann Arbor, Michigan

Benjamin W. Starnes, MD

Seattle, Washington

W. Charles Sternbergh III, MD

New Orleans, Louisiana

Scott L. Stevens, MD

Knoxville, Tennessee

David H. Stone, MD

Hanover, New Hampshire

Gregg W. Stone, MD

New York, New York

Patrick A. Stone, MD

Nashville, Tennessee

Michael C. Stoner, MD

Rochester, New York

Martin Storck, MD, PhD

Karlsruhe, Germany

Julianne Stoughton, MD

Boston, Massachusetts

Timothy M. Sullivan, MD Livingston, Montana

Sherif A.H. Sultan, MD, PhD

Galway, Ireland

Bauer E. Sumpio, MD, PhD

New Haven, Connecticut

Gabriel Szendro, MD

Beer Sheva, Israel

Wilson Y. Szeto

Philadelphia, Pennsylvania

Piotr Szopinski, MD, PhD Warsaw, Poland

• • • • • • • • Fadi Taher, MD

Vienna, Austria

Lawrence N. Tanenbaum, MD

Riverside, Connecticut

Apostolos K. Tassiopoulos, MD

Stony Brook, New York

Vicki J. Teodorescu, MD

Atlanta, Georgia

Gunnar Tepe, MD

Rosenheim, Germany

Jörg Tessarek, MD Lingen, Germany

Pierre-Olivier Thiney, MD Lyon, France

Matt M. Thompson, MD

Irvine, California

Robert W. Thompson, MD

St. Louis, Missouri

Bryan W. Tillman, MD, PhD

Columbus, Ohio Carlos H. Timaran, MD

Dallas, Texas

Giovanni B. Torsello, MD

Münster, Germany

Margaret Tracci, MD, JD

Charlottesville, Virginia

Kenneth Tran, MD Stanford, California

Santi Trimarchi, MD, PhD Milan, Italy

Patrick Troy, MD Hartford, Connecticut

Yamume Tshomba, MD

Rome, Italy

Nikolaos Tsilimparis, MD, PhD Munich, Germany



Jorge H. Ulloa, MD

Bogota, Colombia

Gilbert R. Upchurch, MD

Gainesville, Florida

Tomasz Urbanek, MD

Katowice, Poland

FACILITY

VISIT WWW.VEITHSYMPOSIUM.ORG FOR FULL FACULTY LISTING

Marco V. Usai, MD

North Rhine-Westphalia, Germany



Torsten Vahl, MD New York, New York

Claude D. Vaislic, MD

Le Chesnay, France

Domenico Valenti, DMChir, PhD London, United Kingdom

S. Rao Vallabhaneni, MD Liverpool, United Kingdom

Jos C. van den Berg, MD, PhD Lugano, Switzerland

Joost van Herwaarden, MD, PhD Utrecht, The Netherlands

Isabelle Van Herzeele, MD, PhD Ghent, Belgium

Marc R.H.M. van Sambeek, MD,

Eindhoven, The Netherlands

Ramon L. Varcoe, MBBS, MS Sydney, Australia

Ravi K. Veeraswamy, MD Charleston, South Carolina

Frank I. Veith, MD Cleveland, Ohio & New York, New York

Maarit Venermo, MD, PhD Helsinki, Finland

Hence J.M Verhagen, MD, PhD Rotterdam, The Netherlands

Eric L.G. Verhoeven, MD, PhD Nuremberg, Germany

Fabio Verzini, MD, PhD Turin, Italy

Todd R. Vogel, MD, MPH Columbia, Missouri



Jason K. Wagner, MD Sarasota, Florida

Reese A. Wain, MD Old Westbury, New York

Thomas W. Wakefield, MD

Ann Arbor, Michigan

Ajay K. Wakhloo, MD, PhD Boston, Massachusetts

Ron Waksman, MD Washington, District of Columbia

Craig M. Walker, MD Houma, Louisiana

Grace J. Wang, MD, MSCE Philadelphia, Pennsylvania

Anders Wanhainen, MD, PhD Uppsala, Sweden

Haimanot (Monnie) Wasse, MD MPH

Chicago, Illinois

Fred A. Weaver, MD, MMM Los Angeles, California

Ido Weinberg, MD, MSc Boston, Massachusetts

Mitchell D. Weinberg, MD

Staten Island, New York

Harold J. Welch, MD Burlington, Massachusetts

Paul W. White, MD

Falls Church, Virginia

Rodney A. White, MD Long Beach, California

Mark S. Whiteley, MS, FRCS Guildford, United Kingdom

Michael H. Wholey, MD, MBA

San Antonio, Texas Kayla Wieseckel, MHSc, RVT, RVS,

Atlanta, Georgia

David M. Williams, MD Ann Arbor, Michigan

David M. Williams, MS, RDCS, RVT Florence, South Carolina

Willem Wisselink, MD Chicago, Illinois

Cees H.A. Wittens, MD, PhD The Hague, The Netherlands

Mathew D. Wooster, MD, MBA Charleston, South Carolina

I-Hui Wu, MD, PhD Taipei, Taiwan



Wayne F. Yakes, MD

Englewood, Colorado

Kak Khee Yeung, MD, PhD Amsterdam, The Netherlands

Alexander Yevzlin, MD Madison, Wisconsin

Richard L. Zampolin, MD

New York, New York

Christopher K. Zarins, MD Stanford, California

Hany M. Zayed, MD

London, United Kingdom

Clark J. Zeebregts, MD, PhD Groningen, The Netherlands

Thomas Zeller, MD

Bad Krozingen, Germany

Sara L. Zettervall, MD Seattle, Washington

Wayne W. Zhang, MD Seattle, Washington

Wei Zhou, MD

Tucson, Arizona

R. Eugene Zierler, MD, RPVI

Seattle, Washington

VEITHSYMPOSIUM ON DEMAND

www.veithondemand.com



Purchase all the Talks, Slides, and Videos
- fully synchronized - and all the Panels.
This Library or Components thereof can be used
as an Educational Resource or Teaching Tool.

For more information on how to obtain the VEITHsymposium Online Library, please call 800-987-9314 (select option 3).

www.veithsymposium.org

REGISTRATION

Tuesday, November 14 - Saturday, November 18, 2023 New York Hilton Midtown

FULL REGISTRATION (TUESDAY - SATURDAY)

Tuition

Tuition includes access to any Thursday and Saturday Only Component.

Registration fee includes breakfast, lunch and breaks Physicans (excluding Fellows/Trainees and Residents)

\$1399

Physician Combination Rate - VEITHsymposium and AlMsymposium

\$1899

US 2nd Year Fellows in an RRC-approved 2-Year Vascular

Complimentary

Fellowship OR 5th-Year Vascular Resident in an approved Vascular Surgery Residency as of November 2023, AND Canadian Vascular Surgery Fellows in Training (Tuition is provided through an Educational Grant by W.L. Gore & Associates Inc.) Letter of verification on official hospital stationery must be obtained prior to registration and emailed to registrar@veithsymposium.org. The letter must include the start and end date of vascular fellowship.

PGY-6 Fellows & PGY-4 Residents

Complimentary tuition is available but limited. Contact admin@ veithsymposium.org for more details.

Complimentary

\$699

Non-US Fellows and Residents (Trainees) Letter of verification from Chief of Service must be obtained prior to

\$650

registration and emailed to registrar@veithsymposium.org. Non-Finishing U.S. Fellows/Residents, Nurses, Technologists

\$500

Medical Students (Letter of verification from Dean must be obtained prior to registration and

emailed to registrar@veithsymposium.org.) Allied Health Care Professionals, Venture Capitalists, and All Others

\$950 \$25

Venous Venous Venous® Workshop

Wednesday, November 15, 2023 from 1:35 P.M. - 6:45 P.M., Americas Hall 2, 3rd Floor

Registration is limited to 200 fully paid VEITHsymposium registrants

including Industry Personnel. (This is a non-CME Activity.)

THURSDAY ONLY - NOVEMBER 16, 2023

Multidisciplinary Acute Stroke Management 8:00 A.M. to 12:30 P.M.

\$349

Murray Hill Suites, 2nd Floor

Potential Employer/Recruiter

Tuition includes access to any VEITHsymposium Thursday Sessions.

FRIDAY ONLY - NOVEMBER 17, 2023

VEITHsymposium Fellows & Residents Career Development Program 8:00 A.M. to 5:00 P.M.

Americas Hall, 3rd Floor (This is a non-CME Activity.)

\$500

(For Employers/Recruiters not registered at VEITHsymposium) Tuition includes access to VEITHsymposium Friday Sessions.

\$349

SATURDAY ONLY COMPONENTS - NOVEMBER 18, 2023

Hemodialysis Access (Physicians only) 8:00 A.M. - 4:00 P.M.

Tuition includes access to any Saturday Only Component. VEITHsymposium (Miscellaneous Topics)

\$349

7:00 A.M. - 12:30 P.M. Tuition includes access to any Saturday Only Component.

Hemodialysis Access

\$150

8:00 A M - 4:00 P M (Non-physician, clinician rate [not available to industry personnel]) Tuition includes access to Hemodialysis Access Only.

Cancellation Policy: There is a \$95 cancellation fee if canceled in writing by October 21, 2023. No refunds will be made thereafter.

Online: www.veithsymposium.org/registration

Phone: 800-987-9314, (select option 2) with payment information

Please make checks payable to the Cleveland Clinic Educational

Foundation and print and mail your receipt to:

The Cleveland Clinic Educational Foundation

Attn: EHCC081 P.O. Box 931653

Cleveland, OH 44193-1082

Please notify registrar@veithsymposium.org if sending by overnight mail or courier service.

Email: registrar@veithsymposium.org

Checks must be received by October 21, 2023

REGISTER ONLINE AT WWW.VEITHSYMPOSIUM.ORG/REGISTRATION App To Stay Up To Date

Cleveland Clinic

THE CLEVELAND CLINIC EDUCATIONAL FOUNDATION

CLEVELAND, OH 44193-1082 PO BOX 931653

WEDNESDAY, NOVEMBER 15, 2023

Venous Venous Venous® Workshops at VEITHsymposium **THURSDAY, NOVEMER 16, 2023**

Multidisciplinary Acute Stroke Management

AGAIN THIS YEAR

Associate Faculty Global Podium Presentations Program - Wednesday - Friday, November 15-17, 2023

at VEITHsymposium - Wednesday - Friday, November 15-17, 2023

SVS/AVF/AVLS Guidelines on Varicose Veins - Wednesday, November 15, 2023

World Federation of Vascular Surgery at VEITHsymposium - Thursday, November 16, 2023 BEST-CLI: New Data and Evolving Perspectives - Thursday, November 16, 2023

J. Leonel Villavicencio Latin-American Program at VEITHsymposium - Friday, November 17, 2023

Fellows & Residents Career Development Program - Friday, November 17, 2023

VEITHsymposium is Compliant with the MedTech Europe Code of Ethical Business Practice.



www.veithsymposium.org

SATURDAY, NOVEMBER 18, 2023

Advances in Vascular Imaging and Diagnosis (Friday, November 17, 2023 - PROGRAM M) Hemodialysis Access

(Saturday, November 18, 2023 - PROGRAM P)

The Frank J. Veith International Society Associate Faculty Global Podium Presentations Program

